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Abstract 
Neurobeachin (Nbea) is a large multi-domain, brain-enriched protein. It is a 
candidate gene for autism spectrum disorders (ASD). In one NBEA 
haploinsufficient ASD patient, a study of blood platelets revealed aberrant dense-
core granule (DCG) morphology. DCGs in the brain can also contain neurotrophic 
hormones and a defect in their regulated secretion might contribute to ASD, at 
least in a subgroup of patients. In vitro, NBEA seems to be a negative regulator of 
regulated secretion. Nbea+/- mice show ASD-like behaviors, aberrant 
neurotransmission and have dwarfism. Despite its conserved domains, the 
molecular functions of NBEA have been poorly described.  
The main goal of this project was to gain more insights into the physiological role 
of NBEA. This was achieved by studying the underlying mechanism of the dwarf 
phenotype and by characterizing the blood platelet phenotype in Nbea+/- mice. 
Another approach was to discover novel interaction partners for NBEA, by 
performing Y2H screens with two conserved domain modules of NBEA.   
We unveiled that the GH240B Nbea+/- mouse model used in the host laboratory 
contained an artifact, in which aberrant expression of human GH in the 
hypothalamus caused a negative feedback loop, resulting in decreased mouse GH 
secretion and dwarfism. Study of the GH240B Nbea+/- blood platelets showed an 
aberrant DCG morphology, as was described in the Nbea haploinsuffient patient. 
Furthermore, support for the role of NBEA as an A-kinase anchoring protein was 
provided by analyzing the phosphorylation of PKA sites in protein extracts of 
platelets. Lastly, Y2H analysis led to the discovery of a novel function for NBEA, 
regulation of transcription, more specifically Notch-mediated transcription. This 
finding is consistent with the observation that a small but significant fraction of 
NBEA is present in the nucleus.  
The combined information obtained from the NBEA haploinsufficient patient, the 
Nbea knockout mouse model and in vitro data has provided novel insights into the 
molecular mechanisms of NBEA. On the other hand, several findings need to be 
further explored. Confirming interaction networks for NBEA, will help in finding 
important pathways for the pathogenesis of ASD, at least in a subgroup of 
patients.
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1.1. Autism spectrum disorders 
1.1.1. Diagnosis, prevalence and treatment 
Autism spectrum disorders (ASD) are neurodevelopmental disorders. To date, ASD 
diagnosis is still only based on behavioral analysis of symptoms instead of its 
etiology. This is done by observation of the child and interrogation of the parents 
to see if the conditions of the fifth edition of the diagnostic and statistical manual 
of mental disorders (DSM-5) are met. The most commonly used rating scale-
instruments are the autism diagnostic observation scheme and the autism 
diagnostic interview revised 1,2.  
Since the first description of autism by Dr. Kanner and Dr. Asperger, the 
conditions for a diagnosis have been adapted. Now, according to the DSM-5 ASD 
is firstly characterized by deficits in social interaction and social communication. 
This includes deficits in social-emotional reciprocity, in non-verbal communicative 
behavior and in developing, maintaining and understanding relationships. 
Secondly, restricted, repetitive patterns of behavior, interests or activities are 
present. This, for example, may include insistence on sameness, inflexible 
adherence to routines and hypo- or hyperreactivity to sensory input 3–5. These 
symptoms must be present early during development, since ASDs develop before 
the age of 3 years. However, it can be that these symptoms are masked due to 
learned, compensating strategies and that they only become apparent when the 
environment becomes highly, socially demanding. Furthermore, each symptom 
can vary in its severity between each individual with ASD, which is why the term 
‘spectrum’ is used (Fig 1.1)3. 
During childhood, social deficits can interfere with learning. In addition, 
individuals with ASD often have problems with planning and organizing, making it 
even more difficult to obtain any academic achievements. In adulthood, only a 
minority will be able to work and live independently. Their insistence on routine 
and problems with novelty and change can interfere with being independent, but 
also with eating and sleeping 3,6.  
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Figure 1.1: Examples of ASD symptoms. 
Examples of ASD symptoms in the everyday life of a child. These symptoms can occur with 
varying degrees of severity. Adapted from http://www.disabilitynews.org/wp-
content/uploads/2009/04/autism_syptoms.jpg. 
 
The prevalence rate for ASDs seems to range from 0.1% to 2% and still seems to 
be increasing. However, it is unsure whether this is a true increase or just due to 
an increased awareness of ASD by the public and professionals, combined with 
more services to support children with ASD. Furthermore, these rates should not 
be compared since the diagnostic criteria, as stated in the different versions of the 
DSM have changed over time 3,7–9.  
The male to female ratio for ASD diagnosis is 4:1. Females diagnosed with ASD are 
more associated with intellectual impairments, suggesting females with ASD 
might be underdiagnosed because of better intellectual coping strategies. In 
general there is a high co-occurrence of ASD with intellectual impairments (70-
80%) 3,7. 
ASD can’t be “cured”, but can be supported. Currently the only scientifically based 
and recommended treatment is applied behavior analysis therapy, which is a non-
medical treatment based on behavioral principles 10,11.  
1.1.2. Phenotypic heterogeneity and co-occurring disorders 
As stated in the DSM-5 the symptoms of ASD can range from mild to severe 
through three levels, depending on the support that is needed 3. ASD can be 
associated with (mono-)genetic disorders or medical conditions, like epilepsy 3. 
About 70-80% of individuals with ASD have a co-occurring mental or 
developmental disorder 3,6,12. ASD can be, but is not always, accompanied by 
intellectual disability (18%) and/or language impairments. ADHD/ADD (21%), 
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epilepsy (25%), sleep problems (60%) and gastro-intestinal problems (45%) often 
co-occur with ASD. Macrocephaly is reported in 20% of the ASD population, but 
more contradictory findings exist for macrocephaly described in adults compared 
to observations of macrocephaly in children 3,9,12–14. A young child is often 
diagnosed with ASD because of the presence of these co-occurring 
disorders/symptoms, but would still be diagnosed as having ASD only 15. However, 
taking these co-occurring disorders into account when diagnosing can be 
important for improving treatment, since some of the observed symptoms might 
not be due to ASD. Furthermore, a complete diagnosis can be important for 
research to improve the signal-to-noise ratio when studying specific groups of ASD 
patients 16. These co-occurring disorders might even have a common underlying 
cause. To support a complete diagnosis, the DSM-5 now specifically advises to 
assess possible co-morbidities and environmental factors (e.g. very low birth 
weight, exposure to valproate) 3.  
On the other hand these co-occurring disorders might also mask ASD symptoms 
during early childhood and result in no or a late diagnosis of ASD 12.  
1.1.3. The neurobiology of ASD 
The macrocephaly found in one fifth of the ASD population may be associated 
with increased cell number and size or impaired developmental cell death 17. 
During early childhood the brain volume seems to be increased by 5-10% with 
greater increases in white matter compared to grey matter, but it is not clear if 
this persists into adulthood 18. Several, but not all, brain regions have been 
analyzed in a few post mortem studies 17,19,20. However, in these post mortem 
studies causal differences in neuroanatomy cannot be distinguished from 
secondary, compensatory or downstream differences. Alterations in the 
cerebellum, amygdala, hippocampus, limbic system, brainstem and brain cortex 
have been described. A decrease of Purkinje cell density in the cerebellum of 
people with ASD seems to be one of the re-occurring findings. Studying patients 
with lesions in the cerebellum, show the cerebellum is not only important for 
motor functions, but is also involved in attention, cognition, language and 
imitation 19,21.  
Studies looking at functional connectivity in the brain currently suggest high local, 
short-range connectivity and decreased long-range connectivity 22. This 
connectivity hypothesis could be the result of prenatal developmental defects, 
like neural migration, and/or postnatal developmental defects, like dendritic 
development and synaptogenesis 23. 
However, since a lot of studies describing neuroanatomy in ASD were done on 
patients with co-occurring disorders, like mental retardation or epilepsy, more 
studies are needed to unravel ASD-specific brain abnormalities 18. The existing 
anatomical heterogeneity did not lead to a large contribution in unravelling the 
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etiology of ASD. Therefore, researchers are focusing more on genetics to gain 
more insights 24. 
1.1.4. The heterogeneous etiology of ASD: nature vs. nurture 
In the period following the first description of ASD by Dr. Kanner and Dr. Asperger 
in the 1940s, the mother’s frigid behavior was thought to cause the autistic 
behavior of a child 4,5. Thanks to twin and family studies, this nurture hypothesis 
of “Refrigerator mothers” was replaced by a nature hypothesis, namely genetic 
causality. In monozygotic twins the concordance rate for ASD is higher (47-88%) 
compared to dizygotic twins (14-31%). These twin studies find a high genetic 
influence and a moderate nonshared environmental influence, the latter 
explaining the less than 100% concordance for ASD in monozygotic twins 25,26. 
Furthermore, in families the probability of a second sibling being diagnosed with 
ASD is 12% when the first sibling has ASD, compared to 1.3% when there’s no ASD 
sibling in the family 27. If there are multiple children (at least two) with ASD in the 
family, the recurrence risk is 30% 28.  
This evidence for a genetic basis has led to linkage and association studies, 
mutation screenings, genome scans and chromosomal rearrangement analyses 24. 
These studies have shown that copy number variations can be found in 10% of the 
ASD population 28. Another 10% of individuals with ASD have an identifiable 
monogenic disorder, like tuberous sclerosis or the fragile X syndrome, referred to 
as syndromic ASD 11. A higher rate of de novo mutations in ASD patient population 
(13.8%) compared to controls (7.1%) has been described 29. These genetic studies 
have discovered rare causal genes, causal syndromic genes, risk genes and 
chromosomal regions containing autism susceptibility loci 24. 
Now, 30-40% of individuals with ASD have a ‘known’ genetic etiology. However, 
between 200-1000 genes are implicated in ASD and the most commonly affected 
chromosomal loci still account for only 1% of the total ASD population, pointing to 
a large genetic heterogeneity underlying ASD 28,30. This makes the search for a 
unifying etiology very difficult and raises the question if many different 
mechanisms may underly different subgroups within the ASD spectrum. 
Furthermore, copy number variations found to be causal in some studies, still 
encompass a range of candidate genes of which it is difficult to distinguish which 
gene is really causal for ASD. Since ASD is characterized by a large phenotypic and 
genetic heterogeneity, it has been suggested not to refer to it as a single disorder 
but as ‘the autisms’ 23. Another starting point to unravel this complexity would be 
to distinguish ‘ASD only’ from ASD with co-occurring disorders, because many of 
the ASD-implicated genes are not unique for ASD 9. This is supported by the 
Autworks database, where several disorders significantly share several implicated 
genes with ASD (Fig 1.2) 31. Oligogenic, polygenic or multifactorial mechanisms 
might play a role in the cases of idiopathic ASD 30,32. 
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Figure 1.2: Disorders with significantly common genes shared with ASD 
A network shows disorders that have a significant amount of common genes with autistic 
disorder/ASD. The p-value is shown. These results were obtained from the Autworks 
database 31. 
 
The lack of complete concordance for ASD in monozygotic twins is predicted to be 
caused by environmental factors, such as fetal exposure to the anticonvulsant 
valproate or the immunomodulatory drug thalidomide 9,33,34. In addition a novel 
field of research is expanding, which also supports the interaction between 
genetics and the environment, namely epigenetics. ‘Epigenetics’ refers to the 
study of heritable phenotypes caused by other mechanisms than changes of DNA 
sequence, like DNA methylation, chromatin modification or RNA-mediated 
silencing (microRNAs). Since these studies are still in its infancy, it remains to be 
explored whether epigenetics might unravel etiologies in part of the 60-70% of 
ASD cases that are still called idiopathic and even more how the environment can 
influence epigenetic changes 24,35.  
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1.1.6. Protein networks implicated in ASD 
Although there is a large genetic heterogeneity within ASD, it might be that these 
different genes are part of the same protein signaling networks. Disorder-linked 
proteins are more likely to have direct protein interactions with each other, than 
be isolated in a network 36. The number of direct protein-protein interactions (PPI) 
was higher than expected for ASD-implicated proteins 36,37. So despite a large 
genetic heterogeneity with little overlap, ASD-implicated genes might converge on 
important key pathways 30. Several bioinformatics analyses (functional 
annotations, co-expression analyses, PPI analysis and mouse model phenotypes) 
have been performed to discover protein signaling networks implicated in ASD, 
starting from known ASD (candidate) genes. This approach has identified several 
pathways or molecular mechanisms. The main biological processes seem to be 
synaptic function, neurite outgrowth, axon guidance and cellular transport 29,36–44. 
Although most attention in ASD research goes to synaptic function, analysis with 
emerging technologies, like whole exome sequencing, also find chromatin 
remodeling and transcription regulation as enriched processes, which will need 
further consideration 29,37–39,41–43. In addition, an analysis of 6 independent 
genome-wide association studies found 10 A-kinase anchoring proteins (AKAP) to 
be associated with ASD. These proteins could be interesting targets because they 
regulate several of these biological processes 40. Furthermore they suggest a 
contribution of PKA signaling to the pathogenesis of ASD. 
Although these converging biological processes, like synaptic function and neurite 
outgrowth, support the connectivity hypothesis at a higher level, they are not 
specific to ASD etiology only. Many of these networks show overlap with epilepsy, 
schizophrenia and/or intellectual disability 29,44.  
Several ASD-associated proteins contribute to multiple mechanisms during 
different phases of neuronal development. Therefore it is crucial to determine the 
space-time window for the development of ASD. Four studies looked at the 
spatial-temporal window of expression of ASD-implicated genes in humans and all 
had prenatal cortical development in common. This also converges with the 
neuroanatomical findings mentioned above 39,42,45. 
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1.1.6.1. Synaptic function and transmission 
ASD-associated mutations in the X-linked genes Neuroligin (NLGN) 3 and 4 helped 
to pave the way for linking defects in synaptic function to ASD. They encode 
postsynaptic cell adhesion proteins that bind to presynaptic neurexin proteins in 
order to form a functional activity-dependent synaps 46. They were also the first 
genes found to contribute to non-syndromic ASD. Several other postynaptic 
proteins, like the scaffolding proteins SHANK2 and SHANK3, were found to be 
mutated in ASD cases as well. These scaffolding proteins bind to NLGNs 
intracellularly. In addition, presynaptic proteins, like the NLGN ligand Neurexin1, 
were found to be mutated in ASD cases as well 29. 
NLGNs, and their binding partners, are important for the formation of functional 
synapses. An ASD-associated mutation in NLGN3 resulted in an in vivo imbalance 
in the excitatory/inhibitory neurotransmission 47,48. The popular hypothesis that 
an excitatory/inhibitory imbalance might cause ASD is supported by frequent co-
occurring disorders and symptoms, like epilepsy and sensory hypo-
/hypersensitivity. In addition, this imbalance could also be observed in other 
autism mouse models, as reviewed in 49. 
The hypothesis of excitatory/inhibitory imbalance also suggests an important role 
for the excitatory glutamatergic and inhibitory γ-aminobutyric acid (GABA) 
neurotransmitter signaling. Loss of function of Fragile X mental retardation 
protein (FMRP), an RNA-binding protein, is the most prevalent cause of 
(syndromic) ASD co-occurring with the fragile X syndrome and leads to an 
excitatory/inhibitory imbalance in the Fmr1-/- mouse model. The GABAergic 
system is downregulated in these mice. Defects of FMRP cause decreased binding 
and thus decreased stability of its mRNA targets, like the GABAA receptor subunit 
mRNA 50–52. In general, GABAA receptor subunit expression seems to be decreased 
in cortical and cerebellar regions of individuals with ASD 53. In addition genetic 
studies found an association between ASD and polymorphisms in the GABAA 
receptor β3-subunit gene and several glutamate receptor subunit genes (GLUR6, 
GRM8 and GRIN2A) 38,39,41,54–57.    
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1.1.6.2. Neural (out)growth and migration 
We already discussed macrocephaly in the ASD population. In line with this, ASD 
networks also seem to contribute to neural (out)growth and migration 36–38,40. 
PTEN (phosphatase and tensin homolog), TSC1 (tuberous sclerosis complex 1), 
TSC2 and NF1 (neurofibromin) are all tumor suppressor genes that have been 
associated with (syndromic) ASD 58,59. These genes, together with other ASD-
associated genes, are enriched in the PI3K/AKT/mTOR pathway. This pathway can 
be activated by metabotropic glutamate receptor signaling, but also by insulin-like 
growth factor 1 (IGF-1) and is important for cellular proliferation and 
differentiation. Controversially, altered IGF-1 levels have been reported in 
cerebrospinal fluid, plasma or urinary excretion of individuals with ASD 60,61. 
Reelin (RELN), another ASD candidate gene, the ASD-associated gene LAMB1 
(laminin β1) and FMRP are important for neuronal migration and positioning 
during brain development 29,51,62,63. Recently, a boy with a duplication containing 
RELN was described with ASD, seizures and neuronal migration disorder 64. In 
Fmr1-/- mice a defect of multipolar to bipolar transition of newly generated 
neurons, causes a defect in neuronal migration. Neuronal migration can be 
regulated by the Wnt signaling pathway (CTNNB1, DVL, AXIN1, DVL1/2/3, Rac1, 
JNK, …), which has also shown to be associated with ASD 44,65,66. This is a complex 
pathway, not only regulating neuronal migration and brain development, but 
synaptic function as well. During development, the Wnt signaling pathway is 
intertwined with the Notch signaling pathway. Limited evidence exists that the 
Notch signaling pathway also plays a role in ASD. Three ASD cases have been 
described with mutations in Notch receptor ligands (DLL1 and DNER) or in a 
modulator of Notch activity (LFNG) 37,67,68. Two ASD network analysis studies not 
only found an enrichment of the Wnt signaling pathway, but also the Notch 
signaling pathway 29,69. Lastly, two gene expression analysis studies of ASD blood 
samples found the Notch pathway to be dysregulated as well 70,71. Further 
research is needed to explore if an interplay between the Notch and Wnt signaling 
pathway might be implicated in the etiology of ASD, at least in a subgroup of 
cases 68. 
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1.1.6.3. Cellular transport and the cytoskeleton 
Enrichment analysis of ASD-associated genes also picks up the terms cytoskeletal 
regulation and/or intracellular transport 29,36,65,72. TSC1 and TSC2 are known to 
modulate the actin cytoskeleton, which affects neuronal morphology and cell 
migration 73.  SHANK3 interacts with anchoring proteins, the actin cytoskeleton 
and glutamate receptors, but also several actin regulators. Postsynaptic glutamate 
receptor delivery has shown to be dependent on SHANK3-mediated actin 
dynamics 74. In addition, specific ASD-linked GTPases (RAB39B and RAB11FIP5) 
support a role for vesicular trafficking of proteins 75. Lastly, not only the actin, but 
also the tubulin network can be implicated in ASD (TUBB2A, TUBA1A and TUB-
GCP5) 37,76. 
In summary, modulation of the cytoskeleton can affect the development of the 
central nervous system at multiple levels: cell migration, neuronal morphology 
and neurite outgrowth, receptor and protein trafficking 77.  
 
1.1.6.4. Chromatin remodeling and regulating transcription 
Histone-modifying genes, including many members of the histone lysine 
demethylation family (KDM4B/5B/6B) and BRG1- and BRM-associated factor 
(BAF) subunits, seem to be implicated in ASD 29,78. They can regulate the 
development of the brain by remodeling chromatin, causing an altered expression 
of important genes. Neurons need a chromatin remodeling BAF complex 
containing other BAF subunits than the BAF complex in neural precursor cells. A 
defect in this subunit switch can cause prenatal problems with neurogenesis, but 
can also result in postnatal defects in synaptic functioning 39,78. All described ASD 
cases with mutations in chromodomain helicase DNA-binding protein 8 (CHD8) 
had macrocephaly. BAF subunits and CHD8 converge in regulating Wnt/β-catenin 
target genes and it has been shown that stabilized β-catenin expression results in 
a brain overgrowth phenotype  29,37,39,41,43,78. 
ASD-associated transcription regulation is mediated by transcription factors like 
engrailed 2 (EN2). EN2 is a homeobox transcription factor important for 
neurogenesis and cerebellar and brainstem development. EN2 knockout mice 
have less Purkinje cells, similar to the post mortem studies of ASD patients 32,77,79. 
Other associated transcription factors are FOXP2 (neuronal development and 
functioning), PAX5 (neuronal development) and ADNP (neuronal cell 
differentiation and maturation) 37,38,41,43,80.  
Since these chromatin remodelers and transcription factors can affect the 
expression of multiple target genes, more studies are now focusing on gene 
expression profiling of ASD individuals. 
However, it should be noticed that the proteome of an individual is also regulated 
at the (post-)transcriptional level. The ASD-associated proteins FMRP and RBFOX1 
are both RNA-binding proteins. FMRP mediates mRNA stability and represses 
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translation, while RBFOX1 regulates alternative splicing. RBFOX1 has also been 
implicated in other neurological disorders like schizophrenia and intellectual 
disability. The expression of RBFOX1 changes during brain development, which is 
paralleled by splicing changes. There is a significant overlap between RBFOX1 
target genes and autism-susceptibility genes, as well as FMRP target genes 29,38,81–
83.  
Lastly, loss of function of the ubiquitin-ligase UBE3A plays a role in development 
of Angelman’s syndrome, which shows autism-like features. A role for the 
ubiquitin pathway, regulating protein degradation, is further supported by 
additional ASD-linked ubiquitin-ligases encoded by MIB1, RNF8, PARK2, RFWD2 
and TRIP12 9,29,43,84. 
 
1.1.6.5. AKAP proteins modulate cAMP/PKA signaling 
In neurons, cyclic adenosine monophosphate (cAMP) is an important second 
messenger for neuron outgrowth, synaptic transmission, long term changes, 
transcription and cytoskeleton regulation. The principal enzyme activated by 
cAMP is protein kinase A (PKA), a serine/threonine (S/T) kinase. PKA is a 
heterotetramer consisting of 2 catalytic and 2 inhibitory regulatory subunits. 
When cAMP levels rise in the cells, two cAMP molecules will bind to each 
regulatory subunit, resulting in a release and subsequent activation of the 
catalytic subunits (Fig 1.3) 85. 
PKA recognizes a consensus sequence (-R-R-X-S/T-X-), which can be found in many 
proteins. Nonetheless, phosphorylation happens in a very specific and strictly 
regulated manner. PKA-mediated phosphorylation can be regulated on different 
levels. There exist two classes of regulatory subunits, RI and RII, with different 
sensitivity to cAMP levels and different subcellular localizations. The main 
function of regulatory subunits is to keep the catalytic subunits of PKA inactive. 
The second function is to determine the subcellular localization of the PKA 
catalytic subunits. RI subunits reside mostly cytoplasmic, while RII subunits are 
often associated with organelles and other cellular structures. The specific 
localization of the PKA holoenzyme, can be regulated by the binding of RII 
subunits to A-kinase anchoring proteins (AKAPs). AKAP proteins are functionally 
related and share a common α-helical PKA RII binding domain or A-kinase 
anchoring protein domain. Their expression and subcellular localization is 
member-specific. The expression can be ubiquitous or cell-type specific, and the 
localization can be, amongst others, the Golgi-complex, the cytoskeleton, the 
nucleus and the mitochondria. Depending on cAMP levels, R subunit class and 
bound AKAP member, PKA will actively phosphorylate different substrates that 
are in close proximity 85–87. 
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AKAPs are known to bind several proteins, protein phosphatases and other 
protein kinases, forming different combinations of signaling complexes and very 
tightly regulating local phosphorylation levels. Even some PKA substrates bind to 
AKAPs, bringing them in closer proximity to PKA 85–87. 
Several AKAP genes have been associated with ASD (AKAP5, AKAP7, AKAP8, 
AKAP9, AKAP10, AKAP11, AKAP13, MAP2, MSN and NBEA). In addition, five of 
these AKAPs are targets of differentially expressed microRNA’s in ASD patients 40. 
This shows cAMP/PKA signaling is important in ASD etiology and AKAPs might be 
the link between different ASD-implicated biological processes (as discussed in 40). 
 
 
Figure 1.3: AKAPs regulate cAMP/PKA signaling. 
Prototypically, AKAPs are associated with organelles or cytoskeletal components. AKAPs 
can bind to PKA substrates and bind the regulatory subunit (R) dimer of the PKA 
holoenzyme. When cAMP rises in the cell and four cAMP molecules bind to R, the PKA 
catalytic subunits are released (C). These subunits will become active and will 
phosphorylate (P) PKA substrates in close proximity. 
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1.2. The Neurobeachin gene 
Partially adapted from 88: 
Creemers JWM, Nuytens K, Tuand K: Neurobeachin Gene in Autism. In 
Comprehensive guide to autism. Edited by Patel VB, Preedy VR, Martin CR. New 
York: Springer New York; 2014:825–844. 
1.2.1. NBEA is a candidate gene for autism spectrum disorders 
The human NBEA gene, also known as BCL8B or LYST2, is present on chromosome 
13q13.2. It consists of 58 exons spanning 730 kb of the genome and encodes a 
transcript of 10.8 kb 89,90. Within this 730 kb region, a common fragile site 
(FRA13A) of 650 kb can be found, spanning exon 34 to 40 90. Common fragile sites 
(CFS) range from just under 1Mb to over 10Mb, are present in every individual 
and are prone to chromosomal breakage under replication stress. Transcription of 
large genes (> 1 Mb) in the CFS can take so long that it will interfere with DNA 
replication and cause genomic instability in this region 91. Several of these fragile 
sites have shown to be implicated in neurological disorders 92–94.  
The NBEA gene was first described as an ASD candidate gene in a boy with a de 
novo balanced chromosomal translocation t(5;13)(q12.1;q13.2) 95. This boy with 
ASD has no family history of ASD or other psychiatric disorders. He has no mental 
retardation, nor did he show physical abnormalities. Already during childhood 
there was no joint attention, insistence on sameness and an obsession for music. 
At the age of three he did not speak for a year, had a delayed development of 
gross motor skills and handflapping was observed. The breakpoint of the 
translocation is located in intron 2 of NBEA, which results in haploinsufficiency of 
NBEA, but does not disrupt the MAB21L1 gene nested within intron 41 of the 
NBEA gene (Fig 1.4A). No gene was disrupted on chromosome 5. The co-
occurrence of this de novo disruption of the NBEA gene with the incidence of ASD 
in a patient without a family history of ASD, makes NBEA an interesting candidate 
gene 95,96. Two deletions, one duplication and even one common associated SNP 
within the NBEA gene have been found in ASD patients (Fig 1.4A) 97–100. Although 
NBEA contains many conserved domains, the ASD-implicated mutations only 
affecting the NBEA gene are not clustered in any of these domains. Only one 
deletion seems to affect the Concanavalin A-like lectin domain 98. Furthermore 
several deletions or duplications encompassing the NBEA gene are found in 
patients with ASD or intellectual disability, but here other genes could be involved 
as well (Fig 1.4B) 101–104. 
The NBEA gene lies between two ASD-linkage peaks on chromosome 13 
(MMLS/het score of 2.3 between markers D13S217 at 17.21cM and D13S1229 at 
21.51 cM) (Fig 1.4B). In addition three microRNA’s (mir-93, -106B and -211) that 
were repeatedly implicated in ASD etiology were predicted to downregulate NBEA 
expression 40,105. The microRNA 106B was also significantly downregulated when 
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unrestricted somatic stem cells were induced into neural differentiation, together 
with 6 other microRNAs (mir-137, -17, -18a, -218, -138 and -19a) that also had 
NBEA as a common, validated target 106. 
Finally, loss of function of the ASD-associated FMRP protein causes destabilization 
of many mRNA targets, of which the GABAA receptor subunit mRNA has already 
been discussed, or can increase localized translation of mRNA targets. A big 
screen for FMRP mRNA targets also picked up NBEA mRNA as one of the FMRP 
targets 107. 
 
 
Figure 1.4: NBEA is an ASD candidate gene. 
(A) As shown on the legend, the described balanced chromosomal translocation, two 
deletions, one SNP and one duplication in the NBEA gene are shown that have been 
observed in five different patients with ASD. The vertical lines represent the exons of 
NBEA with their corresponding exon number. (B) The location of the NBEA gene on 
chromosome 13 is shown, together with an ASD-linked chromosomal region. Four and two 
ASD patients have been described with a deletion (black bar) or duplication (white bar) 
encompassing NBEA, respectively. This figure was adapted from 88 and shows data 
obtained from 95,97,98,101–105. 
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1.2.2. NBEA is implicated in cancer, obesity and bipolar disorder with 
migraine 
CFS are instable genomic regions, that often contain large genes and thus are 
prone to deletions, translocations and other alterations 108. NBEA, residing in 
FRA13A, is also a target of translocations and recurrent interstitial deletions in 
multiple myeloma 109,110. The deletions of NBEA always coincided with a mono-
allelic deletion in the known RB1 tumor suppressor gene. The fact that no 
alteration could be found in the RB1 gene on the second allele, suggests an 
important contribution of the NBEA deletion to tumor development 109. NBEA is 
one of the six large genes in a CFS, that showed a decreased expression in tumors 
of patients with (a subtype of) head and neck cancer. Head and neck tumors with 
a decreased expression of these six CFS large genes had a higher risk of tumor 
recurrence. Two of these six CFS large genes are known tumor suppressors, which 
suggests NBEA will be a tumor suppressor as well. 91,108. This is supported by 
decreased NBEA expression in breast, ovarian, endometrial and brain cancer cell 
lines 111. 
Two intronic SNPs in the NBEA gene were associated with BMI in a cohort of 
overweight adult men. This was consistent with the finding that NBEA can 
regulate energy balance in mice at the level of the neural circuitry (see below) 112. 
Bipolar disorder is characterized by alternating phases of elevated and lowered 
mood with peaks of psychosis and severe depression, respectively. Since the 
prevalence of migraine in bipolar disorder is 2-3 times higher than in the general 
population, a genome-wide association study was performed comparing patients 
with or without co-morbid migraine. An intronic SNP in the NBEA gene was a risk 
factor for migraine in patients with bipolar disorder, but the NBEA locus was not 
associated with bipolar disorder or migraine alone. However, this finding could 
not be replicated in a smaller sample group 113. 
Taken together, haploinsufficiency of NBEA is not only a risk factor for ASD, but 
also for other polygenic disorders with a behavioral phenotype, like obesity, or 
even cancer, depending on the set of additionally mutated risk genes 112. 
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1.2.3. Neurobeachin is a multi-domain scaffolding protein 
N-terminally, NBEA contains a Concanavalin A-like lectin (CALL) domain flanked by 
Armadillo (ARM) repeats (ACA domain module) (Fig 1.5). The CALL domain 
consists of a typical fold of 3 β-sheets in a β-sandwich structure. Lectins in general 
are known to bind carbohydrates. The CALL domain shows a significant similarity 
with the N-terminal heavy chain domain (HCN) of clostridial neurotoxins, like 
botulinum and tetanus neurotoxin 114. These neurotoxins impair synaptic vesicle 
release through proteolysis of their fusion machinery. Their HCN or CALL domain is 
suggested to function in intracellular sorting of the neurotoxin 115.   
The ARM repeats flanking the CALL domain consist of 42 amino acids forming a 
platform of three helices, mediating many protein interactions 114,116. Several ARM 
repeat proteins interact with the cytoskeleton. The ARM repeats can bind to the 
cytoplasmic tail of Cadherin proteins, which are important for cell adhesion and 
are in close cooperation with the cytoskeleton 116.  
In addition, NBEA contains an AKAP domain, characterized by its secondary 
structure: an amphipathic α-helix, with hydrophobic residues along one face and 
charged residues along the other 86,117. This domain can bind with high affinity to 
the regulatory RII subunit of PKA. The role of NBEA as being an AKAP will be 
discussed below. 
A domain of unknown function (DUF1088) is only found in NBEA and its paralog 
LPS-responsive beige-like anchor protein (LRBA). It is suggested that this domain 
represents a specific, yet unknown function only shared by these two proteins 118. 
NBEA belongs to the family of BEACH proteins because it contains a beige and 
Chediak-Higashi (BEACH) domain, consisting of 280 amino acids and highly 
conserved between at least 10 distinct mammalian gene products 118,119. All 
members of the BEACH family are large proteins (>100 kDa) and are thought to be 
implicated in (membrane) trafficking 118. In humans, nine BEACH-containing 
proteins have been identified, of which five already have been associated with a 
neurological phenotype (Table 1.1). Recently, a second BEACH protein has been 
associated with ASD, namely WD repeat and FYVE domain containing 3 (WDFY3, 
also known as ALFY) 29,120–123. WDFY3 also contains a PH-like-BEACH-WD40 domain 
module, like NBEA, but no AKAP, nor ARM domains. WDFY3 contains a CALL 
domain as well, but with very low sequence identity compared to the CALL 
domain of NBEA. Unlike NBEA, WDFY3 has been categorized into the transcription 
regulation network implicated in ASD 29.  
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Table 1.1: Clinical features of human BEACH proteins.a 
BEACH 
protein 
Associated disorders Neurological 
phenotype 
Reference 
NBEA Autism spectrum disorder Yes 95,97,98 
LRBA Immunodeficiency with 
autoimmunity 
No 124 
LYST Chediak-Higashi syndrome Yes 125 
NBEAL1 Glioma Yes 126 
NBEAL2 Gray platelet syndrome No 127–129 
WDFY3/ALFY Autism spectrum disorder Yes 29,121–123 
WDFY4 Systemic lupus erythematosus No 130 
NSMAF/FAN / / / 
WDR81 Cerebellar ataxia, mental 
retardation and quadrupedal 
locomotion syndrome (CAMRQ2) 
Yes 131 
a Adjusted from 118. 
NBEA: Neurobeachin; LRBA: LPS-responsive beige-like anchor protein; LYST: Lysosomal 
trafficking regulator; NBEAL1: NBEA-like 1; NBEAL2: NBEA-like 2; WDFY3/4: WD and FYVE 
domain containing 3 or 4; ALFY: Autophagy-linked FYVE protein; NSMAF: Neutral 
sphingomyelinase (N-SMase) activation associated factor; FAN: Factor Associated with N-
Smase activation; WDR81:WD repeat domain 81 ; CAMRQ2: cerebellar ataxia, mental 
retardation, and quadrupedal locomotion syndrome 
 
The BEACH domain is preceded by a Pleckstrin Homology-like (PH-like) domain, 
with a secondary structure highly similar to the PH domains, but with a low 
sequence homology. PH domains can bind to phosphatidylinositol lipids through 
two binding sites, which in NBEA are blocked by the BEACH domain and by an α-
helix. Therefore it is suggested that the PH-like domain of NBEA cannot bind to 
phospholipids 132,133. Based on their crystal structures there is a tight interaction 
between the PH-like and the BEACH domain, which was confirmed by biochemical 
assays. The groove that is found between the PH-like and the BEACH domain 
might facilitate interactions with other proteins 132.  
C-terminally, the BEACH domain is followed by the WD40 domain containing 
seven repeats of 40 amino acids, ending in the dipeptide Trp-Asp (WD40 repeats). 
WD40 domains mostly mediate PPI and are involved in scaffolding, cooperative 
assembly and regulation of dynamic subunit complexes 134. The surrounding 
sequences contribute to the specificity of WD40 proteins.  
With the exception of the WD40 domain, the amino acid sequences of BEACH 
proteins are unique, which makes it difficult to deduce their function based on 
their secondary structure 132.  
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Figure 1.5: NBEA is a large multi-domain protein. The domain structure of NBEA is shown, 
consisting of a Concanavalin A-like lectin domain (C) flanked by Armadillo repeats (A) that 
might be important for subcellular localization and protein-protein interactions (PPI). The 
AKAP domain can bind to the RII subunit of PKA. C-terminally NBEA contains a big domain 
module comprising the DUF1088-PH-like-BEACH-WD40 domains (DPBW). DPBW is 
thought to be important for (membrane) trafficking and PPI. AA = amino acids 
1.2.4. Brain-enriched NBEA is mostly expressed in a punctate manner 
near the trans-Golgi 
In Homo sapiens NBEA mRNA is consistently highly expressed in the brain, but 
also in the thymus, spleen and the ovaries or testis and prostate. Lower 
expression is observed in heart, kidney, pancreas, colon and small intestines. 
Placenta, lung and liver do not express NBEA at all 89,95. Based on expressed 
sequence tags (ESTs) from human tissues, NBEA ESTs seem to be enriched in 
neural and endocrine tissues 117. In the human brain the highest expression of 
NBEA mRNA can be found in the cerebellum, amygdala, hippocampus, thalamus 
and the cerebral cortex, specifically in the occipital and frontal lobe. These brain 
regions are all regions that still undergo plasticity in adulthood 89.  
Nbea was detected with RNA in situ hybridisation to be expressed from E11.5 in 
murine embryos. More specifically Nbea was expressed in the midbrain, branchial 
arches, limb buds, otic vesicles, somites, eyes and neural tube 95,96,135. In adult 
mouse tissue, Nbea mRNA was highly enriched in the brain, the cerebellum and 
the pituitary and also showed expression in endocrine tissues, similar to human 
NBEA 117,135. In postnatal brain Nbea mRNA is the highest during the neonatal 
period and declines until 50% during the first 25 postnatal days 117. 
In neurons and neuro-endocrine cells, NBEA is expressed in a punctate manner 
throughout the cell body, often co-localized with TGN38, a Golgi marker. Often 
NBEA-positive perinuclear ribbons or clusters are described. In neurons NBEA is 
also expressed in the dendrites, while it was rarely detected at the pre-synaps 
117,136–138. Depolarization of neurons mainly caused a dispersion of the punctate 
NBEA staining in the dendrites. Furthermore, the N-terminus of NBEA is important 
for its subcellular localization, since a deletion of this part in NBEA causes a diffuse 
staining pattern 137. This supports the role for the CALL domain in the subcellular 
localization of NBEA.  
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Immuno-electron microscopy for NBEA shows NBEA at the cytosolic side of 
vesicular and tubular intracellular membranes, consistent with the absence of a 
signal peptide. NBEA-positive vesicle clusters were often detected at the trans 
side of Golgi stacks. Reactivity was also seen on buds of the plasma membrane 
and occasionally on extensive endomembrane fields 117.  
Co-localizations between NBEA and different membrane markers have been 
assessed to discover with which tubulovesicular membranes NBEA can be 
associated, but often no significant co-localization was observed 117,138. The 
perinuclear ribbons of NBEA did partially co-localize with Giantin, a Golgi marker 
important for spatial Golgi organization and Golgi anterograde cargo transport 
117,139. Treating neuroendocrine cells (PC12 cells) with aluminum fluoride, which 
disperses the Golgi apparatus and redistributes Golgi markers and the 
microtubule cytoskeleton towards the microtubule organizing center, caused a 
similar redistribution of perinuclear NBEA. This suggests a functional or physical 
link between perinuclear NBEA and the Golgi-network or the microtubuli 117. 
Subcellular fractionation studies of mouse NBEA suggest NBEA is mainly a 
cytosolic protein, but a subpool is firmly bound to a cytoskeletal-like subcellular 
fraction 117.  
Coat proteins involved in vesicle budding at the (trans-)Golgi network are 
associated with these membranes in a GTPase-dependent manner. When 
Brefeldin A is used to block GDP-to-GTP exchange in PC12 cells, perinuclear NBEA 
is dispersed very quickly. This suggests NBEA is part of a vesicle-coat complex, but 
distinct from the known vesicle-coat proteins 117. 
1.2.5. Nbea murine knockout and heterozygous phenotype 
Nbea, the mouse homolog of NBEA, resides on chromosome 3 and thus shows a 
new region of homology between mouse chromosome 3 and human chromosome 
13 119. Two Nbea knockout mouse models have been generated. The GH240B 
Nbea mouse model was a result of the disruption of the Nbea locus in intron 1 by 
a random anti-sense insertion of a supposedly non-expressing transgene, 
containing a minimal genomic fragment of human growth hormone 135,140. The 
insertion of a gene-trap vector into intron 6 of Nbea resulted in the gene-trap 
Nbea mouse model 141. 
In both mouse models a homozygous loss of Nbea causes perinatal death, due to 
asphyxia 135,141. This results from a paralysis of the respiratory muscles 135. The 
cytoarchitecture of the brain and the neuromuscular junction of Nbea-/- mice 
showed no gross abnormalities. In addition no differences were found in synaptic 
vesicle number at the neuromuscular junction (NMJ). In the NMJ, NBEA is 
essential for nerve-evoked presynaptic vesicle release. NBEA loss did not have any 
effect on the vesicle release machinery, since spontaneous vesicle release was 
normal. Possibly NBEA regulates NMJ nerve-evoked vesicle release by affecting 
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action potential invasion in the nerve terminal or by coupling the action potential 
invasion to vesicle secretion, through regulation of Ca2+ levels 135.  
In the brainstem and in hippocampal cell cultures of gene-trap Nbea KO mice a 
significantly decreased frequency of spontaneous and miniature excitatory 
postsynaptic currents (sEPSCs and mEPSCs) is observed, while their amplitude is 
unchanged. This suggests a presynaptic role for NBEA on vesicle release 141,142. The 
rise- and decay-time of mEPSCs in hippocampal Nbea KO cultures were faster, 
pointing to a postsynaptic effect for NBEA as well 142. When studying inhibitory 
synapses, Nbea knockout not only decreased the frequency, but also decreased 
the amplitude of spontaneous and miniature inhibitory postsynaptic currents 
(sIPSCs and mIPSCs). The inhibitory synapses in the brainstem and hippocampal 
cultures seemed to be more affected by a loss of Nbea compared to excitatory 
synapses and a decrease in amplitude suggests an additional postsynaptic role for 
NBEA 138,141,142. The latter is consistent with the observed expression of NBEA in 
the dendrites of neurons 117,136. When evoking inhibitory postsynaptic currents 
(eIPSCs) in neurons of the Nbea-/- brainstem, no decrease was seen in amplitude, 
nor in frequency, but there was a higher failure rate. This suggests that, similar to 
the NMJ, there is a problem with the coupling between action potential and 
vesicle release. A reduced number of excitatory synapses was observed 141. 
Consistently, a reduction of excitatory spinous synapses was observed in 
hippocampal gene-trap Nbea-/- cultures. Fewer spines are present on excitatory 
dendrites, but the present spines have a normal morphology. In addition, the 
diameter of secondary dendrites seemed to be reduced 142. Less synapses were 
formed on spine heads, while an increase in excitatory synapses was found 
between axons and dendritic shafts. Consistent with this, PSD-95 clusters were 
reduced in dendritic spine heads and increasingly present in dendritic shafts 142. It 
was hypothesized that the observed reduction in inhibitory synapses was to 
compensate for the reduction of excitatory axo-spinous synapses 142. 
The Nbea heterozygous mice are viable and fertile 112,143. In the gene-trap model, 
even heterozygous Nbea mice showed a reduction in axo-spinous excitatory 
synapses in neo-cortical tissue, together with a faster rise time of mEPSCs. 
Haploinsufficiency of Nbea did not affect synaptic vesicle numbers, nor the 
establishment of the synaps. Nbea haploinsufficiency will mostly affect the 
postsynaps, while a total loss also affects the presynaptic compartment 142. 
In conclusion, loss of Nbea can lead to pre- and postsynaptic defects, with a 
reduction in spine density and an impaired postsynaptic organization 142. 
However, one study showed that the function of NBEA could only be in the 
postsynaps, since combining a presynaptic Nbea KO neuron with a postsynaptic 
wildtype neuron, did not result in altered post-synaptic currents 138. In general, 
the synaptic release machinery does not seem to be affected in Nbea KO mice 138. 
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The observed dwarfism in the GH240B Nbea+/- mouse could not be validated in 
the gene-trap Nbea+/- mouse. Although this dwarfism can point to a role for NBEA 
in regulated secretion of mouse growth hormone (mGH), this phenotype could 
also be caused by the nature of the mutation in the Nbea gene in these GH240B 
mice 112.  
Behavioral studies of GH240B Nbea haploinsufficient mice revealed an ASD-like 
phenotype, showing increased repetitive behavior and conditioned fear 
responses, reduced social behavior and impaired spatial learning and memory 143. 
A decreased expression of Zif268, an immediate early gene in spatial memory 
formation, was measured in the dorsomedial striatum and the hippocampal CA1 
region of Nbea+/- mice. These two brain regions are both important for spatial 
learning and memory. It was hypothesized that the observed enhanced long-term 
potentiation (LTP) measured in slices of the Nbea+/- hippocampal CA1, could cause 
a saturation, leading to inefficient learning and memory. These mice also showed 
increased BDNF levels in their hippocampus compared to wildtype 143. BDNF is 
important for neural outgrowth and elevated levels of BDNF have been reported 
in ASD patients 144–146. The gene-trap Nbea+/- mice showed increased mean 
locomotion activity, while this was not observed in the GH240B Nbea+/- mice 
112,143. 
In concordance with the obesity-associated SNPs in NBEA, a standard phenotypic 
screening on gene-trap Nbea+/- mice showed these mice were mildly obese. 
Nbea+/- mice tended to overeat when fastened overnight, which could be 
explained by the observed higher expression of hypothalamic, orexigenic gene 
products. The hypothalamus forms an important neural circuit for regulating food 
intake and therefore obesity can also be described as being a neurobehavioral 
disorder. This suggests that Nbea haploinsufficiency in the brain can affect several 
neural circuits 112. 
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1.2.6. Homologs 
Based on their conserved domain structure, homologs of NBEA can provide 
insights into to the function of NBEA as well. The lipopolysaccharide (LPS) 
responsive beige-like anchor (Lrba) gene is a mammalian paralog of Nbea and 
shares a common ancestral gene in Drosophila melanogaster (rugose (Rg) or 
Drosophila AKAP 550 (Dakap550)) and Caenorhabditis elegans (sel-2 or F10F2.1.) 
96. Recently, a homolog of Nbea has also been studied in Danio rerio 147. 
 
The mammalian paralog: LRBA 
 
Although the proteins NBEA-like 1 (NBEAL1) and NBEAL2 are mammalian BEACH 
proteins, LRBA  has the highest homology with NBEA, with a 63% total identity.  
The NBEA/LRBA-like sequence seems to be specific for eukaryotes since at least 
one copy of this sequence can be found in all eukaryotes, but not in prokaryotes. 
NBEA and LRBA both form a highly conserved nested gene pair with MAB21L2 and 
MAB21L1, respectively. These MAB21 homologous genes reside in an intronic 
sequence of NBEA or LRBA and arose from a duplication event. Probably, the 
duplication of this gene locus, which also resulted into a separate Lrba and Nbea 
gene happened during the transition from invertebrates to vertebrates 96,118.  
Structurally LRBA contains the same conserved domains as NBEA, with at least 
70% sequence identity between each corresponding domain, except for the AKAP 
domain. The crystal structure of the LRBA PH-like-BEACH domain module is similar 
to the NBEA PH-like-BEACH domain module, but has to be rotated 4 degrees for 
the best superposition 133. In contrast to NBEA, LRBA is predicted to contain two 
AKAP domains. However, wether or not LRBA is a genuine AKAP protein is still 
controversial. LRBA co-localized with the RII subunits of PKA, but, contradictorily, 
an RII binding analysis did not find any interaction with a LRBA-fragment 117,148. 
However, this LRBA-fragment contained only one of the predicted AKAP binding 
domains, which still makes it plausible that LRBA is an AKAP protein as well 148. 
The DUF1088 domain is only shared by LRBA and NBEA, which may suggest a 
specific function of these two BEACH proteins, not shared by others 118.  
LRBA and NBEA show a strikingly similar expression pattern in human tissue and 
during mouse embryogenesis 96. However, only immunological, but no 
neurological phenotypes have been described following LRBA deficiency 124,149. 
Furthermore, ESTs from human tissue suggest that LRBA is expressed less in the 
brain and shows a broader expression in different tissues, compared to NBEA 
which only has ESTs coming from neural and endocrine tissues 117. There is no 
compensatory increased expression of LRBA in Nbea+/- mice 112,141. 
Like NBEA, the exact molecular mechanisms for LRBA are still unknown. LRBA was 
first described as a LPS upregulated gene in B-cells and macrophages. Because LPS 
stimulation leads to an increased vesicular localization of the LRBA BEACH-WD40-
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GFP fusion protein, LRBA may play a role in polarized trafficking of intracellular 
vesicles towards activated receptor complexes to facilitate polarized secretion 
148,150. Recently, it has been described that LPS-stimulation of mouse bone marrow 
cells can also increase nuclear expression of LRBA 148.  
LRBA is implicated in the development and function of B-cells and regulatory T-
cells 124,149. Common variable immune deficiency patients with LRBA deficiency 
have B-cells that are deficient in autophagy and in their development and 
activation. These cells also show a higher susceptibility to apoptosis 124.  
Furthermore, different cancers show an up-regulation of LRBA, supporting a role 
as a negative regulator of apoptosis 151. In contrast to the potential tumor 
suppressor role of NBEA, LRBA is considered to be an oncogene. Its effect on the 
growth of cancer cells is possibly related to the observed reduction of 
phosphorylated EGFR after EGF stimulation and inhibition of LRBA 151. Sel-2 and 
Rg, shared homologs for NBEA and LRBA, further support a role in the EGFR 
pathway (see below). 
 
Lessons learned from flies, worms and fish 
 
The first AKAP protein identified in D. melanogaster is a homolog for NBEA/LRBA, 
namely Rugose (Rg) or Drosophila AKAP 550 (DAKAP550) 117,152. Rg, like LRBA, 
contains two AKAP domains instead of one 152. The most C-terminal AKAP domain 
has the highest affinity for the PKA RII subunit. Rg is expressed at each stage of 
Drosophila development and in most tissues, but shows an enrichment in anterior 
tissues (head) 152,153. Rg is concentrated apically in polarized cells of the embryonic 
hindgut, trachea and salivary gland 152. This could be in function of polarized cAMP 
signaling 152. There is a high expression in subpopulations of the peripheral and 
central nervous system 152–154. In the larval brain, Rg is expressed in neural cells, 
but not in glial cells 155. Rg generally seems to accumulate in areas of neurogenesis 
154. Subcellularly, a granular, cytosolic staining was described, consistent with the 
expression of mammalian NBEA 152,155. Remarkably, during embryonic 
developmental stages 8-9, a nuclear presence of Rg in neuroblasts delaminating 
from the ectoderm is detected 152.  
Rg expression levels seem to be important for short term memory following 
associative odor learning 155,156. Although the short term memory was affected, 
the long term memory seemed to be intact in Rg mutants 156. Impaired learning 
and memory was also seen in Nbea+/- mice 143.  Rg deficiency did not affect fear 
extinction 157. The mushroom bodies, important for memory formation, showed 
an abnormal morphology, which was dependent on Rg expression during their 
development 155. However, short term memory was still reduced when Rg levels 
were only decreased from adulthood onwards, which was dependent on the 
genetic interaction between Rg and PKA signaling 156. Rg will probably affect short 
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term memory formation both during development of the nervous system and in 
adulthood through PKA signaling.  
Rg mutants have a rough eye phenotype, characterized by a loss of cone and 
photoreceptor cells and a mis-orientation of ommatidia 153,154,158. Eye 
development is regulated by different signaling cascades, like EGFR, cAMP-PKA 
and Notch signaling 153. The tight balance between these signaling cascades 
determines the survival of a cell 158. The rough eye phenotype in Rg mutants is 
enhanced by a mutant of the PKA catalytic domain and by mutants of components 
in the EGFR and the Notch pathway 153,154,158. Since Rg expression is not regulated 
by Notch-mediated transcription, it is suggested that there might be physical 
interactions with components of Notch signaling. Rg mutants did not show an 
altered distribution of the Delta ligand 154. Rg mutants also have an altered 
synaptic architecture, wing vein defects and show an embryonic semi-lethal 
phenotype 153,155.  
Taken together, these phenotypes all point to an important role for Rg during 
embryonic development through an (indirect) interaction with cAMP-PKA, Notch 
and EGFR signaling. 
 
SEL-2, the NBEA/LRBA homolog in C. elegans, is also implicated in the Notch and 
EGFR pathway during the development of vulval precursor cells. This development 
is tightly regulated by endocytosis and trafficking of the LET-23/EGFR and LIN-
12/Notch receptor. EGFR stimulation leads to internalization of Notch in the same 
cell, but also to stimulation of Notch in the neighboring cells. In sel-2 (-) mutant 
cells, there is a higher Notch activity and Notch is also expressed at the 
basolateral surface, instead of only apically. In addition, there seems to be an 
accumulation of EGFR at the cell surface, where it should normally be internalized. 
This points to a role for SEL-2 in endocytic trafficking of these receptors. When 
studying the intestine of C. elegans, sel-2 (-) mutants also showed a slower rate of 
endocytic vesicle delivery to the lysosomes. However, a higher basolateral 
expression of Notch alone does not increase its activity, suggesting that SEL-2 
negatively regulates Notch activity at another level than endocytosis 159. 
 
In Danio rerio, nbea is expressed throughout the nervous system as well. It is 
present in the neuronal cell bodies and in the dendrites in a punctate pattern. The 
nbea mutants lived until days post fertilization 14, but died before reaching 
adulthood.  
The nbea gene came to attention when studying electrical synapses. There are 
two ways of synaptic transmission: chemical and electric. While chemical 
transmission is mediated by synaptic vesicles and neurotransmitter receptors, 
electrical transmission goes through gap junctions between neurons that are 
formed by Connexins. Nbea mutants formed significantly fewer electric synapses, 
while the number of neurons was unaffected. Postsynaptic expression of Nbea 
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was sufficient for recovery of these electric synapses. This postsynaptic expression 
was also essential for expression of Glycine receptors (GlyR) at chemical synapses. 
Nbea was required for maintenance of dendritic fine branching, but did not affect 
the initiation of dendritogenesis, nor did it affect axonal growth. In conclusion, 
nbea is an important postsynaptic regulator of synaptogenesis 147.  
Behavioral studies did not show abnormal behavior, but did detect a general 
lower motility of nbea mutants and lower reactivity. Postsynaptic loss of nbea led 
to decreased chemical and electrical synapses which probably rendered an 
underperforming nervous system 147. 
 
1.2.7. Multifunctional NBEA 
NBEA is an AKAP 
 
The Drosophila homolog of NBEA, Rg, had already been described as being an 
AKAP before the characterization of NBEA started 152. Since NBEA and Rg show 
sequence homology, PKA subunit binding was also assessed for NBEA. The AKAP 
domain of NBEA has a very high affinity for the RIIα (Kd, 10 nM) and RIIβ (Kd, 30 
nM) subunits of PKA, while no binding was found between the AKAP domain of 
NBEA and the RI subunits of PKA. Furthermore, not only the isolated AKAP 
domain, but also full length NBEA co-precipitated with the RII subunit. Increasing 
the intracellular cAMP level in a neuroblastoma cell-line did not affect Nbea 
mRNA expression 117. RIIα is ubiquitously expressed, while RIIβ is expressed in 
brain, adipocytes, the ovaries and the testis. RIIα is found perinuclear, co-
localizing with the Golgi compartment and the trans-Golgi network area. More 
specifically, it co-localizes with microtubule-associated vesicles, while RIIβ is 
localized at centrosomes 160. Although the subcellular expression of RIIα appears 
to be similar to NBEA localization, one study challenged this co-localization 117. 
Since NBEA physically interacts with PKA RIIα, it is plausible that NBEA contributes 
to the perinuclear localization of RIIα. 
In neurons, PKA signaling is important for regulating AMPA receptor activity and 
postsynaptic internalization, affecting long-term potentiation and depression 161. 
At the TGN PKA signaling regulates secretory vesicle formation 162,163. By 
regulating the subcellular localization of PKA, the phosphorylation of PKA 
substrates can be dependent on AKAP function. That NBEA, as an AKAP, 
functionally affects PKA mediated phosphorylation has been shown in endocrine 
β-TC3 cells, where knockdown of NBEA caused a significantly increased 
phosphorylation of the PKA substrate CRE-binding protein (CREB). 
Phosphorylation of CREB increases its transcription activity and this could explain 
the observed increased expression of the CREB target gene Bdnf in the 
hippocampi of GH240B Nbea+/- mice 143. Similar to the GH240B Nbea+/- mice, mice 
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with constitutively active CREB had an enhanced LTP, also performed less in the 
Morris water maze and showed enhanced freezing behavior 164–166. 
Since PKA has many substrates, other suggested molecular functions for NBEA 
might be secondary to its effect on PKA-mediated phosphorylation. 
 
NBEA is a neurotransmitter receptor trafficking regulator 
 
A study in mouse neural cell cultures revealed that Nbea KO causes a reduced 
presence of major ionotropic neurotransmitter receptor types at the postsynaps, 
while their general expression levels and extra-synaptic presence were 
unchanged. AMPA receptors were not properly glycosylated and seemed to 
accumulate in the early biosynthetic pathway, namely in the ER or early in the 
Golgi-apparatus. Instead, the GABAA, NMDA and kainate receptors showed no 
altered glycosylation and accumulated late within or downstream of the Golgi 
apparatus. This shows that NBEA might regulate the trafficking of different types 
of neurotransmitter receptors differently 138.  
An interaction between the DPBW domain module of NBEA and SAP102, a 
scaffolding protein important for the trafficking of excitatory AMPA- and NMDA 
receptors, was detected in extracts of embryonic and adult mice. In this case 
NBEA did not co-localize with the AMPA receptor, suggesting NBEA affects its 
trafficking indirectly. Since NBEA is localized near the trans-Golgi and only a small 
fraction co-localizes with SAP102 at the post-synaptic density of hippocampal 
neurons, this further supports that NBEA will probably regulate receptor 
trafficking upstream in the early secretory pathway 137. In addition, the central 
and C-terminal part of NBEA containing the AKAP domain and the DPBW domain 
module interact with the β-subunit of the inhibitory Glycine receptor (GlyRβ). 
Stainings showed a notable co-localization between NBEA and the GlyR 136. In D. 
rerio there was a reduced expression of GlyRs at the synapses of nbea mutants, 
which is in line with the observations for the other neurotransmitter receptors 147. 
This shows that NBEA can bind indirectly and directly to neurotransmitter 
receptors. Furthermore, it is known that PKA signaling stimulates synaptic 
targeting of NMDA receptors 167. It is therefore possible that NBEA forms a protein 
complex with receptors, scaffolding proteins and PKA 137.  
A protein interaction screen for the Bone morphogenetic receptor II (BMPR-II) did 
pick up NBEA 168. In addition, in C. elegans, other receptors, like the Notch and 
EGF receptor, seemed to be mislocalized in polarized cells due to NBEA deficiency 
159. Therefore, it might even be that NBEA regulates receptor trafficking in 
general. 
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NBEA is a negative regulator of regulated secretion 
 
The highest expression of NBEA can be found in (neuro-)endocrine tissues, which 
contain specialized cells with regulated secretion in addition to their constitutive 
secretion. In neurons, the secretion of small synaptic vesicles (SSVs) is regulated. 
In addition, neuropeptides and neurotrophins are also secreted in a regulated way 
and they are contained within large dense-core vesicles (LDCVs). Endocrine cells 
secrete hormones through the regulated secretory pathway. These hormones are 
contained in granules with dense cores when observed using electron microscopy. 
These dense-core granules (DCGs) are the endocrine counterpart of the neural 
LDCVs. Since BEACH proteins are suggested to be involved in trafficking of 
membranes or vesicles, the effect of NBEA knockdown on regulated secretion of 
dense-core granules was assessed in an endocrine cell line (β-TC3 cells). NBEA 
knockdown significantly increased the regulated secretion of DCGs 169. Similar to 
neurons, blood platelets also have DCGs and alpha granules, which are the 
counterpart of LDCVs and SSVs, respectively 170. Blood platelets have the 
advantage over (neuro-)endocrine cells that they can easily be obtained from 
patients. The blood platelets of the previously described ASD patient, with a 
balanced chromosomal translocation in the NBEA gene, were analyzed with 
transmission electron microscopy (TEM). About 50% of the observed DCGs 
showed an altered morphology with a smaller dense-core, located at the 
periphery of the granule. All together, these data suggest that NBEA is a negative 
regulator of the regulated secretion of DCGs in endocrine cells. NBEA 
haploinsufficiency might also increase the regulated secretion of LDCVs and SSVs 
in neurons and this could contribute to ASD pathogenesis, at least in a subgroup 
of patients. To support this, DCGs in blood platelets of a patient with a SHANK3 
deletion showed the same aberrant morphology as in the NBEA patient 169. The 
AKAP NBEA might regulate this regulated secretion through its effect on PKA 
signaling, since in Xenopus laevis it was shown that disrupting the interaction 
between an AKAP and PKA can increase secretion in melanotrophic cells 171.  
Tight regulation of PKA activity is essential for the phosphorylation of SNAREs and 
their regulators and could therefore affect the secretion of SSVs 172. However, 
whether NBEA has a presynaptic function in neurons and thus could affect the 
regulated secretion of SSVs at all remains controversial. It might be that only a 
complete loss of NBEA also has a presynaptic effect. This function might be 
neuron-, region- or tissue-specific, which could explain the observed discrepancies 
between the studies of presynaptic effects in the NMJ, the brainstem, 
hippocampal cultures and isolated neuronal islands 135,138,141,142. Even so, the 
studies that do show a presynaptic function, suggest that NBEA is a positive 
regulator of synaptic vesicle release instead of a negative one, as was shown for 
DCGs 135,141,169.  
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NBEA might modulate the cytoskeleton 
 
The effect of NBEA deficiency on neurotransmitter receptor trafficking, regulated 
secretion, postsynaptic localization of PSD95 and dendritic spine density, together 
with the suggested function for BEACH proteins in membrane/vesicle trafficking, 
suggests that NBEA can affect or interact with the cytoskeleton 173. Loss of NBEA 
in hippocampal cell cultures, caused abnormal clustering of the actin cytoskeleton 
in the cell bodies, dendritic shafts and in axons, with only rare enrichment in 
dendritic spines. These actin clusters colocalized with abnormal synaptopodin 
clusters. Synaptopodin is a spine-associated protein with actin-bundling activity. 
This study suggested NBEA can modulate the actin cytoskeleton or interact with it, 
causing a secondary altered localization of synaptodin 142. 
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1.3. Regulated secretion 
1.3.1. Regulated secretion and its implications in ASD etiology 
Secretion is important for delivery of membrane components to the cell surface 
and of secretory material to the extracellular space. All cells need constitutive 
secretion for the housekeeping of the cell and its environment. This constitutive 
secretion is mediated by small cargo-containing vesicles that move from the trans-
Golgi compartment to the cell surface for membrane fusion and cargo release. 
Regulated secretion differs from constitutive secretion in that it requires a 
stimulus to trigger this membrane fusion or secretion. This stimulus is a rise in 
intracellular Ca2+ concentration, but can be modulated by other signaling like 
cAMP/PKA signaling. Unlike constitutive secretion, regulated secretion occurs only 
in neuronal and (neuro-)endocrine cells and is mediated by different specialized 
vesicles, containing specific cargo. Neurons contain two classes of vesicles: small 
synaptic vesicles (SSVs) containing the classical neurotransmitters and large 
dense-core vesicles (LDCVs) containing peptide hormones, amines and enzymes. 
These two classes of vesicles differ in regulatory machinery affecting their 
sensitivity to Ca2+ levels, time course and signal input, but their molecular 
mechanism of secretion is conserved 174,175. SSVs containing catecholamines also 
have a dense core when observed with electron microscopy, so they are often 
referred to separately as small dense core vesicles 174,176. 
Regulated secretion in neurons is important for synaptic transmission and neural 
growth (neurotrophic peptides/hormones in LDCVs) and can be affected by 
cellular transport, cAMP/PKA signaling and transcription. All of these biological 
processes are involved in the etiology of ASD (see 1.1.6.). Regulated secretion can 
be affected at different levels of the vesicle biogenesis pathway or at the level of 
membrane fusion machinery. NBEA has already been mentioned as a negative 
regulator of regulated secretion of dense-core granules, but other ASD candidate 
genes affect regulated secretion as well 169.  
Many candidate genes seem to influence regulated secretion of 
neurotransmitters (RIMS1, PTPRN2, AMPH, RAB11B and SYNPR) 37,77. A defect in 
regulated secretion of neurotransmitters could contribute to the imbalance in 
excitatory/inhibitory neurotransmission, which is suggested to be at the etiology 
of ASD. Furthermore in 30% of ASD cases elevated serotonin plasma levels has 
been described, suggesting a defect not only in glutamate or GABA 
neurotransmission. Controversially, elevated plasma serotonin levels have been 
suggested to be one of the only useful biomarkers for assessing ASD and have 
therefore been heavily studied, but with inconsistent results 177. 
Genes involved in LDCV biogenesis and/or secretion have also been associated 
with ASD (SCAMP5, NBEA, AMISYN, REEP3, PTPRN2 and CADPS2) 169,178. LDCVs can 
contain neurotrophic factors affecting brain development. While REEP3 plays a 
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role at the biogenesis level of LDCVs, mediating trafficking between ER and Golgi, 
the CADPS2 gene encodes a protein that regulates the exocytosis of BDNF-
containing LDCVs and affects survival of cerebellar Purkinje cells. Elevated 
neurotrophic BDNF levels have been reported in ASD cases and Cadps2 knockout 
mice show ASD-like behaviors 75,178,179. SCAMP5, AMISYN and NBEA have all been 
shown to be negative regulators of regulated secretion of dense-core granules 
and three ASD cases with a loss of function in one of these genes showed 
abnormal morphology of blood platelet dense-core granules (DCGs) 169. This 
shows that aberrant regulated secretion of DCGs might contribute to the ASD 
pathology, at least in a subgroup of cases. 
1.3.2. Dense-core granules in blood platelets 
DCGs not only exist in neurons (LDCVs), but also in (neuro-)endocrine cells, like in 
the pituitary, the endocrine pancreas and in blood platelets. When observed with 
transmission electron microscopy, the condensed proteins in the cargo of these 
granules are observed as an electron-dense signal. This content will differ 
depending on cell-type, but even within a cell different vesicles can contain 
different specialized cargo 174,176.   
Blood platelets are activated upon vascular injury by binding to certain receptors. 
They will undergo a shape change and locally secrete molecules necessary for 
blood clothing (thrombosis) and wound healing. Defects in regulated secretion by 
blood platelets will result in bleeding problems. The mechanisms of biogenesis, 
trafficking and exocytosis in regulated secretion are conserved between neurons, 
(neuro-)endocrine cells and blood platelets. This is useful, since blood platelets 
are more easily obtainable from human individuals than neuronal tissue. Some 
neuropathologies even have co-occurring bleeding problems, like the Hermansky-
Pudlak syndrome.  This supports common mechanisms being affected in neurons 
and blood platelets, resulting in this broad phenotype. Because of these 
similarities platelets are suggested as a model to study regulated secretion in 
neurons 170,176. 
Mice generally have a higher blood platelet count than humans. Blood platelets 
have two classes of regulated vesicles, namely α- and δ-granules, which are often 
compared to the LDCVs and SSVs in neurons (Fig 1.6). The α-granules contain a 
heterogeneous cargo of polypeptides, like adhesion molecules and growth 
factors. δ-granules have a dense core containing small molecules like ADP, ATP 
and serotonin, which is necessary for vasoconstriction upon injury. This dense 
core is surrounded by a clear halo, since the dense core does not fully occupy the 
granule 170,176,180–182.   
Normally, there are 0.5 or 1 δ-granules and 3 or 5 α-granules observed per 
platelet section in mice and humans, respectively. No big morphological 
differences have been described between mouse and human platelet δ-granules 
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182. A lower number or an abnormal morphology of dense or δ-granules, suggests 
a defect in their biogenesis. According to Weiss et al. δ-granules can be 
categorized into 4 types 183:  
• Type 1: solid core occupying more than 50% of the granule 
• Type 2: solid core occupying less than 50% of the granule 
• Type 3: fragmented core 
• Type 4: empty granule, no visible core 
 
 
Figure 1.6: Blood platelets contain α- and δ-granules 
In an electron micrograph of a mouse blood platelet, the dense core granules (DCG) or δ-
granules can be observed with their dense core surrounded by a clear halo. The second 
class of vesicles that undergo regulated secretion are the α-granules (AG). 
 
It has been shown for DCGs in general that the granule size and halo volume 
increase with increasing specific molecular cargo present in the cytoplasm, 
although this was less pronounced for serotonin in blood platelets. An increased 
presence of serotonin, did not result in an increase in granule number. 
Furthermore it has been shown that structural changes of DCGs, affect their 
regulated secretion. This shows an important interplay between granule contents 
and membrane dynamics 184. 
A low number of δ-granules, but a normal amount of α-granules, is observed in 
the recessive platelet storage pool disorder called Chediak-Higashi syndrome. This 
disorder is caused by a loss of function of the LYST gene, which is also a member 
of the BEACH-protein family. LYST is suggested to be a lysosomal trafficking 
regulator. Its phenotype includes albinism, a high rate of infections, lymph node 
enlargement and mental retardation 180,185. The blood platelets of the 3 described 
ASD cases, including the case with a balanced chromosomal translocation in 
NBEA, had δ-granules with irregular, poorly delineated and/or smaller dense cores 
compared to controls 169. The effect of NBEA deficiency on δ-granule 
ultrastructure and serotonin secretion will need further characterization. 
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1.3.3. Growth-hormone containing dense-core granules in the pituitary 
The pituitary or hypophysis is a gland underneath the hypothalamus, consisting of 
a glandular and neuronal part. In mice, a third, intermediate lobe can be defined 
between the anterior and posterior lobe, which contains cells that secrete 
melanocyte-stimulating hormone and endorphins. This lobe is present only 
rudimentarily in humans and is called the pars intermedia. The posterior lobe or 
neuropituitary developed from a hypothalamic down-growth of the floor of the 
diencephalon and mainly contains neurons. The anterior lobe or adenopituitary 
consists of a network of capillaries and five major celltypes that vary in their 
hormonal content of DCGs 186,187: 
• Somatotrophs: containing growth hormone (GH) 
• Lactotrophs: containing prolactin 
• Gonadotrophs: containing follicle stimulating hormone and luteinizing 
hormone 
• Tyrotrophs: containing tyrotrophic hormone 
• Corticotrophs: containing adrenocorticotrophic hormone 
These cells can ultrastructurally be distinguished from each other based on a 
combination of different parameters, such as DCG size, shape and even the 
electron-lucidity of the cytoplasm, as described in 186 (Table 1.2). Somatotrophs 
are medium-sized, rounded and contain numerous, spherical DCG with low size 
variability (Fig 1.7). They constitute 50% of the adenopituitary 186,187. 
 
Table 1.2: Ultrastructural adenopituitary celltype characteristics 
 Somato- Lacto- Cortico- Gonado- Tyro- 
DCG size (nm) 300-350 600-900 ±200 100-300 100-160 
Other DCG 
parameters 
- Numerous 
- Spherical 
- Sparse 
- Elliptic 
- Cell 
periphery 
- Sparse 
- Numerous 
- Variability 
in size 
- Cell 
periphery 
- Numerous  
- Haloed 
 
Cytoplasm / / - Electron-
lucent  
/ / 
Rough 
endoplasmic 
reticulum 
- Extensive 
- Cisterns: 
Long, narrow  
- Sparse 
- Cisterns: 
Short, flat 
- Sparse 
- Cisterns: 
Narrow 
- Extensive 
- Cisterns: 
Small, 
rounded  
- Sparse 
Cell shape - Medium-
sized 
- Round/oval 
- Small 
- Rounded 
- Indented 
- Large 
- Irregular 
- Polygonal 
- Large 
- Rounded 
- Large 
- Irregular 
- Polygonal 
Useful ultrastructural celltype characteristics to identify somatotrophs from other 
celltypes, according to 186. DCG: dense-core granule 
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Figure 1.7: Ultrastructure of a mouse somatotroph compared to a corticotroph 
An electron micrograph of the mouse adenopituitary shows a somatotroph (S in the 
nucleus) and a corticotroph (C in the nucleus). Somatotrophs are rounded and medium-
sized. They contain spherical DCGs, with little size variability (300-350nm). Their extensive 
rough endoplasmic reticulum with long narrow cisterns is visible as well. Corticotrophs 
have an irregular shape, smaller DCGs (±200nm) at the cell periphery and a pale electron-
lucent cytoplasm. 
 
Like all the pituitary hormones, GH is secreted in a pulsatile manner in 
concordance with the pulsatile stimuli coming from the hypothalamus. The 
stimulating GH releasing hormone (GHRH) and the inhibitory somatostatin (SST) 
from the hypothalamus regulate GH secretion through the PKA/cAMP pathway 
that will in turn regulate the intracellular Ca2+ level 187,188. As a short negative 
feedback loop, GH secreted from the pituitary will stimulate SST secretion and 
inhibit GHRH secretion in the hypothalamus. As a long-term negative feedback, 
the primary GH target in the liver, insulin-like growth factor 1 (IGF-1), is suggested 
to affect GH secretion as well. Lastly, Ghrelin, a hormone mainly produced in the 
stomach, is suggested to be another positive regulator of GH secretion 188. 
GH secretion is important for body growth and its effect is mainly mediated by the 
downstream secretion of IGF-1. In the brain, IGF-1 seems to regulate neuronal 
and glial growth, apoptosis and synaptogenesis during early postnatal 
development 189. A defect in GH and/or IGF-1 secretion will result in a short 
stature of the individual or dwarfism 188,190. Furthermore liver-specific IGF-1 
knockout mice show hippocampal problems with spatial learning and memory. 
Finally, the IGF-1/mTor pathway has  been linked to ASD and abnormal IGF-1 
levels have controversially been reported in individuals with ASD, as mentioned 
above (1.1.6.2) 60,189,191,192. 
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At the start of this project the biological role of the ASD candidate gene Nbea was 
unknown. Nbea-/- mice die at birth, because of paralysis of the respiratory 
muscles. Knockout of Nbea causes a deficient synaptic transmission at the NMJ. 
The GH240B Nbea+/- mice show ASD-like behaviors and have dwarfism. In an ASD 
patient, haploinsufficiency of Nbea led to aberrant blood platelet DCG 
morphology, which was also detected in an ASD patient with a SHANK3 deletion. 
Furthermore, NBEA was shown to negatively modulate regulated secretion in a 
neuro-endocrine cell-line.  
 
The aim of this PhD project was to explore the physiological function(s) of the 
ASD candidate gene NBEA.  These studies may provide new insights into the 
etiology of ASD.   
 
Three specific objectives were defined: 
 
The first objective was to determine the molecular mechanism underlying the 
dwarf phenotype in the GH240B Nbea+/- mouse model. The initial hypothesis was 
that NBEA affected the regulated secretion and morphology of GH-containing 
DCGs in the somatotrophs of the pituitary. Levels of insulin-like growth factor 1 
(IGF-1), the major target of GH in the liver, have controversially been reported to 
be elevated or decreased in individuals with ASD 191,192. Therefore unravelling the 
cause of the dwarfism, might indirectly also contribute to insights into the cause 
of ASD, at least in a subgroup of patients. However, the gene-trap Nbea+/- mouse 
model did not have dwarfism. Therefore, this discrepancy between the two 
mouse models was taken into account and we re-evaluated the promoterless 
human growth hormone genomic fragment that was inserted into the Nbea gene 
to generate the GH240B mouse model. 
 
To date, ASD can still only be diagnosed based on behavioral observations and 
interrogations. Blood platelets have a similar secretory machinery as neurons and 
are easily obtained from patients. Therefore they can provide interesting 
biomarkers for any neurological disorder. Four ASD patients, of which one with 
NBEA haploinsufficiency, showed aberrant blood platelet DCG morphology. 
Therefore, the second objective was to ultrastructurally and biochemically 
characterize the blood platelets of Nbea+/- mice.  
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The third objective was to identify novel interaction partners of NBEA with an 
unbiased approach. Two highly conserved domain-modules of NBEA were used in 
two yeast two-hybrid screens, namely the ACA module and the PBW module. The 
molecular pathway downstream of one of the resulting interactions, Notch1, was 
chosen to be assessed in more detail. Knowledge about the functions of these 
interaction partners could indirectly provide novel insights into the molecular 
mechanisms of NBEA and unravel important pathways, that might also contribute 
to the pathogenesis of ASD. Furthermore, it might also unravel important 
common functions shared by members of the BEACH protein family. 
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3.1. Abstract 
Two knockout mouse models for the autism candidate gene Neurobeachin (Nbea) 
have been generated independently. Although both models have similar 
phenotypes, one striking difference is the dwarf phenotype observed in the 
heterozygous configuration of the GH240B model that is generated by the 
serendipitous insertion of a promoterless human growth hormone (hGH) genomic 
fragment in the Nbea gene. In order to elucidate this discrepancy, the dwarfism 
present in this Nbea mouse model was investigated in detail. The growth 
deficiency in Nbea+/- mice coincided with an increased percentage of fat mass and 
a decrease in bone mineral density. Low but detectable levels of hGH were 
detected in the pituitary and hypothalamus of Nbea+/- mice but not in liver, 
hippocampus nor in serum. As a consequence, several members of the mouse 
growth hormone (mGH) signaling cascade showed altered mRNA levels, including 
a reduction in growth hormone-releasing hormone mRNA in the hypothalamus. 
Moreover, somatotrope cells were less numerous in the pituitary of Nbea+/- mice 
and both contained and secreted significantly less mGH resulting in reduced levels 
of circulating insulin-like growth factor 1. These findings demonstrate that the 
random integration of the hGH transgene in this mouse model has not only 
inactivated Nbea but has also resulted in the tissue-specific expression of hGH 
causing a negative feedback loop, mGH hyposecretion and dwarfism. 
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3.2. Introduction 
NEUROBEACHIN (NBEA) has previously been identified as a candidate gene for 
autism spectrum disorder (ASD) based on associations and linkage studies and 
patients with monoallelic inactivation of NBEA [1–8]. 
To further investigate the function of NBEA, Nbea heterozygous and knockout 
mouse models have been used. Independently, two models have been generated 
in which the Nbea gene is disrupted [9,10]. The first model was serendipitously 
generated via random integration of a construct containing a minimal human 
growth hormone (hGH) genomic fragment. In the GH240B transgenic line this 
insertion occurred in intron 1 of Nbea leading to a genuine null allele [10]. 
Expression of the hGH minigene was examined and could not be detected. The 
second Nbea mouse model was generated by means of the gene-trap vector 
system (further referred to as the gene-trap mouse) [9]. Both mouse models show 
similar phenotypes in which bi-allelic inactivation of Nbea results in neonatal 
paralysis and death. This is caused by a complete block of evoked neuromuscular 
synaptic transmission as was shown in the GH240B Nbea-/- mice [10]. The GH240B 
Nbea+/- mice also revealed abnormal morphology of dense-core granules in blood 
platelets, similar to the first described patient with NBEA haploinsufficiency. 
Furthermore, a decrease in several actin-associated peptides was observed. In 
addition, these studies in blood platelets confirmed the important role of NBEA as 
an A-kinase anchoring protein, affecting phosphorylation levels of several PKA 
substrates [11]. Increased BDNF levels in the hippocampus of these mice are 
probably caused by an increased CREB phosphorylation level as described in β-TC3 
cells. 
Behavioral studies in this mouse model showed an autism-like phenotype with 
increased repetitive self-grooming behavior, increased conditioned fear, 
decreased sociability and a delayed spatial  learning and memory [12]. Studies in 
the gene-trap mouse models showed that loss of NBEA leads to an imbalance in 
excitatory and inhibitory signaling with a more affected inhibitory network, an 
ectopic accumulation of F-actin in the neuronal cell body, the dendritic shafts and 
axons and a decrease in surface levels of GABAA and glutamate receptors 
[9,13,14]. Reduced glutamate responsiveness was measured and confirmed in 
both lines [13]. 
One striking difference between both mouse models is the presence of a dwarf 
phenotype in Nbea+/- mice. This growth deficiency is only present in the GH240B 
Nbea+/- mouse model [10] whereas the gene-trap Nbea+/- mice have a normal 
stature accompanied by a higher body weight due to an increased adipose tissue 
mass [15]. 
In order to elucidate this discrepancy, the dwarf phenotype of GH240B Nbea+/- 
mice was investigated in detail. A growth curve was generated and the expression 
of genes in the GH pathway was measured at mRNA and protein level. Alterations 
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in body composition were detected via dual-energy X-ray absorptiometry (DEXA). 
Pituitary cell numbers were determined and pituitary size and the ultrastructure 
of somatotrope cells were examined. The responsiveness of somatotrope cells to 
secretagogues was analyzed in ex vivo cultures of anterior pituitaries. Finally, hGH 
expression, which was previously found to be undetectable, was re-examined in 
serum, pituitary, hypothalamus, hippocampus and liver. 
 
3.3. Materials and methods 
3.3.1. Animals 
The GH240B transgenic line [10] was backcrossed for at least 10 generations with 
C57BL/6JRj mice (Janvier). Mice were housed in standard cages (wood-shaving 
bedding) under conventional 
laboratory conditions (12/12h light/dark cycle, lights on at 8am; 22°C) and were 
allowed food and water ad libitum. All experiments were performed with 12 week 
old male mice unless otherwise stated. 
3.3.2. Ethics statement 
All experiments were approved by the ethical research committee of KU Leuven in 
accordance with the declaration of Helsinki (project number P182/2011). 
3.3.3. Assessment of a growth curve 
Mice were weighed weekly starting at postnatal day 2 until mice reached 
adulthood (12 weeks of age). Afterwards, mice were weighed once a month until 
they were 1 year of age. In total 10 male Nbea+/+ mice and 17 male Nbea+/- mice 
were included. 
3.3.4. Whole body dual-energy X-ray absorptiometry (DEXA) 
Mice were anesthetized by intraperitoneal injection with 10 mg/kg Xylazine 
(Rompun, Bayer, Germany) and 100 mg/kg Ketamine (Ketamine 1000 CEVA, Ceva 
Sante Animal, Belgium). 
The body composition of anesthetized mice (n= 5/genotype) was measured by 
DEXA (PIXImus densitometer, Lunar Corp., Madison, USA) using ultra-high 
resolution (0.18×0.18 pixels, resolution of 1.6 line pairs/mm) and software version 
1.45. 
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3.3.5. RNA extraction and quantitative reverse transcription PCR (qRT-
PCR) 
RNA of the anterior pituitary, hypothalamus and liver was extracted with the 
Nucleospin RNA XS or L kit (Macherey-Nagel, Germany) according to the 
manufacturer’s protocol. Per experiment, an equal amount of RNA was reverse 
transcribed to cDNA using the iScript cDNA synthesis kit (Bio-Rad, California, USA). 
Real-time qRT-PCR was performed using iQ SYBR Green Supermix (Bio-Rad). 40 
cycles of annealing/extension for 1 min at 60°C were carried out with the MyiQ 
single color real-time PCR detection system (Bio-Rad). The relative amount of 
mRNA expression was calculated using the method of Livak with normalization to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as reference gene [16]. The 
primers used are given as supporting information (Table S3.1). 
3.3.6. Quantification of growth hormone (GH) and insulin-like growth 
factor 1 (IGF-1) 
Murine (m)GH levels were quantified using the Rat/Mouse Growth hormone 
ELISA (Millipore, Darmstadt, Germany) according to the supplier’s protocol. The 
content of human (h)GH was calculated by means of the HGH human direct ELISA 
kit (Invitrogen, Paisley, UK) according to the manufacturer’s instructions. The 
plasma samples measured were derived from blood taken at 3 different time 
points to cover the peak of GH release in the mouse, namely 09:30 h, 10:00 h and 
10:30 h [17]. Hippocampi were dissected and immediately put on -80°C. Tissue 
was homogenized in sucrose buffer (3.18 mM sucrose; 4 mM Tris-HCl pH 7.4) 
containing a protease and phosphatase 
inhibitor cocktail (Roche Diagnostics GmBH, Mannheim, Germany). IGF-1 levels in 
plasma, derived from the blood samples taken at 10:30 h, (n =3/genotype) were 
measured using the Quantakine ELISA Mouse/Rat IGF-1 Immunoassay (R&D 
systems, Minneapolis, USA) according to the supplier’s guidelines. 
3.3.7. Transmission electron microscopy (TEM) of somatotrope cells 
Mice were anesthetized with an intraperitoneal injection of 50 mg/kg Nembutal 
(CEVA Sante Animale, Brussels, Belgium). After gravitational perfusion of the mice 
with Karnovsky’s fixative (2.5% glutaraldehyde, 2% formaldehyde in 0.1 M sodium 
cacodylate buffer; pH 7.4), pituitary glands were isolated and additionally fixed for 
2 hours at room temperature, followed by an overnight immersion at 4°C in 
Karnovsky’s fixative. After the samples were washed and postfixed with 1% OsO4, 
they were dehydrated through a series of increasing ethanol concentrations and 
embedded in epoxy resin. Ultrathin sections (70 nm) were collected on formvar-
coated copper grids and stained with lead citrate and uranyl acetate. TEM of 
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adenopituitary tissue sections was performed at 80 kV using a JEM1400 
transmission electron microscope (JEOL, Tokyo, Japan). All micrographs were 
acquired on a SIS Quemesa camera with the same spatial resolution. One pixel 
corresponds to 12.44 nm. Somatotropes were identified based on their 
morphological description as defined in [18]. 
3.3.8. Quantification of the different hormonal cell types in the anterior 
pituitary 
This experiment was performed as described before [19]. Briefly, naive mice were 
euthanized by CO2 asphyxiation followed by immediate decapitation. The neural 
and intermediate lobes of the pituitary were discarded using a stereomicroscope. 
The anterior lobe (anterior pituitary) was isolated and dissociated into individual 
cells with trypsin. Cells were resuspended in serum-free defined medium (SFDM; 
Invitrogen) and spun down on Cytospin slides (SuperfrostPlus; Thermo Scientific, 
Rockford, USA). Cells were permeabilized with 0.5% saponin (Sigma-Aldrich, St. 
Louis, USA) after fixation in 4% paraformaldehyde, and were incubated overnight 
with antibodies against murine GH (1/10,000), prolactin (PRL) (1/10,000), 
adrenocorticotropic hormone (ACTH) (1/ 5,000) and α-glycoprotein subunit 
(αGSU) (1/1,000). Hormone antisera were obtained from Dr. A. F. Parlow 
(National Hormone and Peptide Program, Harbor-UCLA Medical Center, Torrance, 
CA). Subsequently, cells were incubated for 1 h with fluorescently labeled 
secondary antibodies (Invitrogen; 1/1,000) and 6-diamidino-2-phenylindole 
(DAPI). Images were captured using an Olympus IX81 microscope. Cells were 
counted using ImageJ (NIH, Maryland, USA) in at least 5 random cytospin fields 
(1,000– 2,000 cells per hormone per group) and the proportions of 
immunopositive cells on the total anterior pituitary cells were determined. To 
take into account the smaller size of the anterior pituitary and the 
correspondingly lower number of total anterior pituitary cells (about 2-fold, see 
Results) in the Nbea+/- GH240B mice, we calculated the decrease in absolute cell 
number of the different cell types (using their proportion and the total number of 
anterior pituitary cells obtained per group of mice). 
3.3.9. Primary anterior pituitary cell culture and regulated secretion assay 
Primary cultures were generated based on the protocol described [19]. Briefly, 
anterior pituitaries were dissected and dissociated into single cells as reported 
above. Cells were resuspended in  FDM, quantified using a Z2 Coulter counter 
(Analis, Namur, Belgium), and seeded in cell culture plates with Primaria surface 
treatment (BD Biosciences, Bergen County, USA). Basal GH secretion was defined 
as the content GH in SFDM without secretagogues after 2 h incubation, 
normalized for the total amount of GH in medium samples plus lysates. cAMP-
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induced GH release was measured after a 2 h incubation in SFDM containing the 
non-specific inhibitor of phosphodiesterases 3-isobutyl-1-methylxanthine (IBMX; 
100 mM) and the adenylate cyclase activator Forskolin (1 mM). Stimulated 
secretion was defined as the amount of GH secreted after stimulation with 
IBMX/Forskolin minus basal release and normalized for the total amount of GH in 
medium samples plus lysates. Afterwards, cells were lysed in RIPA buffer (25 mM 
Tris-HCl pH 7.6; 150 mM NaCl; 1% NP-40; 1% sodium deoxycholate; 0.1% sodium 
dodecyl sulfate) containing a protease and phosphatase inhibitor cocktail. 
3.3.10. Immunoblotting 
Anterior pituitary, hypothalamus and liver were homogenized in RIPA buffer 
containing a protease and phosphatase inhibitor cocktail. Anterior pituitaries and 
hypothalami of littermates were pooled and homogenization was performed 
manually using a pellet pestle for 1.5 ml tubes. Liver tissue was homogenized with 
a motor-driven Potter-Elvehjem tissue grinder (Wheaton, Millville, USA). The 
protein concentration of the samples was quantified with a BCA protein assay 
(Thermo Scientific, Rockford, USA). 25 mg of lysate was loaded on a 10% Bis-Tris 
gel (Bio-Rad, California, USA). Proteins were transferred to Protran Nitrocellulose 
membrane (Schleicher&Schuell, Dassel,  Germany) and incubated with antibodies 
against human GH (hGH) (Abcam, Cambridge, UK; 1/1,000) and actin (Sigma-
Aldrich; 1/5,000), used for normalization. Afterwards, membranes were incubated 
with HRP-conjugated secondary antibody (1/2,000; Dako, Glostrup, Denmark) and  
proteins were visualized with western blotting ECL detection reagent. 
3.3.11. Immunofluorescent staining of human GH in total pituitary 
Total pituitaries were dissected, followed by an overnight fixation in 4% 
formaldehyde. After rinsing in 70% ethanol, pituitaries were embedded in paraffin 
according to standard procedures. Tissue blocks were cut in 5 mm sections with 
subsequent removal of paraffin with Histo-Clear (National Diagnostics, Hessle, UK) 
and dehydration through serial ethanol solutions. Preceding a 30 min block in 10% 
goat serum in PBS with 2% BSA, sections were incubated for 20 min in target 
retrieval solution, pH 6 (Dako). Sections were incubated for 1.5 h with mouse anti-
hGH antibody (Abcam; 1/1,000) and subsequently for 1 h with Alexa 488–labeled 
anti-mouse antibody (Molecular probes, Paisley, UK; 1/500) before mounting in 
ProLong Gold Antifade Reagent (Dako) containing DAPI. Immunofluorescence was 
visualized by Axiovision software (Zeiss, Heidelberg, Germany) with the Axio 
Imager Z1 microscope (Zeiss). 
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3.3.12. Statistical analysis 
Data are presented as mean with standard error of the mean (SEM). Significance 
of differences between mean values were analyzed using (where appropriate) 
two-tailed t test, analysis of variance (ANOVA) or repeated measures (RM)-
ANOVA procedures with Tukey test post hoc comparison using Statistica version 
9.0 (StatSoft, Oklahoma, USA). All statistical tests were performed with 0.05 as the 
α level of significance (*: P < 0.05, **: P < 0.01 and ***: P < 0.001). 
 
3.4. Results 
3.4.1. Reduced body weight of mice heterozygous for Nbea 
To characterize the growth retardation of Nbea+/- GH240B mice, their body weight 
was measured from postnatal day 2 until mice were 1 year old (Figure 3.1A). The 
body weight of Nbea+/- mice was initially significantly lower than the weight of 
their wildtype littermates (RM-ANOVA: main effect of genotype: F(1,25) = 17.3, P 
< 0.001). This dwarf phenotype was apparent after 4 weeks and became 
statistically significant starting 7 weeks after birth and persisted into adulthood. 
As mice became older, Nbea+/- mice showed an increased weight gain in 
comparison to Nbea+/+ mice (RM-ANOVA: interaction genotype x age: F(22,550)= 
8.4, P < 0.001) (Figure 3.1A). At 1 year of age, mice were sacrificed and their body 
length was measured. Heterozygous mice were significantly smaller than their 
wild-type littermates (t = 3.39, P = 0.002), despite similar weight (Figure 3.1B). 
3.4.2. Different body composition of Nbea+/+ and Nbea+/- mice  
A significant interaction effect of genotype with age in the body weight curve 
might be indicative for alterations in fat percentage of Nbea+/- mice. Therefore, 
the body composition of adult mice was determined by DEXA. Although the total 
tissue mass was significantly lower in Nbea+/- mice than in Nbea+/+ mice (t = -7.91, 
P < 0.001) (Figure 3.1C), Nbea+/- mice contain an increased fat mass percentage 
and an accordingly decreased lean mass percentage (%fat: t = 5.50, P < 0.001; 
%lean: t =25.3, P < 0.001) (Figure 3.1D and E). In addition, the bone mineral 
density of Nbea+/- mice was significantly lower compared to Nbea+/+ mice (t 
=213.1, P < 0.001) (Figure 3.1F). 
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Figure 3.1: Nbea+/- mice show postnatal, sustained growth retardation and an altered 
body composition. (A) Male mice were weighed from postnatal day 2 until week 52. (B) 
Male mice were sacrificed at 1 year of age revealing a reduced body length of Nbea+/- mice 
compared to Nbea+/+ mice (Nbea+/+ mice: n = 10, Nbea+/- mice: n = 17). (C–F) DEXA 
measurements were performed to analyze the body composition (n = 5/ genotype; 12 
weeks old). (C) Nbea+/- mice have a reduced total tissue mass accompanied by an increase 
in percentage fat mass (D) and a decreased percentage lean mass (E). (F) Also, the bone 
mineral density of Nbea+/- mice was significantly reduced in comparison with Nbea+/+ mice. 
*: P < 0.05, **: P < 0.01; ***: P < 0.001. 
3.4.3. The GH/IGF-1 axis is affected in Nbea+/- mice 
The observed dwarf phenotype of Nbea+/- mice in combination with the altered 
body composition  suggested abnormalities in the GH signaling cascade. To assess 
alterations in the GH/IGF-1 axis, mRNA expression of the relevant genes was 
analyzed in anterior pituitaries, hypothalami and livers from adult mice (Figure 
3.2A). In the hypothalamus, a significant reduction in Gh-releasing hormone 
(Ghrh) expression was detected (t = 3.91, P = 0.008) (Figure 3.2B). The expression 
level of Ghrelin was too low to be conclusive. The expression levels of 
somatostatin (Sst), Sst receptors (Sstr) 4 and 5, and Gh receptor (Ghr) did not 
significantly differ between genotypes (Sst: t =1.85, P = 0.11; Sstr4: t = 1.62, P = 
0.15; Sstr5: t = 0.18, P = 0.86; Ghr: t = 22.29, P = 0.07). In the anterior pituitary, a 
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significant decrease in Gh mRNA expression was accompanied by a significant 
increase in Ghr and the most abundantly expressed somatostatin receptor Sstr2 
mRNA expression (Gh: t = 3.55, P = 0.012; Ghr: t =22.96, P = 0.025, Sstr2: t =25.19, 
P = 0.002) (Figure 3.2C). No significant differences in the expression level of Ghrh 
receptor (Ghrhr), Ghrelin receptor (Ghrlr) and Sstr5 were detected (Ghrhr: t = 1.71, 
P = 0.14; Ghrlr: t = 0.09, P = 0.86; Sstr5: t = 0.41, P = 0.70). One of the main 
consequences of peripheral GH signaling is the production of IGF-1 in the liver 
[20]. Therefore, Igf-1 mRNA levels in the liver were determined, combined with 
the quantification of IGF-1 present in plasma. A significant decrease in Igf-1 mRNA 
in the liver was detected (t = 3.37, P = 0.028) which resulted in a significantly 
reduced level of IGF-1 in the plasma (t = 8.36, P = 0.001)  Figure 3.2 D and E). 
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Figure 3.2: Alterations in the GH signaling cascade of Nbea+/- mice.  
(A) Schematic representation including the members of the GH pathway of which the 
mRNA level was measured by qRT-PCR. Black arrows indicate receptor binding, a + or – 
added to the arrow implicates a stimulation or inhibition effect, respectively. (B) In the 
hypothalamus of Nbea+/- mice, the expression level of Ghrh was significantly reduced. The 
mRNA level of Ghrelin was too low to generate conclusive data (n = 4 litters/genotype; 12 
weeks old). (C) In the anterior pituitary, the mRNA level of Gh was significantly decreased 
in Nbea+/- mice. Moreover, the expression level of Ghr and Sstr2 was significantly 
increased in Nbea+/- mice (n = 4 litters/ genotype; 12 weeks old). (D) The mRNA level of 
Igf-1 was significantly reduced in the liver of Nbea+/- mice (n = 3/genotype; 12 weeks old). 
(E) The reduced mRNA level is reflected in a decrease of plasma IGF-1 in Nbea+/- mice (n = 
3/genotype; 12 weeks old). Gh: growth hormone; Ghr: Gh receptor; Ghrh: Gh-releasing 
hormone; Ghrhr: Ghrh receptor; Sst: somatostatin; Sstr: Sst receptor; Ghrlr: Ghrelin 
receptor; Igf-1: insulin-like growth factor 1; *: P < 0.05, **: P < 0.01; ***: P < 0.001. 
3.4.4. Reduced presence and GH content of somatotrope cells in Nbea+/- 
mice 
During microdissection of the anterior pituitaries, abnormal morphology of the 
pituitary of Nbea+/- mice became apparent (Figure 3.3A). The size of the anterior 
pituitary seemed to be reduced in Nbea+/- mice, while the size of the 
neuropituitary appeared to be unchanged by visual inspection. To assess which 
cell types are affected, anterior pituitaries were dispersed into single cells, fixed, 
and marker proteins for specific cell types were fluorescently labeled and 
immunopositive cells counted. In accordance with the smaller size, a reduction in 
total anterior pituitary cell number was detected for Nbea+/- mice compared to 
Nbea+/+ mice (330,000 and 300,000 cells versus 650,000 and 660,000 cells; n 
=2/genotype). Furthermore the cell composition of these anterior pituitaries was 
assessed and a 55% ± 3 and 55% ± 9 decrease in the absolute number of GH- and 
prolactin- (PRL) positive cells, respectively, was detected in the anterior pituitary 
of Nbea+/- mice when compared to control mice (Figure 3.3B; n= 2). The number 
of cells containing adrenocorticotropic hormone (ACTH) and αGSU, which is the α-
glycoprotein subunit of the thyroid-stimulating hormone (TSH), follicle- 
stimulating hormone (FSH) and luteinizing hormone (LH), is low and was therefore 
too variable to allow firm conclusions. In addition, the total GH content of the 
anterior pituitary of Nbea+/- and Nbea+/+ mice was measured to assess if the GH 
content of the remaining somatotrope cells was affected. Based on the reduced 
presence of somatotrope cells by approximately 50%, a similar decrease in GH 
content per anterior pituitary is expected if the remaining somatotrope cells 
contain normal amounts of GH. However, in Nbea+/- mice compared to Nbea+/+ 
mice, a decline in GH content per anterior pituitary, with a ratio of 1/6.32±0.17 
was observed, instead of the expected 2-fold (Nbea+/+ mice: 117.01±8.5 mg GH 
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per anterior pituitary; Nbea+/- mice: 18.5±1.16 mg GH per anterior pituitary; t = 
11.48, P < 0.001; n =3/genotype) (Figure 3.3C). 
To investigate any morphological abnormalities of the GH-producing cells, 
transmission electron microscopy was performed. However, the ultrastructure of 
the somatotrope cells and the large electron-dense granules containing GH 
appeared unaffected (Figure 3.4). 
 
 
 
Figure 3.3: Somatotrope cells in Nbea+/- mice are less numerous and contain less GH 
than Nbea+/+ mice.  
(A) The pituitary of Nbea+/- mice is smaller. More specifically, the anterior pituitary is 
affected since the size of the posterior pituitary (dashed line) appears to be unaffected. (B) 
Percent change in absolute number of growth hormone (GH) and prolactin (PRL) 
immunopositive cells in the anterior pituitary of Nbea+/- compared to control mice, shown 
for 2 experiments separately (1,000–2,000 cells per hormone were counted per genotype; 
the experiment was conducted twice on 12 weeks old male mice). (C) In addition to the 
reduced presence of somatotrope cells in the anterior pituitary of Nbea+/+ mice, they also 
contained significantly less GH (n = 3/genotype; 12 weeks old). (D) Primary anterior 
pituitary cell cultures of Nbea+/- mice secrete similar to Nbea+/+ mice under basal 
conditions and upon stimulation with IBMX and Forskolin (Stim.), after we normalized the 
GH content in the medium for the total GH level in somatotropes (n = 4/genotype). *: P < 
0.05, **: P < 0.01; ***: P < 0.001. 
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Figure 3.4: Normal morphology of somatotrope cells of Nbea+/- mice.  
Electron microscopic views show representative somatotrope cells of 12 weeks old 
Nbea+/+ and Nbea+/- mice with no apparent ultrastructural differences. Nu: nucleus of a 
somatotrope cell. 
3.4.5. Normal responsiveness of the somatotrope cells in Nbea+/- mice 
In order to evaluate the responsiveness of the remaining somatotrope cells, 
primary anterior pituitary cell cultures were generated allowing GH 
measurements under basal conditions and after stimulation with IBMX and 
Forskolin, secretagogues mimicking the cAMP-stimulating effect of GHRH (Figure 
3.3D) [21]. Primary cultures of Nbea+/- mice secreted significantly less GH 
compared to Nbea+/+ mice (ANOVA: main effect of genotype: F(1,18)=32.3, P < 
0.001 and post hoc comparison: basal medium: P < 0.001 and stimulated medium: 
P < 0.001) (Figure 3.3D). In addition, the remaining GH in the cell lysate was 
significantly lower in cell cultures derived from Nbea+/- mice (ANOVA: interaction 
genotype x condition: F(2,18)= 21.0, P < 0.001 and post hoc comparison: cell 
lysate: P = 0.003). Consistent with a reduced amount of GH per somatotrope cell 
in Nbea+/- mice, the total GH content of 200,000 anterior pituitary cells, defined as 
the sum of GH in basal and stimulated medium and the cell lysate, was decreased 
in Nbea+/- mice with 71% ±3 compared to the total GH content as measured in 
Nbea+/+ mice (t = 5.15, P = 0.002), while the reduction of GH cells was only 55% 
(see above). We analyzed the effect on secretion by normalizing the absolute 
amount of GH in the medium for their total GH content and found no significant 
difference for genotype in basal nor in stimulated secretion (two-way ANOVA: 
genotype: F (1,12) =1.28, P = 0.27; condition: F (1,12) = 1135.9, P < 0.0001; 
interaction genotype x condition: F (1,12) = 0.212, P = 0.65), indicating a normal 
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responsiveness of GH secretion upon stimulation (Figure 3.3D). Taken together, 
Nbea+/- anterior pituitary cell cultures contain less GH but respond normally to 
secretagogues. 
3.4.6. Expression of human GH in the pituitary and hypothalamus of 
Nbea+/- mice 
The Nbea mouse model used in this study was generated serendipitously by 
integration of a transgenic construct of hGH into intron 1 of the Nbea gene 
resulting in a Nbea null allele. Although the absence of hGH expression in the 
pituitary was previously shown by RT-PCR [22] a more extensive analysis of hGH 
expression was conducted here. 
Relative mRNA expression of hGH was determined in different tissues (Figure 
3.5A). In the anterior pituitary of Nbea+/- mice, the mRNA level of hGH was 
comparable to Gapdh mRNA levels while it was undetectable in Nbea+/+ mice (t = 
13.94, P < 0.001). Although the hGH expression in the hypothalamus was also 
significantly higher compared to Nbea+/+ mice (t = 4.48, P = 0.01), the hGH 
expression was much lower in comparison to the anterior pituitary, albeit still 
clearly detectable. The liver of both Nbea+/- and Nbea+/+ mice contained at best 
trace levels of hGH mRNA (t = 0.14, P = 0.89). 
To assess whether the mRNA levels correlated with protein levels, a western blot 
of hGH was performed on lysates of the same tissues (Figure 3.5B). hGH protein 
was detected in the anterior pituitary of Nbea+/- mice, but not in the 
hypothalamus and liver. As expected, no hGH could be detected in anterior 
pituitary, hypothalamus and liver of Nbea+/+ mice. 
To obtain insight into which lobes of the pituitary express hGH, 
immunofluorescent staining of hGH was performed on sections of the total 
pituitary. An immunopositive signal was detected in the 
anterior and to a lesser extent the intermediate lobe of the pituitary of Nbea+/- 
mice (Figure 3.5C). In order to determine the ratio of hGH relative to murine GH 
(mGH) in the anterior pituitary of Nbea+/- mice, an hGH ELISA was performed on 
anterior pituitary lysates. In addition, lysates of the hypothalamus were included 
since an ELISA is more sensitive than a western blot. In the anterior pituitary of 
Nbea+/- mice a total of 37 ± 9 ng hGH was present (Figure 3.5D), leading to an 
mGH/hGH ratio of 505. In the hypothalamus of Nbea+/- mice, hGH was also 
detected with the sensitive ELISA (0.11±0.01 ng), but at much smaller amounts 
than in the pituitary which is consistent with mRNA data (Figure 3.5D). It is worth 
noting that the signal detected in all wild-type samples was under the detection 
limit of the hGH ELISA. 
To find out whether hGH is more generally expressed in the brain, levels were also 
measured in lysates of the hippocampus since this region has the highest 
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expression of NBEA. The values detected in both wild-type and heterozygous mice 
were below the detection limit of the ELISA (Figure 3.5D). 
To analyze whether hGH is secreted under basal and stimulated conditions, the 
hGH levels were measured in the samples of the primary anterior pituitary cell 
cultures. Under basal conditions, 0.99±0.10 ng hGH was detected in the medium, 
just above the detection limit of the ELISA. After stimulation with IBMX and 
Forskolin, 3.3±0.3 ng hGH is secreted in the medium, which is 79 times less than 
mGH. The remaining level of hGH in the cell lysate was 3.5±0.1 ng hGH (Figure 
3.5E). The signal detected in all wild-type samples was under the detection limit, 
thereby excluding 
statistical comparison. 
To assess whether hGH could be detected in the circulation, blood samples were 
taken at 3 different time points, namely 09:30 h, 10:00 h and 10:30 h, 
encompassing the peak of GH release in the mouse [17]. No hGH signal could be 
detected at any of the 3 time points in both wild-type and heterozygous samples 
(data not shown). 
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Figure 3.5: Presence of hGH mRNA and protein in the pituitary and hypothalamus of 
Nbea+/- mice.  
(A) The qRT-PCR data are represented as Δct values (Gapdh expression) [16]. In Nbea+/- 
mice, the highest hGH mRNA levels were detected in anterior pituitary followed by the 
hypothalamus. No signal was detected in liver samples of both Nbea+/- and control mice (n 
= 3/genotype). (B) Western blot shows that in the anterior pituitary of Nbea+/- mice hGH 
protein is present whereas no hGH could be detected in the hypothalamus and liver. All 
tissue from Nbea+/+ mice was negative for hGH (n = 3/genotype). (C) Immunofluorescent 
staining of hGH gives a positive signal in the anterior (A) and intermediate lobe (I) of the 
pituitary of Nbea+/- mice. No signal was detected in the neural lobe (N) of Nbea+/- mice. (D) 
The anterior pituitary of Nbea+/- mice contained approximately 40 ng hGH, measured by 
ELISA for hGH. A significant amount of hGH in the hypothalamus of Nbea+/- mice was 
detected (n = 3/genotype). (E) Under basal conditions, a limited amount of hGH was 
secreted in anterior pituitary cell cultures. Upon stimulation, approximately half of the 
total amount of hGH was secreted. No signal of hGH could be detected in all wild-type 
samples (n = 3/genotype). ND: not detectable; *: P < 0.05, **: P < 0.01; ***: P < 0.001. 
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3.5. Discussion 
In this study we have delineated the dwarf phenotype in the Nbea+/- GH240B 
mouse model generated by Su et al [10]. We have established that Nbea+/- 
GH240B mice have an increased percentage of fat mass concomitant with a 
decrease in lean mass and bone mineral density. This phenotype is the result of 
alterations in the GH/IGF-1 axis caused by hGH expressed from the transgene in 
the pituitary and hypothalamus of Nbea+/- GH240B mice. GHRH levels in the 
hypothalamus are suppressed, resulting in reduced somatotroph stimulation, 
causing reduced cell 
numbers and mGH content. 
When the transgenic construct of hGH was accidently inserted in intron 1 of Nbea, 
the absence of expression of hGH in the pituitary was verified by RT-PCR [10,22]. 
Expression in other tissues was not examined. The discrepancy between the two 
Nbea+/- mouse models regarding dwarfism prompted us to reevaluate the 
expression of hGH, especially since 5 different transgenic mouse models were 
generated with the same transgenic hGH construct and analysis of pituitary mRNA 
revealed hGH expression in 3 of these mouse models [22]. Expression of hGH was 
unexpected since the two pituitary specific DNase I hypersensitive sites I and II (HS 
I and II), which are essential to drive high levels of somatotrope-specific hGH 
expression, were not incorporated in the transgenic construct [22–24]. hGH 
mRNA and protein were detected in the anterior pituitary and hypothalamus of 
Nbea+/- GH240B mice, using qRT-PCR and ELISA. 
Most likely, the absence of HS I and II resulted in a minimal expression of hGH 
reflecting the basal functions of the proximal regulatory elements of the hGH 
gene present in the transgenic construct [24]. 
The presence of hGH in the hypothalamus of Nbea+/- GH240B mice is probably at 
the basis of the observed GH deficiency and subsequent dwarfism. Other 
transgenic mouse models with targeted expression of hGH in the hypothalamus 
also present dwarfism and similar alterations at the level of the pituitary to 
Nbea+/- GH240B mice [25,26]. The proposed molecular mechanism of their 
observed dwarf phenotype is a dominant negative feedback loop in which hGH is 
capable of binding the mGH receptor (mGHR) present in the hypothalamus 
[27,28]. As a result, Ghrh mRNA in the hypothalamus is significantly reduced 
leading to a decrease in pituitary mGh mRNA and protein levels [25]. Recently, a 
similar phenotype was observed in the AlfpCre mouse model in which the entire 
hGH gene was inserted into the AlfpCre transgene leading to the presence of hGH 
protein in the hypothalamus and pituitary [29,30]. 
The 500-fold lower levels of hGH in the pituitary compared to mGH and the 
undetectable levels in the blood preclude a significant effect of hGH on IGF-1 
production in liver, while the low expression level of hGH in hypothalamus is 
apparently sufficient to locally activate the mGHR and suppress GHRH expression. 
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A possible explanation can be that, since mGH is not expressed in hypothalamus 
and can only activate the mGHR in this tissue through an endocrine mechanism, 
the hGH/mGH ratio in hypothalamus will probably be many times higher than in 
pituitary. However, we did not determine this ratio in the hypothalamus. No hGH 
was detected in the hippocampus of Nbea+/- GH240B mice, the brain region with 
the highest expression of Nbea, indicating that expression of hGH is not directed 
by the Nbea promoter but promoter elements in the hGH transgene itself, only 
activated in specific tissues. This is also consistent with the fact that the two genes 
are in opposite directions [10]. 
Similar to Nbea+/- GH240B mice, the total number of GH and PRL-producing cells 
in the pituitary of mice with transgenic hGH expression in the hypothalamus is 
reduced whereas other cell types were unaffected leading to hypoplasia of the 
pituitary [26]. 
Pituitary hypoplasia is also present in other mouse models with affected GHRH 
signaling, more specifically the Ghrhr deficient little mice and the Pc1/3 knockout 
mice in which the maturation of proGHRH is blocked [31,32]. The selective 
reduction of GH and PRL-producing cells has also been observed in a transgenic 
rat model with hGH expression under the control of the Ghrh promoter [33]. The 
reduction of these two cell populations can be explained by developmental 
relationship and/or paracrine interplay [34]. 
The somatotrope cells present in the transgenic mice expressing hGH in the 
hypothalamus retain their functional capacity for GH secretion in ex vivo cell 
cultures both under basal condition and upon stimulation with GHRH [26]. In 
primary cultures of anterior pituitary cells of Nbea+/- GH240B mice, Forskolin and 
IBMX were applied as secretagogues mimicking the rise in cAMP caused by GHRHr 
activation [21]. A similar ratio of stimulated to basal GH release was measured for 
both genotypes indicating a normal responsiveness of the remaining GH-
producing cells in Nbea+/- mice. The observed reduced presence of GH in the 
medium of cell cultures of Nbea+/- mice, both in basal and stimulated conditions, is 
most likely caused by the reduced presence of somatotrope cells in the anterior 
pituitary of Nbea+/- mice and the lower GH content per GH-producing cell. Since 
NBEA has been identified as a negative regulator of regulated secretion in vitro 
[35], the ratio of GH released upon stimulation versus basal release was 
anticipated to be higher in ex vivo cell cultures derived from Nbea+/- mice. A 
possible explanation for the similar ratios is that compensatory mechanisms in the 
somatotrope cell population of Nbea+/- GH240B mice mask any ex vivo effect of 
Nbea haploinsufficiency on regulated secretion. 
For the assessment of the mRNA profile of members of the GH cascade, only the 
most relevant SST receptors were included, although 5 different SST receptors are 
present both in pituitary and hypothalamus [36]. In the arcuate nucleus of the 
hypothalamus, Sstr4 and 5 were selected due to their predominant presence on 
neurons producing GHRH and Ghrelin [36]. In GH producing cells, Sstr2 and 5 are 
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most highly expressed [37]. Of note is that Sstr2 and 5 are also expressed in 
thyrotrophs [38]. The observed decrease in Ghrh mRNA in the hypothalamus in 
combination with the increased mRNA level of Sstr2 in the anterior pituitary might 
be at the basis of the reduced mGh mRNA detected in the anterior pituitary of 
Nbea+/- mice. Most likely, in an attempt to compensate for the decrease in mGH, 
the mRNA level of Ghr is elevated in the anterior pituitary of Nbea+/- mice. 
The 85% reduction in mGh in anterior pituitaries of Nbea+/- mice causes a 50% 
decrease in Igf-1 mRNA in the liver and a 66% decrease in IGF-1 protein detected 
in plasma. Reduced plasma IGF-1 levels correlate with the dwarf phenotype and 
increased fat percentage [20]. 
The dwarf phenotype in the Nbea GH240B mouse model used in our experiments 
obfuscates the interpretation of body weight, although the body weight of 1-year-
old Nbea+/- mice exceeds the 
body weight of Nbea+/+ mice. Normal growth was reported for the Nbea+/- gene-
trap mice and they also have an increased ratio of adipose tissue resulting in a 
higher body weight [15]. These findings suggest that the increase in adipose tissue 
is correlated with Nbea haploinsufficiency rather than solely with the method of 
generating the Nbea mouse model. However, it cannot be excluded that the gene-
trap insertion has affected the expression of other genes involved in adipogenesis. 
An important issue arising from this study is whether the mouse model is still 
useful for studying NBEA function and its role in ASD. The two models are highly 
similar with the exception of growth deficiency. In addition, behavioral studies 
with the GH240B mouse model have shown abnormalities in sociability, and 
spatial learning and memory and show an increase in conditioned fear and in 
repetitive self-grooming behavior, making this a highly promising model for the 
study of ASD [12]. However, we cannot exclude the fact that the disturbed 
GH/IGF-1 axis contributes to the behavioral abnormalities since low IGF-1 levels 
have been suggested to contribute to the development of ASD in a subgroup of 
patients [39,40] and SHANK3-deficient ASD patients are being treated with IGF-1 
in a clinical trial (Clinicaltrial.gov NCT01525901). On the other hand, no growth 
retardation nor IGF-1 deficiency has been reported in any of the NBEA 
haploinsufficient ASD patients and another study in children with ASD measured 
an increased level of IGF-1 instead of a decrease, making the influence of IGF-1 in 
ASD a controversial issue that should be further assessed [41]. Behavioral studies 
in the other Nbea knockout model and/or the mouse models expressing 
transgenic hGH should be performed to exclude the role of hGH in the behavioral 
phenotype. To the best of our knowledge, there are no documented patients with 
isolated congenital growth hormone deficiency that also have psychiatric 
disorders. Therefore, we assume that the ASD-like phenotype in our mouse model 
can be attributed to NBEA haploinsufficiency. Another argument highlighting the 
usefulness of the GH240B model is that abnormalities in platelet morphology, 
which were first noticed in several ASD patients including one with NBEA 
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haploinsufficiency, are also observed in platelets of this mouse model [11]. This 
study has also demonstrated an altered phosphorylation pattern of PKA 
substrates. Since Nbea is an AKAP, these results suggest that this mouse model 
may be most useful in the identification of PKA substrates whose phosphorylation 
is regulated by Nbea. The first such PKA substrate that was identified using this 
mouse model is the transcription factor CREB [12]. 
3.6. Conclusion 
This study has unveiled the molecular basis for the discrepancy between the two 
commonly used mouse models for NBEA deficiency. Despite the growth deficiency 
caused by recombinant hGH expression, the two Nbea mouse models are mostly 
comparable. Taken together, this correlation between the two mouse models, 
combined with correlations with the ASD patient and cell lines, gives credence to 
all findings regarding NBEA function. However, to exclude the confounding effects 
of hGH we recommend using the gene-trap mouse models in the future to study 
the physiological function of NBEA and its role in the pathogenesis of ASD. 
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3.8. Supporting Information 
Table S3.1 Primers per gene used for quantitative reverse transcription PCR. The 
sequences of the primers are presented in a 5’ to 3’ orientation. Gh: growth hormone; 
Ghr: Gh receptor; Ghrh: Gh-releasing hormone; Ghrhr: Ghrh receptor; Sst: somatostatin; 
Sstr: Sst receptor; Ghrelinr: Ghrelin receptor; hGH: human GH; Igf-1: insulin-like growth 
factor 1; Gapdh: glyceraldehyde 3-phosphate dehydrogenase. 
 
Genes Forward Reverse 
Nbea  CTTTGTGCGGATCAACAGG  CATTGATGGAGTTGGCAAGA  
Gh  CCTCAGCAGGATTTTCACCA  CTTGAGGATCTGCCCAACAC  
Ghr  CCAGGATCTATTCAGCTGTACTATGC  TGGGTCCATTCATGAGCAATT  
Ghrh  GCAGAACCTCAATCGGAGAG  TGGTGAGGATGAGGATCACA  
Ghrhr  ACCCGTATCCTCTGCTTGCT  AGGTGTTGTTGGTCCCCTCT  
Sst  CCCAGACTCCGTCAGTTTCT  GGGCATCATTCTCTGTCTGG  
Sstr2  GAGGCCTTTCCCCTAGAGTT  CACCGTAACGCTTGTCCTT  
Sstr4  TCTGCATCGTCCTGGCTTT  CTTGGCCAGTTCCTGTTTCC  
Sstr5  TGGTCTTTGGGAAGGTGAAAG  TGTCCACAGTCGGAAATGGT  
Ghrelin  CCAGAGGACAGAGGACAAGC  CATCGAAGGGAGCATTGAAC  
Ghrelinr  GACCAGAACCACAAACAGACAG  GGCTCGAAAGACTTGGAAAA  
hGH  CCAGGAGTTTGAAGAAGCCT  GGAGGTCATAGACGTTGCTGT  
Igf-1  GCTCTTCAGTTCGTGTGTGGAC  CATCTCCAGTCTCCTCAGATC  
Gapdh  ATGGCCTTCCGTGTTCCT  CAGGCGGCACGTCAGAT  
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4.1. Abstract 
Background: Neurobeachin (NBEA) has been identified as a candidate gene for 
autism spectrum disorders (ASD) in several unrelated patients with alterations in 
the NBEA gene. The exact function of NBEA, a multidomain scaffolding protein, is 
currently unknown. It contains an A-kinase anchoring protein (AKAP) domain 
which binds the regulatory subunit of protein kinase A (PKA) thereby confining its 
activity to specific subcellular regions. NBEA has been implicated in post-Golgi 
membrane trafficking and in regulated secretion. The mechanism of regulated 
secretion is 
largely conserved between neurons and platelets, and the morphology of platelet 
dense granules was found to be abnormal in several ASD patients, including one 
with NBEA haploinsufficiency. Platelet dense granules are secreted upon vascular 
injury when platelets are exposed to for instance collagen. Dense granules contain 
serotonin, ATP and ADP, which are necessary for platelet plug formation and 
vascular contraction. 
Methods: To further investigate possible roles for NBEA in secretion or dense 
granule morphology, platelets from Nbea+/− mice were analyzed 
morphometrically, functionally and biochemically. A differential proteomics and 
peptidomics screen was performed between Nbea+/− and Nbea+/+ mice, in which 
altered Talin-1 cleavage was further investigated and validated in brain samples. 
Finally, the phosphorylation pattern of PKA substrates was analyzed. 
Results: Platelet dense granules of Nbea+/− mice had a reduced surface area and 
abnormal dense-core halo, but normal serotonin-content. Nbea haploinsufficiency 
did not affect platelet aggregation and ATP secretion after collagen stimulation, 
although the platelet shape change was more pronounced. Furthermore, 
peptidomics revealed that Nbea+/− platelets contain significantly reduced levels of 
several actin-interacting peptides. Decreased levels were detected of the actin-
binding head and rod domain of Talin-1, which are cleavage products of Calpain-2. 
This is most 
likely due to increased PKA-mediated phosphorylation of Calpain-2, which renders 
the enzyme less active. Analysis of other PKA substrates revealed both increased 
and reduced phosphorylation. 
Conclusion: Our results show the pleiotropic effects of alterations in PKA activity 
due to Nbea haploinsufficiency, highlighting the important function of the AKAP 
domain in Nbea in regulating and confining PKA activity. Furthermore, these 
results suggest a role for Nbea in remodeling the actin cytoskeleton of platelets. 
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4.2. Background 
The genetic architecture of autism spectrum disorders (ASDs) is highly 
heterogeneous and to date more than 100 genes have been reported to be 
deleted, duplicated, mutated or disrupted by a translocation breakpoint in ASD 
patients [1,2]. One of these candidate genes, Neurobeachin (NBEA) [MIM: 
604889] was identified in a patient with a de novo balanced chromosomal 
translocation t(5;13)(q12.1; q13.2) with one breakpoint in intron 2 of NBEA 
resulting in a NBEA haploinsufficient status [3]. Additionally, four unrelated ASD 
patients with a monoallelic deletion of NBEA were reported [4-7], and three novel 
CNVs were detected within the NBEA gene in three unrelated individuals 
diagnosed with ASD [8-10]. Moreover, a single nucleotide polymorphism (SNP) in 
intron 38 of NBEA has been associated with ASD [11]. The NBEA gene contains a 
low frequency common fragile site (FRA13) linked to ASD and is located in a 19 cM 
region identified as a candidate region for ASD by a linkage study (MMLS/het 
score of 2.3 between markers D13S217 at 17.21 cM and D13S1229 at 21.51 cM) 
[12-14]. 
NBEA, a brain-enriched multidomain scaffolding protein, is located at the 
tubulovesicular endomembranes near the trans-Golgi network [15,16]. The N-
terminal region contains a Concanavalin A-like lectin domain flanked by armadillo 
repeats suggested to play a role in intracellular trafficking [17,18]. Distal from 
these regions, an A-kinase anchoring protein (AKAP) domain is present, recruiting 
cAMP-dependent protein kinase A (PKA) by high-affinity binding to its regulatory 
RIIα subunit [16]. The C-terminal part of NBEA possesses a pleckstrin homology - 
beige and Chediak-Higashi (BEACH) - WD40 domain module which is thought to 
be implicated in vesicle trafficking [16,19]. 
NBEA and eight other human proteins contain the highly conserved BEACH 
domain, and thus belong to the family of BEACH proteins [20]. Although the exact 
function of NBEA is currently unknown, a complete loss of Nbea in mice leads to a 
perinatal lethal phenotype due to a complete block of evoked neuromuscular 
transmission [21]. By studying neuronal cultures derived from E18 Nbea−/− mice, a 
role emerges for Nbea in trafficking important cargo to pre- and postsynaptic 
compartments, as these cultures have shown abnormal large clusters of actin in 
the soma, dendritic shafts and axons, and a reduced level of neurotransmitter 
receptors has been detected at the surface of the postsynaptic membrane 
[22,23]. Moreover, knockdown of Nbea in a neuroendocrine cell line (βTC3 cells) 
leads to enhanced secretion of dense-core secretory granules, the 
neuroendocrine counterpart of large dense-core vesicles (LDCVs) in neurons, 
making Nbea a negative regulator of the regulated secretion [24]. 
Blood platelets are the first players to be activated upon vascular injury. They are 
essential for initiating platelet plug formation and do so by secreting the content 
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of their secretory granules. Similar to neurons, platelets contain two types of 
secretory granules, namely the alpha and dense granules, corresponding to the 
small synaptic vesicles (SVs) and LDCVs in neurons, respectively [25]. Blood 
platelet alpha granules have a heterogeneous cargo of polypeptides ranging from 
adhesion molecules to growth factors, whereas dense granules contain the small 
molecules ATP, ADP and serotonin, necessary for vasoconstriction. 
Due to the similar regulation of granule formation and transport, platelets were 
put forward as a model system to study the biology of granule formation, 
trafficking and secretion in neurons [26,27]. Preliminary in vivo analysis unveiled 
an abnormal morphology of the dense granules in platelets of our reported 
patient with a chromosomal translocation in NBEA [24]. Moreover, similar platelet 
granule abnormalities were observed in ASD patients with chromosomal 
rearrangements in Amisyn or SCAMP5, and in an ASD patient with a deletion 
including SHANK3 [24]. Interestingly, mutations in LYST and NBEA-like 2 (NBEAL2), 
two other BEACH proteins, are described in patients with Chediak-Higashi and 
Gray platelet syndrome and result in abnormal to absent platelet dense and alpha 
granules, respectively [28,29]. 
As platelets can easily be obtained from patients, further insights into platelet 
abnormalities might lead to the identification of biomarkers associated with ASD. 
We have characterized platelets from mice heterozygous for Nbea to substantiate 
the causality of NBEA haploinsufficiency for the abnormal platelet phenotype. The 
ultrastructure of the dense granules of murine platelets was analyzed and platelet 
function was investigated. Moreover, serotonin levels were determined in both 
serum and platelets, as hyperserotonemia is the only biochemical anomaly 
reported in approximately 30% of ASD patients. Serotonin is a hormone and 
monoamine neurotransmitter that can induce vasoconstriction and is implicated 
in neuron outgrowth, maturation, function and plasticity. It is synthesized in 
serotonergic neurons of the central nervous system and in the intestine, and more 
than 99% of whole blood serotonin is stored in blood platelets [30]. To assess 
whether Nbea haploinsufficiency affects the protein and peptide content of 
platelets, a full proteomic and peptidomic analysis was performed and results 
were further validated in platelets and in total brain. 
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4.3. Methods 
All experiments were approved by the ethical research committee of KU Leuven in 
accordance with the declaration of Helsinki (project number P182/2011). 
4.3.1. Animals 
The GH240B transgenic line described in Su et al. [21] was backcrossed for at least 
10 generations with C57BL/ 6JRj mice (Janvier). Peripheral blood samples were 
obtained from adult (12-week-old) female mice. 
Brains were dissected from 12-week-old mice and immediately put at -80°C. 
Tissue was homogenized in sucrose buffer (3.18 mM sucrose; 4 mM Tris–HCl pH 
7.4) containing a protease and phosphatase inhibitor cocktail and a complete 
protease inhibitor cocktail (both from Roche Applied Science, Penzberg, 
Germany). 
4.3.2. Platelet function analysis and platelet counts 
Murine blood was anticoagulated with 3.2% trisodium citrate (9:1) and mean 
platelet volume (MPV) and platelet count were determined on an automated cell 
counter (Cell-Dyn 1300 Abbott laboratories, Abbott Park, IL, USA). Platelet-rich 
plasma (PRP) was obtained after centrifugation at 3,000 rpm for 30 sec followed 
by 800 rpm for 5 minutes. The platelet count was adjusted to 250,000 platelets/ μl 
with autologous plasma. Platelet aggregation and secretion were performed as 
described after stimulation with Horm collagen (5 μg/ml) [31,32]. Platelet 
secretion was determined 
by measuring the release of ATP using luciferin/luciferase reagent (Kordia, Leiden, 
The Netherlands).  
Electron microscopy analysis of murine platelets was performed as previously 
reported [33]. Additional ultra-thin sections of 50 to 70 nm were cut, stained with 
uranyl acetate and lead citrate, and examined at 80 kV using a JEM1400 
transmission electron microscope (JEOL, Tokyo, Japan). Micrographs were 
acquired on an SIS Quemesa camera (Olympus, Münster, Germany). The number 
of dense granules per platelet and dense granule dimension and morphology 
were further assessed with the ImageJ imaging system (National Institutes of 
Health, Bethesda, MD, USA) (n = 200 platelets/genotype). Dense granules were 
classified as different types: type 1, solid core occupying more than 50% of the 
granule; type 2, solid core occupying less than 50% of the granule; type 3, 
fragmented core; or type 4, empty granule/no visible core [34,35]. 
 
4.Nbea+/- mouse platelets display protein changes related to aberrant PKA activity. 
 
68 
 
4.3.3. Determination of platelet size and distribution by flow cytometry 
Integrin αIIbβ3 expression was measured in whole blood by incubation with 
fluorescein isothiocyanate (FITC)-conjugated anti-CD41/61 monoclonal antibody 
(BD Biosciences, Bergen County, NJ, USA) for 15 minutes. Forward and side scatter 
and percentage platelets to total cell number were analyzed using FACSDiva 
version 6.1.2 software (BD Biosciences) on a FACSCalibur flow cytometer (BD 
Biosciences). 
4.3.4. Platelet isolation for protein analysis 
Peripheral blood samples were obtained from the retro-orbital sinus 
(anticoagulated with ACD pH6.5 (7 mM citric acid; 93 mM sodium citrate; 140 mM 
dextrose); 9:1). 
PRP was obtained as described above. Platelets were obtained by PRP 
centrifugation at 2,300 rpm for 10 minutes and washed twice with ACD pH6.5. For 
proteomic purposes, PRP of littermates with the same genotype was pooled to 
yield sufficient protein contents to prepare the platelet pellets. 
4.3.5. Determination of serotonin levels in platelets and serum 
Serum was obtained from blood coagulated for 30 minutes at 37°C in glass 
cuvettes followed by centrifugation at 2,300 rpm for 10 minutes. Serotonin 
content of platelets, isolated as mentioned above, and serum was calculated using 
the serotonin research ELISA (Labor Diagnostika Nord, Nordhorn, Germany) 
according to the protocol of the manufacturer (n = 8 mice/genotype). 
4.3.6. Two dimensional-differential gel electrophoresis (2D-DiGE) 
Platelet pellets (n = 4 samples/genotype) were lysed in DiGE lysis buffer 
containing 7 M urea, 2 M thiourea, 4% CHAPS and 30 mM Tris pH 8.5 and a 
complete protease inhibitor cocktail (Roche Applied Science, Penzberg, Germany). 
The samples were purified with the 2D Clean-Up Kit (GE Healthcare, 
Buckinghamshire, UK) and the concentration was determined using the 2D Quant 
Kit (GE Healthcare) according to the manufacturer’s guidelines. Proteins were 
labeled with carbocyanine (Cy) dyes as previously described [31]. Briefly, 50 μg of 
each sample was labeled with 200 pmol of Cy3 or Cy5. To avoid possible bias due 
to labeling efficiency, two samples of each genotype were labeled with Cy3 and 
the other two with Cy5. The internal standard consisting of a pool of all samples 
was labeled with Cy2 allowing a quantitative comparison for a protein of two 
samples resolved on the same gel (ratio Cy3/Cy2 and Cy5/Cy2) and a quantitative 
comparison of multiple gels. Mixtures of Cy3-, Cy5- and Cy2-labeled samples were 
diluted 1:1 with lysis buffer containing 0.5% IPG buffer (pH 4 to 7) and 1.3% 
dithiothreitol (DTT) and applied by cup loading on rehydrated IPG strips (pH 4 to 
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7, 18 cm). The first dimension was carried out in an IPGphor system (GE 
Healthcare) with the following conditions: 1 h 30 minutes at 150 V, 2 h at 500 V, 5 
h at 
1,000 V, 3 h at 8,000 V in gradient and 5 h at 8,000 V. IPG strips were 
subsequently incubated in equilibration buffer (6 M urea, 30% glycerol, 2% SDS 
and 50 mM Tris pH 8.5) supplemented with 65 mM DTT for 20 minutes and 
followed by incubation in equilibration buffer supplemented with 200 mM 
iodoacetamide and 0.02% bromophenol blue for 20 minutes. The second 
dimension was performed on 11% polyacrylamide gels on the Hoefer DALT 
vertical system (GE Healthcare). 
Visualization and analysis of the images as well as the identification of 
differentially expressed proteins were executed as described previously [31]. 
4.3.7. Immunoblot analysis 
Platelet pellets were resolved in lysis buffer (1% Igepal; 0,015% DTT; 1 mM 
ethylene diamine tetraacetic acid (EDTA) in PBS supplemented with a complete 
protease inhibitor cocktail) (Roche Applied Science). Protein concentration of the 
platelet and brain lysates was quantified with a bicinchoninic acid (BCA) protein 
assay (Thermo Scientific, Rockford, IL, USA). Depending on the molecular weight 
of the protein of interest, 25 μg of platelet or brain lysates was loaded on a 10% 
Bis-Tris gel (Bio-Rad, Hercules, CA, USA) or 3 to 8% Tris-Acetate gel (Life 
technologies, Paisley, UK). Proteins were transferred to Protan Nitrocellulose 
membrane (Schleicher & Schuell, Dassel, Germany) and incubated with antibodies 
against Munc13-4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1/1,000), 
Rab27b (homemade antibody, 1/1,000), Calmodulin (kindly provided by Professor 
H Desmedt, KU Leuven; 1/1,000), Talin-1 (Cell Signaling Technology, Danvers, MA, 
USA; 1/500), Calpain-2 large subunit (Cell Signaling Technology; 1/1000), Calpain-4 
regulatory subunit (Santa Cruz Biotechnology; 1/1,000), phospho-(Ser/Thr) PKA 
substrate antibody (Cell Signaling Technology; 1/1,000), and actin (Sigma-Aldrich, 
St Louis, MO, USA; 1/5,000), used for normalization. Equal amounts of actin 
protein expression were verified after incubation with an antiglyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (Abcam, Cambridge, UK; 1/15,000). 
Afterwards, membranes were incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody (1/2,000; DAKO, Glostrup, Denmark) and proteins 
were visualized with western blotting ECL detection reagent. Quantification was 
performed using the Kodak Imager software (Kodak, Rochester, NY, USA). 
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4.3.8. Immunoprecipitation 
Per sample, 20 μl of 50% bead slurry of protein A agarose beads (GE Healthcare) 
was used and washed twice with PBS before use. All incubations were performed 
at 4°C on a mechanical rotator. Prior to immunoprecipitation, pre-clearing of the 
platelet or brain sample was performed as follows. Protein A agarose beads were 
incubated with rabbit serum (ImmuniBioScience, Mukiltoe, WA, USA) for 1 h after 
which 60 μg of platelet or brain sample was added for 1 h. The 
immunoprecipitation was subsequently performed with the pre-cleared 
supernatant by adding phospho-(Ser/Thr) PKA substrate antibody (Cell signaling 
technology; 1/100) for overnight incubation, followed by an additional 2 h 
incubation with protein A agarose beads. Beads were washed five times with PBS 
and proteins were harvested by resuspension of the beads in sample buffer (50 
mM Tris–HCl pH 7; 10% glycerol; 2% SDS; bromophenol blue) compatible with 
immunoblot analysis. 
4.3.9. Peptidomics 
Platelets were isolated as described above with modification of the final wash 
buffer, which was now replaced by PBS. The procedure for processing the platelet 
pellets (n = 5 mice/genotype) for mass spectrometry analysis was performed as 
reported [36]. DeCyder MS 2.0 (GE Healthcare) is a differential analysis software 
tool that also allows for easy visualization of liquid chromatography mass 
spectrometry (LC-MS) runs by creating artificial two-dimensional maps with the 
m/z values and retention times in the first and second dimension, respectively. 
Time alignment, intensity normalization and statistics were performed using this 
software. Peptides were identified in additional LC-MS/MS runs of the pooled 
samples as reported in [36] using LC quadrupole time-of-flight (Q-TOF) MS. 
4.3.10. Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM). Significance of 
differences was analyzed using (where appropriate) the two-tailed t-test, t-test for 
single means, Mann–Whitney U-test (MWU) or Pearson Chi-square test using 
Statistica version 9.0 (StatSoft Inc., Tulsa, OK, USA). All statistical tests were 
performed with 0.05 as the α-level of significance (*P <0.05, **P <0.01 and ***P 
<0.001). 
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4.4. Results 
4.4.1. Nbea+/- mice have normal platelet counts and MPV 
Heterozygous Nbea mice had a similar platelet count (n = 10/genotype; two-tailed 
t-test, P = 0.20 (Table 4.1) and MPV (n = 10/genotype; two-tailed t-test, P = 0.58) 
(Table 4.1) compared to wild-type mice. The normal platelet size, distribution and 
count was confirmed by means of flow cytometry analysis, as no differences could 
be detected in forward and side scatter or in percentage CD41/61-positive 
platelets relative to the total blood cell-number (n = 10/genotype; two-tailed t-
test, P = 0.83, P = 0.34 and P = 0.10, respectively) (Table 4.1). 
4.4.2. Abnormal dense granules in platelets of Nbea+/- mice 
The ultrastructure of the platelets of Nbea+/− mice (n = 200 platelets/genotype) 
was assessed to detect previously described alterations in dense granule cores as 
described for a patient haploinsufficient for NBEA [24] (Figure 4.1A). The number 
of dense granules per platelet was similar for Nbea+/− and Nbea+/+ mice (MWU, P = 
0.94) (Table 4.1). However, the total surface area within the limiting membrane of 
the dense granules of platelets of Nbea+/− mice was significantly reduced (MWU, P 
<0.001) (Table 4.1, Figure 4.1), due to a reduced surface area of the halo 
surrounding the dense-core (MWU, P = 0.001) (Table 4.1). Based on the 
appearance of the dense-core, dense granules were subdivided into 4 different 
types according to Weiss et al. [35]. No significant difference between genotypes 
was detected in the presence of the four types of granules in platelets (Pearson 
Chi-square test, P = 0.73) (Table 4.1). 
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Table 4.1: Morphological and functional characteristics of blood platelets 
haploinsufficient for Neurobeachin 
 Nbea+/+ Nbea+/− P 
Platelet count (103/μl) 943.6 ± 41.9 864.9 ± 42.2 0.20 
Mean platelet volume (fL) 6.52 ± 0.11 6.61 ± 0.12 0.58 
Flow cytometry    
 forward scatter (AU) 13,683.3 ± 667.3 13,853.8 ± 255.9 0.83 
 side scatter (AU) 1,038.5 ± 21.5 1,012.4 ± 13.3 0.34 
 platelets/cell total (%) 9.88 ± 0.53 8.46 ± 0.57 0.10 
Dense granules    
 number/platelet 0.445 ± 0.028 0.441 ± 0.028 0.94 
 surface area (nm2) 18,063.1 ± 696.2 14,331.3 ± 649.7 <0.001 
 dense-core area (nm2) 2,375.4 ± 251.2 1,706.4 ± 183.0 0.52 
 halo area (nm2) 15,687.7 ± 654.1 12,624.9 ± 607.4 0.001 
Dense granule classification    
 type 1 (%) 13.4 10.6 0.73 
 type 2 (%) 26.7 29.3 
 type 3 (%) 1.4 1.9 
 type 4 (%) 58.5 58.2 
Serotonin content    
 serum (ng/μl) 1.99 ± 0.25 2.21 ± 0.14 0.45 
 platelets (μg/109 PLTs) 7.59 ± 1.62 6.84 ± 1.61 0.75 
Aggregation (amplitude %)    
 collagen (5 μg/ml) 54.4 ± 5.7 52.8 ± 3.8 0.82 
ATP secretion (μM)    
 collagen (5 μg/ml) 1.58 ± 0.41 1.71 ± 0.67 0.87 
Platelet count and size were investigated in 10 mice/genotype. Dense granule morphology 
(MWU test) and classification was analyzed in 200 platelets/genotype. Dense granule 
classification was based on the study by Weiss et al. [35] and the total amount of dense 
granules counted per genotype was set at 100% yielding the above-mentioned separate 
percentage per dense granules type. The distribution of the dense granules into the 
classification types was compared between Nbea+/− and Nbea+/+ mice using the Pearson 
Chi-square test. Serotonin content was measured in eight mice/genotype. Platelet 
function was assessed in four mice/genotype. ATP secretion and aggregation were 
measured for 5 minutes after collagen stimulation. Unless stated otherwise, parameters 
were compared between genotypes using the two-tailed t-test. Data are represented as 
mean ± standard error of the mean. AU, arbitrary units; PLT, platelet. 
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Figure 4.1: Reduced total surface area of dense granules due to a decrease in surface 
area of the halo in platelets of Nbea+/− mice. (A) Electron microscopic view of a blood 
platelet of Nbea+/+ and Nbea+/− mice. Dense granules are indicated with black arrows. (B) 
Distribution of dense granule number according to their surface area. Dense granules of 
platelets of Nbea+/− mice were significantly smaller than dense granules of platelets of 
Nbea+/+ mice (n = 200 platelets/genotype). 
 
4.4.3. Normal serotonin levels in heterozygous Nbea mice 
Serotonin secreted from enterochromaffin cells enters the blood stream where it 
is actively taken up by platelets and stored in dense granules [37]. Platelet and 
serum serotonin levels were measured, but no significant difference could be 
detected between Nbea+/+ mice and Nbea+/− mice (n = 8 mice/genotype; two-
tailed t-test, P = 0.75 and P = 0.45, respectively) (Table 4.1). 
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4.4.4. Subtle changes in platelet function in Nbea+/- mice 
Platelet function was measured by the ATP secretion and aggregation test. In line 
with measurements of comparable serotonin levels, dense granules from wild-
type and heterozygous Nbea mice secrete similar levels of ATP upon collagen 
stimulation (n = 4 mice/genotype; two-tailed t-test, P = 0.87) (Table 4.1). 
Collagen binds to its glycoprotein receptors on the plasma membrane of platelets, 
resulting in the activation of phospholipase γ2 leading to an increase of 
intracellular Ca2+. The subsequent critical event is the reorganization of the actin 
cytoskeleton underlying filopodia and lamellopodia formation. This process is the 
essence of the platelet shape change which precedes platelet aggregation [38]. 
Although platelet aggregation after collagen stimulation was normal for Nbea+/− 
mice (n = 4 mice/genotype; two-tailed t-test, P = 0.82) (Table 4.1), they 
consistently presented with a more pronounced shape change after collagen 
activation (Figure 4.2). 
 
 
Figure 4.2: More pronounced shape change of platelets of Nbea+/− mice upon collagen 
stimulation. Collagen was added to wild-type and heterozygous platelet-rich plasma 
samples, respectively, at time points indicated by the blue and black arrows. Upon 
collagen stimulation, ATP secretion and aggregation were measured in the following 5 
minutes. Trace 1 and 3 visualize the aggregation of platelets from Nbea+/+ and Nbea+/− 
mice, respectively. The shape change preceding the aggregation is indicated with a black 
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rectangle. All replication experiments show a similar, more pronounced shape change for 
Nbea+/− mice. Traces 2 and 4 are the visualization of the ATP secretion of platelets of 
Nbea+/+ and Nbea+/− mice, respectively (n = 4 mice/genotype). Quantification of total ATP 
secretion was done after corrections for background values (ATP secretion in platelet-poor 
plasma). Though it seems that there were differences between the ATP secretion curves 
for Nbea+/+ and Nbea+/− mice in this experiment, quantification of ATP secretion values 
after correction for backgrounds in triplicate experiments, as shown in Table 4.1, showed 
no significant differences between genotypes. 
4.4.5. Proteomic profile of platelets heterozygous for Nbea 
To identify proteins differentially expressed in platelets of Nbea+/− mice, a 2D-DiGE 
experiment was performed (n = 4 samples/genotype). A representative gel of the 
protein profile of platelets of Nbea+/+ and Nbea+/− mice is shown in Additional file 
1. Each gel contained at least 1,432 genuine protein spots, based on a manual 
verification of the three-dimensional profile characteristics. Only proteins present 
in at least 50% of the gel images were included for statistical analysis. A difference 
in expression was found for a total of 21 proteins, with 10 proteins having a 
reduced expression level and 11 proteins with an increased expression level in 
platelets of Nbea+/− mice compared to platelets of Nbea+/+ mice (Additional file 
4.1). Post-translational modifications probably explain the different positions of 
the identified proteins on the gel. However, no significant differences in 
expression level were observed, as the change in these 21 proteins was never 
greater than 1.3-fold, the reliable threshold for differential expression in 2D-DiGE 
experiments. 
In addition, western blot was performed for several proteins related to dense 
granule biogenesis and secretion. The actin protein expression in platelets of 
Nbea+/− mice was comparable with the actin levels in Nbea+/+ mice, although 
contradictory findings are reported with regard to altered total actin levels in 
Nbea−/− mice [22,23,39,40]. 
Additional western blot analysis confirmed no differences in actin protein 
expression levels, when normalized to the GAPDH content, between Nbea+/+ and 
Nbea+/− mice (n = 4 samples/genotype; two-tailed t-test, P = 0.56) (Figure 4.3A). 
Therefore, total actin level can be used as an internal control for western blot 
analysis. The expression of Munc13-4, Rab27b and Calmodulin after actin 
normalization did not significantly differ between Nbea+/+ and Nbea+/− mice (n = 4 
samples/genotype; two-tailed t-test; Munc13-4, P = 0.77; Rab27b, P = 0.51; 
Calmodulin, P = 0.81) (Figure 4.3B). 
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Figure 4.3: Normal expression of actin and the proteins involved in dense granule 
formation and secretion in platelets of Nbea+/− mice. (A) Western blot analysis detected 
no changes in the total actin levels in platelets of Nbea+/− mice compared to Nbea+/+ mice. 
Actin expression was normalized to the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) content and the expression in platelets of wild-type mice was set at 100% (n = 
4/genotype). (B) The total amount of Munc13-4, Rab27b and Calmodulin was unaltered in 
platelets of Nbea+/− mice. Protein levels were normalized to actin and the expression level 
in platelets of Nbea+/+ mice was set at 100% (n = 4 samples/genotype). 
 
4.4.6. Differential peptidomics of platelets of Nbea+/- mice 
Platelets contain a wide variety of peptides as well as proteins [41]. The peptide 
content of platelets of wild-type and heterozygous Nbea mice were compared by 
LC Q-TOF MS. Only peptides that were sufficiently abundant, well-aligned in time 
and present in at least three out of five samples were considered for statistical 
analysis. This resulted in approximately twenty differential peptides of which six 
could be identified (n = 5 mice/genotype) (Table 4.2). Quantification revealed 
significantly lower levels of six peptides, namely Thymosin β4 (full length and 
fragments containing amino acids (AA) 1 to 18 and 19 to 43; two-tailed t-test, P = 
0.048), full length Thymosin β10 (two-tailed t-test, P = 0.020), Talin-1 (peptide 
containing AA 449 to 465; two-tailed t-test, P = 0.032) and the C-terminal part of 
Transgelin-2 (peptide containing AA 178 to 199; two-tailed t-test, P = 0.028). 
Interestingly, all these proteins are described as modulators of the actin 
cytoskeleton. 
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Table 4.2: Differentially expressed peptides in platelets of Nbea+/− mice 
Identification Uniprot 
ID 
MW 
(kDa) 
Identified 
peptide 
Mono-
isotopic 
mass 
Peptide sequence Modification Identification WT/HET 
ratio 
P 
Thymosin β4 P20065 5.05 TYB4 4960.44 SDKPDMAEIEKFDKS 
KLKKTETQEKNPLPS 
acetylation MS/MS, 
clustering 
[42] and [41] 
5.2433 0.048 
KETIEEKQAGES 
   TYB4 2150.07 SDKPDMAEIEKFDKS 
KLK 
acetylation Clustering 
[42] and [41] 
3.9551 0.024 
(1–18) 
   TYB4 2828.36 KTETQEKNPLPSKETI 
EQEKQAGES 
 Clustering 
[42] and [41] 
4.4780 0.036 
(19–43) 
Talin-1 P26039 269.8 TLN 1829.88 LPAIMRSGASGPEN 
FQVG  
Clustering 
[42] and 
identified in 
HEK MS/MS 
2.4572 0.032 
(449–
465) 
Transgelin-2 Q9WVA4 22.4 TAGLN2 2295.06 MGTNRGASQAGMT 
GYGMPRQIL 
 MS/MS and 
[41] 
2.1505 0.028 
(178–
199) 
Thymosin 
β10 
Q6ZWY8 5.03 TYB10 4933.43 ADKPDMGEIASFDKA 
KLKKTETQEKNTLPTK 
acetylation MS/MS 2.0944 0.020 
ETIQEKRSEIS 
The molecular weight (MW) is the MW of the precursor. A positive WT/HET ratio indicates 
a decrease in intensity in platelets of Nbea+/− mice. The length of the identified peptide is 
indicated between brackets with the numbers corresponding to the respective amino 
acids. Genotype differences were tested using the two-tailed t-test (n = 5 mice/genotype). 
 
4.4.7. Altered cleavage of Talin-1 and altered phosphorylation of Calpain-
2 in Nbea+/- mice 
The peptide identified as Talin-1 (AA 449–465) is most likely a degradation 
product as Talin-1 is a high-molecular weight protein of 270 kDa. Talin-1 consists 
of two domains, a head domain (49 kDa) and a rod domain (220 kDa) joined by a 
linker region containing a Calpain-2 (m-Calpain) cleavage site [43,44]. Western 
blot was performed for Talin-1 to assess the expression level and cleavage in 
platelets of Nbea+/− mice (n = 4 samples/genotype). The expression level of full-
length Talin-1 was slightly increased in platelets of Nbea+/− mice but the difference 
was not significant (two-tailed t-test, P = 0.35) (Figure 4.4A). However, the 
presence of cleavage products of Talin-1 was markedly reduced in platelets of 
Nbea+/− mice compared to Nbea+/+ mice, as the expression of both the rod and 
head domain was significantly decreased (two-tailed t-test, P = 0.018 and P = 
0.002, respectively) (Figure 4.4A). To extrapolate these findings to brain, Talin-1 
cleavage was studied in total brain lysates (n = 5 samples/genotype). As with 
platelet samples, the presence of the head domain was significantly reduced in 
the brain tissue of Nbea+/− mice compared to Nbea+/+ mice (t-test for single 
means, P = 0.04) (Figure 4.4B) and full-length Talin-1 showed no significant 
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difference in expression (t-test for single means, P = 0.55). There were several 
unsuccessful attempts to quantify the presence of the rod domain of Talin-1, due 
to a low signal-to-noise ratio for this domain. However, the reduced ratio of the 
head domain versus full-length Talin-1 indicates that in the brain tissue of Nbea+/− 
mice the cleavage of Talin-1 is also reduced. 
The protease responsible for the cleavage, Calpain-2, is a large catalytic subunit 
which forms a heterodimer with a regulatory subunit, Calpain-4 (Calpain small 
subunit 1) [45]. In order to investigate the reduced cleavage of Talin-1, western 
blot for Calpain-2 and -4 was performed and indicated similar expression levels of 
Calpain-2 and -4 in platelets (n = 4 samples/genotype; two-tailed t-test, P = 0.31 
and P = 0.67, respectively) (Figure 4.4C) and in total brain lysates (n = 3 
samples/genotype; t-test for single means, P = 0.34 and P = 0.92, respectively) 
(Figure 4.4D) of wild-type and heterozygous Nbea mice. 
The activity of Calpain-2 is negatively correlated with its phosphorylation status at 
a PKA consensus site [46,47]. As Nbea is an AKAP protein, Nbea haploinsufficiency 
might result in defects in the sequestering of inactive PKA and 
compartmentalization of PKA, leading to altered PKA activity in different 
subcellular locations [48]. Therefore, the phosphorylation status of Calpain-2 in 
resting platelets and brain was examined. The lack of an anti-phosphoCalpain-2 
antibody specific for PKA phosphorylation was overcome by performing 
immunoprecipitation with a phospho-(Ser/Thr) PKA substrate antibody detecting 
proteins containinga phosphorylated serine or threonine with an arginine at the -
3 position, followed by western blot with Calpain-2 antibody. The level of 
phosphorylated Calpain-2 was significantly increased in platelets of Nbea+/− mice 
with an average ratio of 2.8 (n = 6 samples/genotype; two-tailed t-test, P = 0.044) 
(Figure 4.4E). In contrast, the level of phosphorylated Calpain-2 in brain tissue of 
Nbea+/− mice was significantly decreased by a factor of 2.86 (n = 4 
samples/genotype; t-test for single means, P = 0.001) (Figure 4.4F). 
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Figure 4.4: Altered processing of Talin-1 and altered phosphorylation of Calpain-2. (A, B) 
As well as the normal levels of full-length Talin-1, the presence of the cleavage products 
(head and/or rod  domain) was significantly reduced in platelets (A) and in brain tissue (B) 
of Nbea+/− mice (n = 4 samples/genotype). (C, D) Western blots of Calpain-2 and -4, 
responsible for Talin-1 cleavage, indicated a similar expression of both Calpain subunits in 
platelets (C) and in total brain lysates (D) of Nbea+/− and Nbea+/+ mice (n = 4 
samples/genotype and n = 3 samples/ genotype, respectively). (E) Immunoprecipitation of 
phospho-(Ser/Thr) protein kinase A (PKA) substrates in platelets  followed by Calpain-2 
western blot revealed an increase in PKA-mediated phosphorylation of Calpain-2 (n = 6 
samples/genotype). (F) Immunoprecipitation of phospho-(Ser/Thr) PKA substrates in total 
brain tissue followed by Calpain-2 western blot showed a decrease in PKA-mediated 
phosphorylation of Calpain-2 (n = 4 samples/genotype). 
 
To examine whether Nbea haploinsufficiency has a more general effect on PKA-
dependent phosphorylation, western blot of platelet lysate with the phospho-
(Ser/Thr) PKA substrate antibody was performed. Several phosphorylated proteins 
were detected in resting platelets of Nbea+/+ and Nbea+/− mice and the 
phosphorylation of the three proteins with the highest molecular weight was 
significantly increased in Nbea+/− mice (n = 4 samples/genotype; t-test for single 
means, band 1, P = 0.042; band 2, P = 0.027; band 3, P = 0.010) (Figure 4.5A). 
Additionally, the phosphorylation of two other proteins was significantly reduced 
(t-test for single means, band 7, P <0.001 and band 8, P <0.001) whereas the 
phosphorylation of proteins 4 to 6 was unaltered (t-test for single means, P = 0.44, 
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P = 0.30 and P = 0.62, respectively) (Figure 4.5A). The same study was performed 
in brain tissue, which rendered several phosphorylated proteins. The 
phosphorylation of band 4, 6, 9 and 10 was significantly reduced in brain tissue of 
Nbea+/− mice (n = 5 samples/genotype; t-test for single means, band 4, P = 0.047; 
band 6, P = 0.003; band 9, P = 0.009; band 10, P = 0.024) (Figure 4.5B). 
 
 
Figure 4.5: Abnormal Protein kinase A (PKA) phosphorylation pattern in Nbea+/− mice. 
Visualization of proteins phosphorylated by PKA revealed several changes in 
phosphorylation levels of proteins in resting platelets (A) and brain lysates (B) of Nbea+/− 
mice. Phosphorylation levels were first calculated within a litter, followed by t-test for 
single means, with the mean of wild-type samples being 100%, to detect significant 
differences between Nbea+/+ and Nbea+/− mice. (A) In resting platelets the three proteins 
with the highest molecular weight had a significantly higher phosphorylation status. The 
following three bands had an unaltered phosphorylation level whereas the last two bands 
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had a significantly reduced phosphorylation profile (n = 4 samples/genotype). (B) Two 
different exposure times are shown for the PKA phosphorylation pattern of brain tissue, 
which were used for quantification. Image analysis revealed a significant decrease in 
phosphorylation level of four different proteins in brain tissue of Nbea+/− mice (n = 5 
samples/genotype). 
4.5. Discussion 
In this study we have confirmed a causal link between Nbea haploinsufficiency 
and abnormal granule morphology, similar to our previous observation in ASD 
patients [24]. Dense granules of Nbea+/− platelets were significantly smaller and 
showed a more pronounced shape change than Nbea+/+ platelets. However, none 
of the 1,432 proteins identified in a proteomic screen was differentially expressed. 
Differential peptidomics of platelets did identify four actin-interacting peptides 
with a reduced presence in platelets of Nbea+/− mice. Validation of the peptidomic 
screen revealed reduced cleavage of Talin-1, most likely due to increased 
phosphorylation of Calpain-2 by PKA. 
The reduced cleavage of Talin-1 was confirmed in Nbea+/− total brain, but 
phosphorylation of Calpain-2 was decreased. The importance of Nbea as a 
regulator of PKA activity was further substantiated, as haploinsufficiency of Nbea 
positively and negatively affects PKA-mediated phosphorylation of a multitude of 
proteins in resting platelets and in brain. 
Normal serotonin levels were detected in platelets and serum of Nbea+/− mice, 
which is consistent with the similar amount of dense granules per platelet in 
Nbea+/+ and Nbea+/− mice as serotonin is taken up by platelets and stored in the 
dense granules [37]. Hyperserotonemia is one of the few biochemical anomalies 
reported in ASD patients and several possible causes have been suggested, such 
as increased synthesis or altered release of serotonin from enterochromaffin cells 
[49,50]. However, only 30% of ASD patients have been classified as being 
hyperserotonemic and increased levels of serotonin have also been detected in 
relatives of ASD patients [30,51]. These findings highlight the controversy 
regarding hyperserotonemia as a biomarker for ASD. 
Several lines of evidence point to alterations in the cytoskeleton of platelets of 
Nbea+/− mice. First,  an increased shape change upon collagen stimulation was 
observed for platelets of Nbea+/− mice. Interestingly, platelets from patients with a 
dense granule secretion defect also presented with a more pronounced shape 
change [31]. A similar shape change was noticed in platelets of patients with 
Duchenne muscular dystrophy, a disease characterized by a disturbed cytoskeletal 
organization [52]. Second, all peptides that have a significantly different level in 
platelets of Nbea+/− mice are actin-interacting peptides. Transgelin-2, also named 
SMβ22, was identified as an actin-associated protein with an unknown function 
[53]. Thymosin β4 and β10 are the main intracellular G-actin sequestering 
peptides present in most mammalian cells. Binding of Thymosin β to G-actin 
4.Nbea+/- mouse platelets display protein changes related to aberrant PKA activity. 
 
82 
 
prevents the polymerization to F-actin and reduced levels of Thymosin β4 and β10 
lead to excessive formation of F-actin [54]. A decreased presence of Thymosin β4 
and β10 in platelets of Nbea+/− mice might be indicative for a decreased 
expression in neurons as well. This could contribute to the excessive F-actin 
clusters detected in the soma, dendritic shafts and axons of hippocampal 
neuronal cultures of Nbea−/− mice and in the soma of cortical neurons of Nbea+/− 
mice, although the exact mechanism remains to be determined [22]. Of note, a 
proteomic study using platelets from patients with a dense granule secretion 
defect also revealed actin-binding proteins as the major change in differentially 
expressed proteins compared to control platelets [31]. 
Multiple F-actin binding sites have been identified in Talin-1, both in the head and 
rod domain [55,56]. The peptide of Talin-1 identified in the peptidomic screen is 
likely to be a degradation product of the rod domain. The diminished presence of 
this peptide in platelets of Nbea+/− mice correlates with the reduced presence of 
the rod domain detected on western blot. Talin-1 is cleaved by Calpain-2 after 
amino acid 432, yielding the head and rod domain of Talin-1 [44]. Calpain-2 
activity is regulated by phosphorylation of PKA; more specifically, phosphorylation 
of Ser369 or Thr370 results in decreased activity [46,47]. The observed increase in 
PKA-specific phosphorylation of Calpain-2 is therefore a likely cause of the 
reduced cleavage of Talin-1 in blood platelets.  
It is known that the F3 subdomain in the head domain of Talin-1 interacts with the 
cytoplasmic tail of β-integrin during the platelet activation process [57]. 
Therefore, alterations in platelet function might be expected based on the 
reduced presence of the head domain of Talin-1. However, in contrast to the 
conditional-knockout mouse models generated to study the molecular function of 
Talin-1, no complete ablation of Talin-1 was detected in platelets of Nbea+/− mice. 
Of note is the finding that heterozygous conditional Talin-1-knockout mouse 
models do not present alterations in platelet function [58]. 
In Wistar rats, Talin is detected at the membranes of granules and dense 
compartments in the megakaryocytes [59,60]. Wistar Furth rats, a rat model with 
abnormal thrombocytopoietic phenotype associated with morphologically 
aberrant megakaryocytes lack these dense compartments. It is hypothesized that 
the lack of cytoskeletal proteins such as Talin may be responsible for the absence 
of the dense compartments in megakaryocytes of Wistar Furth rats. Therefore, it 
is possible that the observed alterations in Talin-1 in Nbea+/− platelets contribute 
to the morphological differences of dense granules resulting in the reduced size of 
these dense granules. 
Decreased cleavage of Talin-1 was also observed in total brain of Nbea+/− mice. 
However, PKA-mediated phosphorylation of Calpain-2 was decreased, leading to 
increased activity, in contrast to blood platelets. A possible explanation for this 
discrepancy between platelets and brain tissue is that platelets represent a pure 
cell population, whereas the brain is a mixed-cell population. 
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Therefore, it is possible that cells with reduced phosphorylation of Calpain-2 are 
not the cells with high Talin-1 expression. For instance, the brain tissue consists of 
both excitatory and inhibitory neurons and earlier studies using neuronal cultures 
derived from either adult Nbea+/− mice or E18 Nbea−/− mice revealed an imbalance 
in excitatory and inhibitory signaling with a more affected inhibitory 
neurotransmission [22,23,39]. 
Likewise, the phosphorylation status of Calpain-2 might be influenced by the 
excitatory/inhibitory imbalance present in the brain of Nbea+/− mice. In addition, 
the expression level of Nbea varies in different brain regions [16], which is likely to 
contribute to the alterations in PKA mediated phosphorylation on Calpain-2 upon 
Nbea haploinsufficiency. 
The altered level of PKA-phosphorylated Calpain-2 is in line with the reported 
increase in PKA-mediated phosphorylation of the cAMP response element-binding 
protein (CREB) in a neuroendocrine cell line after knockdown of Nbea, and 
indirectly, the increased level of brain-derived neurotrophic factor (BDNF), a 
target of phospho-CREB, in Nbea+/− mice [40]. As well as Calpain-2, the 
phosphorylation status of other proteins is affected in Nbea+/− mice, as indicated 
by the increased or decreased intensity of several proteins detected in a western 
blot of lysates of resting platelets or brain tissue with antiphospho-(Ser/Thr) PKA 
substrate antibody. Although the alterations in PKA-mediated phosphorylation in 
total brain tissue from Nbea+/− mice are more subtle, this might also be the result 
of the mixed-cell population and variable Nbea expression levels. The concurrence 
of increased, unaltered and decreased PKA phosphorylation of different proteins 
caused by Nbea haploinsufficiency can be explained by the compartmentalizing 
role of AKAPs. Because of its AKAP domain, Nbea belongs to the AKAP family of 
proteins, which is known to scaffold PKA near its target proteins in a distinct 
subcellular compartment. Different AKAPs lead to different PKA 
compartmentalizations [48]. Haploinsufficiency of Nbea will lead to an altered 
subcellular distribution of PKA, which will cause a higher, lower or unchanged 
PKA-mediated phosphorylation of target proteins, depending on their subcellular 
presence. With a continuously expanding list of ASD candidate genes, there is 
increasing interest in signaling pathways linking ASD genetics with biological 
functions, such as growth and neurite outgrowth of developing neurons and 
synaptic function [61,62]. There is ample genetic evidence for the involvement of 
AKAPs in the etiology of ASD, and proteins encoded by 10 ASD-linked AKAP genes 
were shown to functionally integrate signaling cascades within and between 
several biological functions [63]. Haploinsufficiency of NBEA, one of the 10 ASD-
linked AKAP genes, is 
thereby suggested to affect multiple pathways, most likely via the pleiotropic 
effect of altered PKA activity. 
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4.6. Conclusions 
The characterization of platelets of Nbea+/− mice provides evidence for a causal 
relationship between NBEA haploinsufficiency in the patient and abnormal 
platelet morphology. Furthermore, the impaired cleavage of Talin-1, increased 
phosphorylation of Calpain-2, and an altered PKA-related phosphorylation 
fingerprint, emphasizes the importance of the AKAP domain of Nbea for its 
function. Spatiotemporal control of PKA activity appears to be an important 
physiological function of Nbea. These findings highlight that alterations in the 
phosphorylation status of proteins might contribute to the pathogenesis of ASD in 
at least a subgroup of patients. 
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4.8. Additional file 
Additional file 4.1: Figure S4.1. The protein content of Nbea+/− mice contained 21 
differentially expressed proteins compared to Nbea+/+ mice.  
 
 
A representative gel of the protein profile of platelets of Nbea+/+ and Nbea+/− mice after 
two dimensional-differential gel electrophoresis (2D-DiGE) is shown. The protein content 
of Nbea+/- mice contained 21 differentially expressed proteins compared to Nbea+/+ mice. 
In total, 21 proteins were differentially expressed in platelets of Nbea+/- mice, marked on 
the gel with green surroundings and numbered. Numbers indicated in white relate to the 
identified proteins. (n = 4 samples/genotype) MW: molecular weight, pI: isoelectric point 
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5.1. Abstract 
Background 
Neurobeachin (NBEA) is an autism spectrum disorders (ASD) candidate gene. 
NBEA deficiency affects regulated secretion, receptor trafficking, synaptic 
architecture and protein kinase A (PKA)-mediated phosphorylation.  
NBEA is a large multidomain scaffolding protein. From N- to C-terminus, NBEA has 
a concanavalin A-like lectin domain flanked by armadillo repeats (ACA), an A-
kinase anchoring protein domain that can bind to PKA, a domain of unknown 
function (DUF1088) and a BEACH domain, preceded by a pleckstrin homology-like 
domain and followed by WD40 repeats (PBW). Although most of these domains 
mediate protein-protein interactions, no interaction screen has yet been 
performed. 
Methods 
Yeast two-hybrid screens with the ACA and PBW domain modules of NBEA, gave a 
list of interaction partners, which were analyzed for Gene Ontology (GO) 
enrichment. Neuro-2a cells were used for confocal microscopy and nuclear 
extraction analysis.  
NOTCH-mediated transcription was studied with luciferase reporter assays and 
qRT-PCR, combined with NBEA knockdown or overexpression. 
Results 
Both domain modules showed a GO enrichment for the nucleus. PBW almost 
exclusively interacted with transcription regulators, while ACA interacted with a 
number of PKA substrates. 
NBEA was partially localized in the nucleus of Neuro-2a cells, albeit much less than 
in the cytoplasm. A nuclear localization signal was found in the DUF1088 domain, 
which was shown to contribute to the nuclear localization of an EGFP-DPBW 
fusion protein. 
Yeast two-hybrid identified the Notch1 intracellular domain as a physical 
interactor of the PBW domain and a role for NBEA as a negative regulator in 
Notch-mediated transcription was demonstrated. 
Conclusion 
Defining novel interaction partners of conserved NBEA domain modules identified 
a role for NBEA as transcriptional regulator in the nucleus. The physical interaction 
of NBEA with NOTCH1 is most relevant for ASD pathogenesis because NOTCH 
signaling is essential for neural development. 
 
Keywords: Neurobeachin, NBEA, Autism, Notch, PKA, PP2A, TUBA1A, gliogenesis, 
GABA, Actin 
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5.2. Background 
Neurobeachin is a candidate gene for autism spectrum disorders (ASD), based on 
haploinsufficiency in several patients with ASD and its chromosomal localization in 
an ASD candidate region [1–8]. NBEA is a large multidomain protein, which is 
highly expressed in mouse brain starting from midgestation (E10.5) [9,10]. It has 
been suggested to affect the synaptic architecture through remodeling the actin 
cytoskeleton [11,12]. In zebrafish, NBEA is essential for the maintenance of 
extensive dendritic branching in mature neurons [13]. Furthermore NBEA affects 
postsynaptic neurotransmitter receptor trafficking to the cell surface and is a 
negative regulator of regulated secretion [12,14]. The homolog of Nbea in D. 
melanogaster, Rugose (Rg), is important for associative learning and also affects 
synaptic architecture [15]. Based on a rough eye phenotype in Rg mutants, 
genetic interactions were observed with components of the Delta-Notch pathway 
[16–18]. Studying the homolog of Nbea, SEL-2, in vulval precursor cells of C. 
elegans also revealed a genetic interaction with the Notch pathway as well as the 
EGFR pathway [19].  
NBEA contains the following domains: a concanavalin A-like lectin (CALL) domain 
flanked by armadillo repeats (ACA), an A-kinase anchoring protein domain (AKAP), 
a conserved domain of unknown function (DUF1088), a pleckstrin homology-like 
domain (PH-like) and the beige and Chediak-Higashi domain (BEACH) followed by 
WD40 repeats (Fig 5.1A) [10,20,21]. The N-terminal ACA domain module of NBEA 
may fulfill a scaffolding function, since Armadillo-repeats are known to mediate 
protein-protein interactions. The role of the concanavalin A-like lectin domain is 
unknown, but based on its high similarity to the N-terminal heavy chain of 
clostridial neurotoxins it might play a role in intracellular sorting [20].  
NBEA is a member of the BEACH family of proteins, containing the conserved 
BEACH domain. Based on the limited knowledge about the protein functions in 
this family, it is thought that BEACH proteins are important for membrane 
dynamics and/or vesicle trafficking and NBEA has been found to negatively 
regulate secretion of dense-core granules [14,22]. It is still not known exactly how 
BEACH proteins contribute to these functions. Recently another BEACH protein, 
WD repeat and FYVE domain containing protein 3 (WDFY3), has been associated 
with ASD. WDFY3 was categorized into the transcription regulation network that 
seems to be implicated in ASD [23]. Specifically in NBEA and its mammalian 
homolog LPS-responsive beige-like anchor protein (LRBA) this BEACH domain is N-
terminally preceded by the DUF1088 domain and the PH-like domain. An 
interaction between the PH-like and the BEACH domain has been reported and 
suggested to form a groove for binding of proteins [21]. The BEACH domain is 
followed by WD40 repeats, which are thought to be important for scaffolding. 
Together these domains will be addressed as a conserved DUF-PH-like-BEACH-
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WD40 (DPBW) domain module or without DUF1088 the PH-like-BEACH-WD40 
(PBW) domain module. 
The AKAP domain of NBEA can bind the regulatory subunit of protein kinase A 
(PKA) [10,24]. Furthermore, NBEA regulates phosphorylation of a number of PKA 
substrates, including CREB and Calpain-2 [25,26]. AKAPs are known to regulate 
PKA subcellular localization through its binding. Some AKAPs have been reported 
to bind to specific PKA substrates, bringing them in closer proximity to PKA for 
phosphorylation [27]. 
The cellular function of NBEA, how it affects regulated secretion and contributes 
to ASD pathogenesis remains elusive. Screening for protein interactors of the N- 
and C-terminal conserved domain modules of NBEA, may help to unravel the 
function of NBEA and to highlight networks that can be important in ASD. In this 
study, we performed a Y2H screen for the ACA and PBW domain modules of 
NBEA. The advantage of Y2H analysis is that weak and transient protein 
interactions can be discovered in addition to strong interactions. Pathway analysis 
of these interactors provided novel insights into the function of NBEA. Although 
one interaction was further validated by functional assays, most of these 
interactions should be interpreted as “not yet validated with other techniques”. 
 
 
 
Figure 5.1. NBEA domain structure and constructs used. 
A) The NBEA protein [GenBank: 158854037] contains several conserved domains. From N- 
to C-terminus it contains a concanavalin A-like lectin domain (C) flanked by armadillo 
repeats (A), an A-kinase anchoring protein domain (AKAP), a domain of unknown function 
DUF1088 (D), the pleckstrin homology-like domain (P), followed by the BEACH domain (B) 
and WD40 repeats (W). The cDNA coding for this protein was used in a pcDNA3.1-FLAG 
plasmid for overexpression of full length NBEA. B) For the Y2H screens, two different well-
conserved NBEA domain modules, the ACA or the PBW modules, were fused C-terminally 
to a DNA-binding domain (DNA-BD). The numbering indicates the range of amino acids of 
NBEA that are included.  
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5.3. Methods 
5.3.1. Identification of PBW or ACA domain module interactors by yeast 
two-hybrid screening 
A partial region of mouse Nbea coding for the PBW domain module [GenBank: 
158854037] (Asn2137-Tyr2936) was cloned into the bait yeast expression vector 
pB27 by Hybrigenics Services (France) (Fig 5.1B). pB27-PBW was transformed into 
the L40ΔGal4 yeast strain and Hybrigenics Services performed a Y2H screening of 
a mouse embryonic (E10.5 and E12.5) brain cDNA library (Hybrigenics) [28].  
The Y2H screen for the ACA domain module of mouse Nbea was performed using 
the MATCHMAKER Two-Hybrid system (Clontech Laboratories Inc, CA, USA). The 
ACA domain module [GenBank: 158854037] (Met1-Met951) was cloned into the 
pGBKT7 plasmid (Fig 5.1B). This plasmid was co-transformed into the AH109 yeast 
strain together with a whole mouse embryonic (E12.5) cDNA pACT2 library [29], 
using the lithium acetate method [30]. After high stringency selection on synthetic 
dropout agar plates lacking leucine, tryptophane, and histidine (SD---), positive 
clones were restreaked on new SD--- plates and grown for another 1 to 2 days. 
Only the prey plasmids of clones that survived the second high stringency 
selection round were extracted using the Prepease yeast plasmid isolation kit (Usb 
Corporations, OH, USA). The corresponding prey fragments were amplified by PCR 
and sequenced at their 5’ junctions. Sequences were then compared with the 
GenBank database using BLAST. 
5.3.2. Construction of expression plasmids 
A pcDNA3.1-FLAG-Nbea plasmid, containing full length mouse Nbea cDNA 
[GenBank: 158854037] and an N-terminal fused FLAG-tag, was used as a template 
for a PCR with the following primers: 5’-GCTCTCGAATTCCTTGCATTTATTGAAC-3’ 
and 5’-CTGAGCGGATCCTCAGTACCTGTTCTG-3’. This PCR fragment contained the 
cDNA coding for the NBEA DPBW domain module [GenBank: 158854037] 
(Leu1948- Tyr2936) flanked by an EcoRI and a BamHI restriction site and was 
cloned in frame into the pEGFP-C2 plasmid, resulting in the pEGFP-DPBW plasmid.  
The sequence coding for the five arginines forming a classical nuclear localization 
signal (NLS) in the DPBW domain module were mutated into alanines using two 
site-directed mutagenesis PCRs on the pEGFP-DPBW template with the 
Quikchange Site-directed Mutagenesis Kit (Stratagene, CA, USA) (S5.1 Table). 
Mutations were sequence verified using Sanger sequencing. 
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5.3.3. Interaction network analysis 
All interactors were uploaded into Cytoscape 3.2.0 to create a network of direct 
protein–protein interactions for the two separate domain modules [31]. The 
BiNGO plug-in was used to assess significant enrichment of gene ontology 
identifications (GO-ID) in the interactor list compared to the whole mouse 
genome (S5.2 and S5.4 Tables) [32]. The threshold for significance was set at 0.01. 
Non-redundant and brain tissue-related significant terms were selected to be of 
interest within the context of ASD. 
On the 9th of April 2015, a Pubmed literature search was performed to find 
publications linking any of the interacting proteins with ASD by combining the 
gene name with the term “autism” as a query. Full articles were then reviewed for 
a relevant link between the gene and ASD pathogenesis. All interacting proteins 
were used as a query in the Online Mendelian Inheritance in Man (OMIM) 
database. 
The interacting proteins were identified as being PKA substrates if they were 
listed as such in the Phosphosite database [33]. 
5.3.4. Bioinformatics analysis 
The mouse NBEA full length FASTA protein sequence [GenBank: 158854037] was 
submitted into several bio-informatics tools (NucPred, PSORT II, PredictNLS and 
NetNES 1.1) to assess its nuclear localization and look for consensus nuclear 
localization signals [34,35]. 
5.3.5. Cell culture and transfections 
The mouse neuroblastoma cell line Neuro-2a (N2a) (CCL-131, obtained directly 
from American Type Culture Collection, UK) was cultured in Dulbecco's modified 
Eagles medium supplemented with 10% fetal bovine serum at 37 °C, 5% CO2. For 
overexpression, cells were transfected using TurboFect Transfection Reagent (Life 
technologies, CA, USA) according to the manufacturer’s protocol. For NBEA 
knockdown, cells were transfected with the SMARTpool siGENOME Nbea siRNA 
(GE Healthcare, UK) using Lipofectamine RNAiMax (Life technologies) according to 
the manufacturer’s protocol. The Stealth RNAi siRNA Negative Control, Med GC 
(Life technologies) was transfected as a control. Cells were harvested 24h after 
transfection, except for experiments with NBEA knockdown, where cells were 
harvested after 72h [14]. NBEA knockdown or overexpression was verified by 
means of a quantitative RT-PCR on mRNA of transfected N2a cells.  
When co-transfecting with other plasmids, knockdown was obtained by 
transfection with the previously described mU6Pro vector containing shRNA for 
Nbea (mU6Pro-shRNANbea) [14]. The construct used for NBEA overexpression 
was pcDNA3.1-FLAG-Nbea, expressing full length mouse NBEA. 
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5.3.6. Luciferase reporter assay 
The CBF1-dependent 4xwtCBF1 firefly luciferase reporter (4xwtCBF1Luc) has 
previously been used to asses NOTCH mediated transcription [36]. N2a cells were 
cotransfected with 390 ng of mU6Pro-shRNA-Nbea or pcDNA3.1FLAG-Nbea 
respectively, and with 320 ng of pCS2-NICD, 250 ng 4xwtCBF1Luc reporter and 40 
ng pRL-TK plasmid. Control conditions were used for NBEA overexpression or 
knockdown, NICD overexpression and for 4xwtCBF1Luc overexpression by 
performing parallel transfections with the empty control plasmids or 
4xmtCBF1Luc.  
The Dual-Luciferase Reporter Assay System (Promega, WI, USA) was used to 
assess the effect of NBEA knockdown or overexpression on Notch-mediated 
transcription. To account for differences in transfection efficiencies, firefly 
luciferase activity was normalized the Renilla luciferase activity. 
5.3.7. RNA extraction and quantitative reverse transcription PCR (qRT-
PCR) 
RNA of N2a cell cultures was extracted with the Nucleospin RNA Midi kit 
(Macherey-Nagel, Germany) according to the manufacturer’s protocol. Per 
experiment, an equal amount of RNA was reverse transcribed to cDNA using the 
iScript cDNA synthesis kit (Bio-Rad, CA, USA). Real-time qPCR was performed using 
iQ SYBR Green Supermix (Bio-Rad). 40 cycles of annealing/extension for 1min at 
60°C were carried out with the MyiQ single color real-time PCR detection system 
(Bio-Rad). The relative amount of mRNA expression was calculated using the 
generalized qBase method [37]. In this method normalization is performed to the 
geometric mean of multiple reference genes. In this case two reference genes 
were used, peptidylprolyl isomerase A (Ppia) and growth arrest and DNA-damage-
inducible alpha (Gadd45a). The primers used are given as supporting information 
(S1 Table). 
5.3.8. Nuclear extraction 
The Nuclear Complex Co-IP kit (Active Motif, Belgium) was used according to the 
manufacturer’s protocol to obtain cytoplasmic and nuclear fractions of N2a cells. 
5.3.9. Immunoblotting 
A bicinchoninic acid protein assay (Life technologies) was used to determine the 
protein concentration of the samples. Samples were dissolved in SDS sample 
buffer. Depending on the molecular weight of the proteins of interest a 10% Bis-
Tris gel (Bio-Rad) or 3-8% Tris-Acetate gel (Life technologies) was loaded with 
25µg of each sample. Proteins were transferred to Protran Nitrocellulose 
5. Nuclear presence of NBEA and interaction with NOTCH1 
 
100 
 
membrane (Schleicher&Schuell, Germany) and incubated with antibodies against 
endogenous NBEA (1/3,000; rabbit polyclonal, homemade against the synthetic 
peptide TKVSDDILGNSDRPGS-Cys-KLHMBS (Eurogentec) as validated in [14] and in 
S5.1 Fig), GAPDH 14C10 (1/5,000; rabbit mAb, #2118S, Cell signaling technology), 
HDAC2 (1/2,000; rabbit polyclonal, sc-7899, Santa-Cruz Biotechnology Inc, CA 
USA) and GFP (1/1,000; mouse mAb, 11814460001, Roche, Germany). Afterwards, 
membranes were incubated with HRP-conjugated secondary antibody (1/2,000; 
Dako, Denmark) and proteins were visualized with western blotting ECL detection 
reagent (Life technologies). Densitometry was performed using Image J analysis 
software (NIH) [38]. 
5.3.10. Confocal microscopy and image analysis 
After washing with PBS, N2a cells were fixed for 30 min with 4% formaldehyde 
(Polysciences, PA, USA) in PBS at room temperature. Cells were washed three 
times with PBS, followed by permeabilization with 0.1% Triton-X100 (Acros, 
Belgium) in PBS for 10 min. After blocking for 20 min with 5% goat serum (Dako) 
and 1% BSA (Sigma-Aldrich, MO, USA) in PBS (blocking buffer), cells were 
incubated with the primary homemade antibody for endogenous NBEA (1/1,000), 
diluted in blocking buffer, for 1h. After three washes, cells were incubated with a 
goat secondary Alexa594- or Alexa488-conjugated antibody (Life technologies) 
and DAPI (1/10,000) for 1h. Finally the cells were washed and mounted on 
microscope slides using Vectashield mounting medium (Vector laboratories, 
Canada). Cells were analyzed using the Olympus Fluoview FV1000 confocal laser 
scanning microscope and a 63x immersion oil objective.  
The tool ‘Z project’ in ImageJ software was used to make a 2D Z-projection of a 
confocal Z-stack. All confocal images shown are single confocal planes, unless 
otherwise specified. 
Quantification of nuclear EGFP fluorescence intensity was performed using Cell 
Profiler cell analysis software [39]. At least 300 transfected cells were measured 
per condition. 
5.3.11. Statistical analysis 
Data are represented as mean ± standard error of the mean (SEM). A student’s t-
test was used, unless stated otherwise. All statistical tests were performed with 
0.05 as the α-level of significance unless stated otherwise. With * P < 0.05, **P < 
0.01 and ***P < 0.001. 
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5.4. Results 
5.4.1. The NBEA PBW domain module interacts with nuclear proteins 
A Y2H screen for the two conserved domain modules ACA and PBW resulted in a 
list of 83 and 25 possible interactions, respectively (Fig 5.2, S5.2 Table and S5.3 
Table). Fourteen of these proteins (13%) have previously been reported within the 
context of ASD. In total, 31 genes (29%) are associated with neurological 
disorders. Five known PKA substrates (FLNA, ACTB, SOX9, MAP4K1 and GBF1) 
interacted with the domain modules of NBEA and three of these are linked with 
neurological disorders (FLNA, ACTB, SOX9). Both the PBW and the ACA domain 
interacted with Cortactin binding protein 2 N-terminal like (CTTNBP2NL). A lot of 
detected interactions were single hits, which highlights the need for further 
validation of these interactions in future experiments. 
A search for GO-ID enrichment in the ACA or PBW interactor group compared to 
the whole mouse genome was performed with BiNGO. For the ACA interactor 
group a significant enrichment was found for the following cellular components: 
cytoplasm (53%; P = 2.3461E-7), nucleus (39%; P = 2.2586E-6), cytoskeleton (13%; 
P = 4.3418E-3), mitochondrial part (8%; P = 7.1712E-3), and collagen (4%; P = 
1.5926E-4) (Fig 5.2, S5.4 Table). 
For the PBW interactors there only seemed to be a significant enrichment for 
proteins present in the nucleus (92%; P = 2.8728E-15) (Fig 5.2, S5.5 Table). These 
interactors mostly have a molecular function in DNA binding (84%; P = 7.5905E-
21) and/or transcription regulator activity (60%; P = 2.7411E-14). The PBW 
domain module also interacted with NUP153, which is a nuclear pore protein (Fig 
5.2). Within the context of ASD it is of interest that there was a significant 
enrichment for biological processes in glial cell differentiation (17%; P = 9.8389E-
7) and the NOTCH signaling pathway (13%; P = 5.7435E-5) (S5.5 Table). 
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Figure 5.2: Y2H screening results for the ACA and PBW domain module. 
The ACA and PBW domain modules of NBEA were used to screen for possible interaction 
partners. The results were visualized with Cytoscape software. Color coding was used to 
show genes related to ASD (red), to other neurologic disorders (orange) or no known 
association (blue). BiNGO enrichment analysis picked up an enrichment of ACA-interacting 
proteins for the cellular components: Cytoskeleton, Nucleus, Mitochondria, Collagen and 
Cytoplasm. The enrichment for cytoplasm is not shown in the figure. BiNGO analysis of 
PBW-interacting proteins only picked up the nucleus as an enriched cellular component. 
Some genes in this compartment also showed enrichment for the biological process of 
glial cell differentiation or Gliogenesis (purple framework). Proteins that are grouped as 
‘Other’ were cytoplasmic or not picked up in the mentioned enrichments for cellular 
component. The rhomboid shape marks PKA substrates. The mutual interaction partner is 
connected with a green line. 
5.4.2. Nuclear presence of NBEA 
Neurobeachin is known to be expressed in the cytoplasm and localized near the 
trans-Golgi network in a punctate pattern. Since the NBEA PBW domain module 
and even the ACA domain module interacted with a large number of nuclear 
proteins, we first used bio-informatics to assess whether full length NBEA could 
be present in the nucleus. PSORT II and NucPred detected classical nuclear 
localization signals (NLS), although PredictNLS failed to detect any nuclear 
localization (Table 5.1, S5.1 appendix). NucPred gave a nuclear localization score 
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of 0.56, meaning there is a 70% chance of nuclear localization. No leucine-rich 
nuclear export signals (NES) were identified (S5.2 appendix). 
In N2a cells, low levels of NBEA (nuclear fraction of 19.1% ± 0.8) were detected in 
the nucleus, in addition to the previously described cytoplasmic localization using 
confocal microscopy (Fig 5.3A, S5.2 Fig) [10]. This nuclear presence was confirmed 
by western blot of nuclear fractions (Fig 5.3B). Furthermore, the online database 
“Human protein atlas” supports these data, since immunostaining with a different 
NBEA antibody also shows NBEA expression in the nuclei of SH-SY5Y, human 
neuroblast, cells (S5.3 Fig) [40].  
Stimulating the cAMP/PKA pathway in N2a cells with Forskolin and IBMX or 
inhibiting nuclear export with Leptomycin B did not increase the nuclear presence 
of NBEA (data not shown). The latter suggests that NBEA is not actively exported 
out of the nucleus by the exportin CRM1, consistent with the fact that no 
consensus NES was detected. 
 
Table 5.1: PSORT II Computer prediction of putative NLSs in mouse NBEA 
 
PSORT II 
Prediction 
Location NBEA domain Patterna Consensus NLS type 
HKRK 768 - 4 (H/P)(K/R)n SV40-like 
RRRR 2066 DUF1088 4 (K/R)4 SV40-like 
RRRR 2067 DUF1088 4 (K/R)4 SV40-like 
aPattern names employed by PSORT II, which were correlated to a consensus NLS 
sequence as described in the consensus column, were used for comparison with the 
primary sequence of NBEA. 
bAmino acid position in NBEA (NP_085098.1) of the first residue in the predicted motif. 
 
 
Figure 5.3: Nuclear localization of NBEA. 
A) Confocal image of endogenous NBEA (yellow) in N2a cells. DAPI (cyan) was used to 
stain the nucleus. The separate images are shown in greyscale. B) Western blot showing 
endogenous NBEA at 327 kDa in cytoplasmic (C) and nuclear (N) fractions of N2a cells. 
GAPDH and HDAC2 were used as cytoplasmic and nuclear markers, respectively. * 
Aspecific band at 460 kDa. 
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5.4.3. The DUF1088 domain in NBEA is important for nuclear localization 
A penta-arginine sequence located in the DUF1088 domain was identified as a 
potential nuclear localization signal by NucPred and PSORT II (Fig 5.4A, Table 5.1, 
S5.1 appendix). An EGFP-DPBW fusion protein was designed to determine its 
localization. The EGFP-DPBW fusion protein was detected in the cytoplasm and 
the nucleus as observed with fluorescence confocal imaging and western blot of 
nuclear and cytoplasmic fractions (Fig 5.4, S5.4 Fig). A diffuse localization was 
observed, rather than a punctate pattern like full length NBEA. To assess if the 
predicted NLS in the DUF1088 domain is important for nuclear localization, the 
five present arginines (R) were mutated into alanines (A) (Fig 5.4A). Mutating this 
sequence resulted in a significant decrease of the confocal nuclear intensity (P = 
0.047) (Fig 5.4B, S5.4 Fig), demonstrating the importance of the NLS sequence for 
the nuclear localization of NBEA. A decrease of the nuclear intensity in nuclear 
and cytoplasmic fractions on western blot could be confirmed, but was not 
significant due to high variability of the overexpression levels between 
experiments (P = 0.063, Wilcoxon one-tailed signed rank test) (Fig 5.4C). 
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Figure 5.4: The DUF1088 domain of NBEA contains a NLS. 
A) EGFP-fused constructs were made containing the DPBW domain module. The NLS 
determined using bio-informatics is shown in an inset. For the EGFP-DPBWMUT construct 
the arginines (R) of the EGFP-DPBW construct were mutated to alanines (A). B) 
Representative confocal image of N2a cells with overexpression of the EGFP-DPBW or the 
EGFP-DPBWMUT fusion protein. DAPI was used to stain the nucleus. Quantification of 
nuclear intensity was based on at least 300 transfected cells per condition. Scale 
represents 5µm. C) Representative western blot of four experiments showing nuclear and 
cytoplasmic fractions of N2a cells transfected with pEGFP, pEGFP-DPBW or EGFP-
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DPBWMUT. For detection of the EGFP-fusion protein (170 kDa) an anti-GFP antibody was 
used (a-GFP). As a control for specificity for the fusion protein, no signal is seen for the 
unfused EGFP protein at this height, since it has a lower molecular weight of 27-30 kDa. 
HDAC2 and GAPDH were used as markers for nuclear and cytoplasmic fractions, 
respectively. 
5.4.4. Neurobeachin affects Notch-mediated transcription in N2a cells 
Previously, Notch has been identified as a genetic interactor of the Nbea 
homologs rugose and SEL-2. In the Y2H screen the NOTCH1 intracellular domain 
(NICD) [Genbank: 224967065] (His2223-Leu2457) was identified to interact with 
the PBW domain module. Upon activation, NOTCH1 is cleaved and its NICD 
translocates to the nucleus to initiate transcription. Therefore, colocalization with 
NICD and the effect of NBEA expression on downstream NOTCH mediated 
transcription were investigated.  
Overexpressed NICD will immediately translocate to the nucleus and only 
colocalized with the nuclear fraction of endogenous NBEA (Fig 5.5, S5.5 Fig). 
However, this colocalization was not mutually exclusive, since the NICD nuclear 
localization was not punctate, but homogenous throughout the nucleus.  
After nuclear translocation, the NICD forms a transcription activating complex 
with C-promotor binding factor 1 (CBF1) and Mastermind. Therefore, the 
previously described 4xwtCBF1 luciferase reporter was used to measure NOTCH 
activity. Overexpressing NICD-myc together with either overexpression (2.6-fold ± 
0.5) or knockdown (0.7-fold ± 0.1) of NBEA, resulted in a 50% decrease (P = 0.004) 
or increase (P = 0.003) in the Notch-mediated transcription of the luciferase 
reporter, respectively (Fig 5.6A and 5.6B). 
To validate the results obtained with the luciferase reporter assay, we performed 
qRT-PCR to assess the expression levels of NOTCH transcriptional targets, namely 
Hes5, Hey1, Id3 and Id4. Combining NICD overexpression with knockdown of 
NBEA (0.3-fold ± 0.1) indeed resulted in a significantly increased expression of all 
the addressed NOTCH targets (Hey1: P = 0.003; Hes5: P = 0.02; Id3: P = 0.02; Id4: P 
= 0.04) (Fig 5.6C), while NBEA overexpression (459-fold ± 161) resulted in a 
significantly decreased NOTCH-mediated transcription of Hes5 (P = 0.04) and Id3 
(P = 0.04). For Hey1 and Id4 the differences were not significant (Fig 5.6D).  
Since the Y2H screen for the PBW domain module also picked up HES5 and HEY1 
as potential physical interactors, we assessed if knockdown of NBEA could also 
affect the transcription levels of NOTCH target genes independent of NICD 
overexpression. Knockdown of NBEA (0.15-fold ± 0.03) resulted in decreased 
expression of Hes5 (P = 0.005) and Id4 (P = 7E-6), while no significant differences 
in expression could be observed for Hey1 and Id3 (Fig 5.6E). This means that the 
transcriptional repression of NOTCH targets by NBEA are mediated by NICD. 
Without NICD no (Hey1 and Id3) or even an opposite effect (Hes5 and Id4) is 
obtained. 
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Figure 5.5: Overexpressed NICD partially co-localizes with NBEA in N2a cells 
Confocal image of endogenous NBEA (yellow) and overexpressed NICD (magenta) in N2a 
cells. DAPI (cyan) was used to stain the nucleus. The separate images are shown in 
greyscale. 
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Figure 5.6: Notch-mediated transcription is affected by NBEA knockdown or 
overexpression. 
A,B) NICD activity was measured with a luciferase reporter assay. The signal of the 
4xwtCBF1 firefly luciferase reporter was measured and normalized to the renilla luciferase 
activity to control for transfection efficiency. The fold change of the normalized luciferase 
signal is shown compared to N2a cells with NICD stimulation (NICD) and without altered 
NBEA expression. N = 3/condition. A) N2a cells with or without NBEA KD (NBEA shRNA) 
were stimulated with overexpression of NICD. A representative western blot shows the 
0.7-fold ± 0.1 KD that is obtained for NBEA. Equal loading of the western blot is shown by 
GAPDH. B) N2a cells with or without NBEA overexpression (FLAG-NBEA) were stimulated 
with overexpression of NICD. A representative western blot shows the 2.6-fold ± 0.5 
overexpression that is obtained for NBEA. Equal loading of the western blot is shown by 
GAPDH. C, D, E) qRT-PCR results are shown for Nbea and for four Notch target genes: 
Hes5, Hey1, Id3 and Id4. The fold change is shown relative to the condition with normal 
NBEA expression levels. C) The results for N2a cells with NICD stimulation together with or 
without knockdown of NBEA (NBEA shRNA) are shown. D) The results for N2a cells with 
NICD stimulation together with or without overexpression of NBEA (FLAG-NBEA) are 
shown. E) The results for N2a cells without NICD stimulation together with or without 
knockdown of NBEA (NBEA shRNA) are shown. 
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5.5. Discussion 
In this study we conducted Y2H screens for the ACA and PBW domain modules of 
NBEA. PBW interacted mostly with nuclear transcription regulators, while the ACA 
interactors were enriched in PKA substrates. Furthermore, NBEA was detected in 
the nucleus in addition to the cytoplasm. A classical nuclear localization signal in 
the DUF1088 domain was identified and validated. These data suggest a role for 
NBEA in regulating transcription, besides the already established function in 
regulating phosphorylation of PKA substrates.  
In the Y2H screen, one of the interacting transcription regulators was NOTCH1, 
and more specifically the NICD. Overexpressing or knocking down NBEA together 
with NICD showed that NBEA is a negative regulator of NOTCH-mediated 
transcription.  
Based on the Y2H screen, the N-terminal ACA domain module seemed to interact 
with several PKA substrates, of which two were ASD-implicated genes. This 
supports the role of NBEA as an AKAP, although, for these proteins, no effect on 
phosphorylation was observed after knockdown (data not shown). Many of the 
NBEA domain interactors were previously linked to neurological disorders and/or 
ASD indicating that NBEA may contribute to ASD by means of one of its 
interaction partners.  
The most established ASD gene is BCKDK which already has been shown to be 
implicated in five unrelated families with patients with ASD or autistic features 
[41,42]. The observed Y2H interaction with NBEA domains provides further 
support for being an ASD gene, since disorder-linked proteins are more likely to 
establish direct protein interactions with each other, rather than be isolated in a 
network [43]. 
One big caveat in this study is that the interactions defined with the Y2H screens 
have not been validated yet with another technique. Furthermore interaction 
with a conserved NBEA domain, does not ascertain an interaction with full-length 
NBEA. Nonetheless, the exploratory nature of this paper will provide an 
informative base for future studies on NBEA molecular functioning. 
5.5.1. Nuclear NBEA may regulate transcription 
LRBA, the closest homolog of NBEA, has recently been shown to shuttle to the 
nucleus in  mouse bone marrow cells after stimulation with LPS [44]. This 
homolog also contains the PBW domain module which is 76 % identical to the 
module of NBEA. Just before the PBW domain module, a domain of unknown 
function (DUF1088) is conserved between both proteins. This domain includes a 
classical NLS consisting of a penta-arginine sequence, in NBEA as well as LRBA. By 
mutating this NLS we showed that the DUF1088 domain is important for the 
nuclear localization of the DPBW module. Despite several attempts, NLS 
mutagenesis of full length NBEA was unsuccessful due to its large GC-rich cDNA 
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sequence. Therefore it is still plausible that other signaling might contribute to the 
nuclear localization of full length NBEA. 
On average, 20% of total NBEA showed a punctate pattern in the nucleus, 
suggesting nuclear compartmentalization. NBEA might have a more pronounced 
nuclear localization after a specific cell stimulus, similar to LRBA. However 
stimulation of cAMP production, important for PKA signaling, did not increase 
nuclear localization of NBEA. Rugose, the shared homolog for LRBA and NBEA in 
D. melanogaster, has also been observed in some nuclei of neuroblasts 
delaminating from the ectoderm during stage 8-9 of embryogenesis [45]. Thus, a 
more pronounced nuclear expression will not only depend on cell stimulus, but 
also on cell type and developmental stage. Information obtained from the Human 
protein atlas further supports nuclear expression of NBEA in neuroblast cell lines 
[40].  
Since NBEA is a large protein (327kDa), it will have to be actively imported into the 
nucleus. Active nuclear import can be mediated by three classes of importins and 
goes through nuclear pores. The Y2H screen for the PBW domain module also 
picked up the nuclear pore component 153 (NUP153) as a possible physical 
interactor, which is important for Importin-β mediated import [46]. Further 
studies will have to point out how NBEA is imported into the nucleus. 
Recently, a second BEACH family member has been found to be implicated in ASD, 
namely WDFY3. WDFY3 also contains a PBW domain module and a CALL domain, 
but with very low sequence identity to NBEA. WDFY3 resides mainly in the 
nucleus, but does not contain a DUF1088 domain. Its function in the nucleus is 
unknown, but WDFY3 was still categorized into the transcription regulation 
network implicated in ASD pathogenesis [23,47,48]. Loss of WDFY3 in mice leads 
to increased proliferation of radial glia cells, increasing the brain cortical size [49].  
Studies documenting networks important in ASD pathogenesis mostly pick up 
protein networks implicated in synaptogenesis and neural growth. But recently 
proteins involved in chromatin remodeling and transcription regulation have 
shown to be enriched protein networks for ASD as well [23,50]. Since, based on 
the Y2H screen, PBW interacted with a number of transcription regulators and 
NBEA is partially distributed in the nucleus, the effect of NBEA on transcription 
warrants further research. 
5.5.2. NBEA is a negative regulator of Notch signaling 
Here we provide support that NOTCH1 and NBEA can physically interact with each 
other and that NBEA expression levels can even affect NOTCH-mediated 
transcription. Studies in D. melanogaster and C. elegans have already suggested 
genetic interactions between the NOTCH pathway and the Nbea homologs, 
rugose and SEL-2, respectively [16,18,19]. Since in Drosophila Rg expression is not 
regulated by NOTCH-mediated transcription, interactions at the protein level with 
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components of NOTCH signaling were suggested [16]. The effect of NBEA levels on 
NOTCH-mediated transcription is downstream of the NOTCH receptor activation, 
followed by its internal and external cleavage. Once NOTCH1 is cleaved, the NICD 
almost immediately translocates to the nucleus to initiate transcription. 
Therefore, there is a high probability that NBEA will interact with NICD mainly in 
the nucleus. Alternatively, NBEA overexpression may interfere with NICD nuclear 
translocation, for instance because they might use the same nuclear transport 
mechanism, namely Importin-β [51]. Interestingly, Yatim et al co-
immunoprecipitated NBEA from nuclear extracts of a T-ALL cell line using NICD as 
bait [52]. These data confirm both the nuclear localization and the potential 
physical interaction of NBEA with NICD, as observed in our study.  
Assessing the effect of NBEA expression on the downstream NOTCH-mediated 
transcription with the generalized CBF1-dependent luciferase assay, suggested for 
NBEA to be a negative regulator. There was an opposite effect between 
overexpression and knockdown of NBEA. This effect could be reproduced when 
studying specific NOTCH target genes with qRT-PCR, but with a somewhat variable 
outcome. The effect of NBEA overexpression on specific NOTCH target genes is 
less pronounced, compared to the effect on expression following NBEA 
knockdown. It can be expected that a more straightforward result is generated 
with the luciferase assay, since this is a general assay based on a luciferase 
plasmid, which is not endogenously expressed. In contrast, the NOTCH specific 
target genes are endogenously present in N2a cells and might be endogenously 
regulated at a more complex level, compared to the luciferase-construct. The 
complete composition of the NOTCH co-activator transcription complex is still not 
fully characterized and some negative regulators of NOTCH-mediated 
transcription have already been described. Furthermore, these target genes can 
be regulated at the level of epi-genetics, for example the methylation status of 
their promoter. A regional difference in the latter case could explain why not all 
NOTCH target genes behave in exactly the same way following altered NBEA 
levels. 
Since NICD most likely physically interacts with NBEA, NBEA might interfere with 
the formation of the co-activating transcription complex of NICD. However, since 
NICD can also be regulated post-translationally and NBEA is an AKAP, NBEA could 
negatively regulate NOTCH-mediated transcription by affecting the 
phosphorylation status of NICD.  
Although only canonical NOTCH target genes were assessed in this paper, it 
should be noted that non-canonical pathways could also be affected and 
contribute to a neuronal phenotype. 
Until now, no ASD patients have been described with mutations in Notch genes, 
which may be because NOTCH is implicated in many biological processes during 
development and will cause more severe developmental disorders. Notch1 
knockout mice already die during embryogenesis [53]. Mutations in human 
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NOTCH1 can cause aortic valve disease and T-cell acute lymphoblastic leukemia 
[54]. However regulators of the NOTCH pathway that are highly expressed in the 
brain, like NBEA, might lead to less severe and tissue-specific symptoms that may 
be important for ASD etiology.  
Recently, an integrated network analysis of de novo mutations in ASD patients has 
highlighted the NOTCH pathway as an important, enriched network. This network 
seemed to be common for ASD patients with and without intellectual disability 
(ID), while a network related to synaptic plasticity was only specific for ASD 
patients with ID [55]. In addition, three gene expression profiling studies of 
cerebellar or blood samples from ASD patients picked up an enrichment of the 
NOTCH pathway compared to controls [56–58]. In the central nervous system the 
NOTCH pathway is important for learning and memory, neuronal maturation and 
glial cell fate specification [59,60]. Conditional deletions of Notch1 in brain regions 
lead to precocious neuronal differentiation [59]. The NOTCH pathway is also 
known to be important in the cell fate decision between neurogenesis and 
gliogenesis. Gliogenesis also happened to be enriched for the Y2H PBW 
interaction list based on the following proteins: NOTCH1, ASCL1, SOX9 and SOX6. 
ASCL1, also known as MASH1, can regulate and is regulated by the NOTCH 
signaling pathway [61]. In contrast to NOTCH1, ASCL1 is a well-known proneural 
transcription factor and blocks gliogenesis [62]. HES1 and HES5, which are 
NOTCH1 transcription targets, can both repress ASCL1 expression and inhibit 
ASCL1 through protein-protein interactions. On the other hand ASCL1 can affect 
NOTCH signaling in neighboring cells by enhancing the expression of DELTA, a 
ligand of the NOTCH receptor [61]. SOX9 is a glial-specification transcription factor 
and has been shown to be a transcription target of NOTCH [63]. SOX6 expression 
can be regulated by SOX9 and has been shown to be important for cell 
specification to the glial lineage of oligodendrocytes, but is also essential for the 
maintenance of neural precursor cells by inhibiting neurogenesis [64,65].  
A gene expression profiling study of lymphoblastoid cell-lines derived from ASD 
patients showed a significantly increased expression of SOX9 [56]. Post-mortem 
neuropathologic studies of persons with ASD often find a decreased number of 
GABA-ergic Purkinje neurons in the cerebellum and Bailey et al. also reported an 
increase of cerebellar Bergmann glia [66,67]. In general, a switch of cell-fate from 
neural to glial cells might contribute to ASD pathogenesis, in which the NOTCH 
signaling pathway can be important and where NBEA might be a relevant 
modulator. 
  
5. Nuclear presence of NBEA and interaction with NOTCH1 
 
113 
 
5.5.3. The AKAP NBEA may bind PKA substrates 
Based on the Y2H screens, the NBEA ACA domain module interacted with a 
number of validated PKA substrates (MAP4K1, ACTB, FLNA and GBF1), while the 
PBW module interacted with one (SOX9). It is known that AKAP-proteins are able 
to bind PKA substrates themselves, bringing the substrates in closer proximity of 
PKA. Since two other PKA substrates (CREB and CALPAIN2) have already been 
shown to have increased phosphorylation in vivo, due to NBEA haploinsufficiency, 
we assessed this for GBF1, ACTB and FLNA (data not shown)[26,68]. In N2a cells 
ACTB did not seem to be phosphorylated by PKA. GBF1 and FLNA showed equal 
expression after NBEA knockdown, but also equal PKA-mediated phosphorylation. 
Previously, we have demonstrated that haploinsufficiency of NBEA in mouse 
platelets affected a significant proportion of the PKA-related phosphoproteome 
[68]. Knockdown of NBEA in N2A cells did not produce such a pronounced effect 
(data not shown), suggesting that the chosen experimental settings may not be 
conductive to study the AKAP function of NBEA. However, it remains tempting to 
speculate that the ACA domain module plays a role in substrate presentation to 
PKA. 
5.5.4. NBEA, neurotransmitter receptor trafficking and the cytoskeleton 
The cytoskeleton was an enriched GO term, when analyzing possible interactors 
of the ACA domain module. This is in line with the suggestion that the 
Concanavalin A-like lectin domain is important for intracellular sorting. In addition 
this GO enrichment can be of interest for two reasons. Firstly, it has been 
suggested that NBEA might affect synaptic architecture through modulating the 
actin cytoskeleton [69]. Here we detected a direct interaction between the NBEA 
ACA domain module and β-ACTIN (ACTB). Secondly, BEACH proteins are suggested 
to be involved in (vesicle) trafficking, in which cytoskeletal proteins play an 
important part. NBEA already has been shown to affect postsynaptic trafficking of 
neurotransmitter receptors [12]. It has been described to bind to Glycine receptor 
β-subunit and Synapse associated protein 2 (SAP102), which is implicated in 
glutamate receptor trafficking. Knockout of NBEA resulted in reduced surface 
levels of glutamate and Gamma-aminobutyric acid A receptors (GABAAR) [24,70]. 
Recent work found that the PKA-binding ability of NBEA can influence GABAAR 
trafficking, but is not essential [71]. Here we discovered a possible interaction 
between the NBEA ACA domain module and the GABAAR-associated protein 
(GABARAP). GABARAP regulates clustering of the GABAAR at the plasma 
membrane and can bind directly to microtubuli and indirectly to the actin 
cytoskeleton [72,73]. Our findings suggest that NBEA might regulate the 
trafficking of the GABAAR through binding with GABARAP and other cytoskeletal 
proteins, like ACTB and the microtubule network.  
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Previously a co-immunoprecipitation with full length NBEA in mouse adult tissue 
identified two tubulins, namely TUBB4A and TUBA4, as possible interactors [24]. 
Our Y2H analysis also picked up a tubulin, namely TUBA1A, further substantiating 
an important role for NBEA to be involved in the cytoskeleton. 
5.5.5. The AKAP NBEA may bind other phosphatases and kinases 
Based on the Y2H screens, CTTNBP2NL was the only common interactor of the 
ACA and the PBW domain module. Interestingly, CTTNBP2NL also interacts with 
two other previously described NBEA interactors, namely Striatin (STRN) and 
Zinedin (STRN4), forming the striatin-interacting phosphatase and kinase complex 
(STRIPAK) [24,74,75]. The STRIPAK complex has been described to be implicated in 
vesicle trafficking, dendritic spine formation and cell migration [75]. Although 
these specific interactions of NBEA with CTTNBP2BL, STRN and STRN4 have not 
been validated yet, the fact that they form a protein complex with each other and 
all have been picked up separately strengthens the possibility that these will be 
genuine interactors.  
PP2A, present in the core of the STRIPAK complex, consists of three functional 
subunits, the structural subunit A, the catalytic subunit C and the regulatory or 
scaffolding subunit B. The subunit B can further be divided into three subgroups: 
B, B’ and B’’ [76]. The striatin family has been suggested to belong to a new B’’’ 
group, but this is still controversial [76,77]. In the Y2H screens the ACA domain did 
interact with other structural subunits of PP2A (PPP2R5E (B’ subunit) and 
PPP2R3C (B’’ subunit)), but we did not find any member of the striatin family to 
be interacting with a NBEA domain module. This raises the hypothesis that NBEA 
is able to interact with the serine/threonine (S/T) kinase PKA, but also with the S/T 
phosphatase PP2A.  
A-kinase anchoring proteins (AKAPs) can form multi-protein complexes binding to 
other phosphatases and kinases as well [27]. In this way there can be a tight 
regulation of S/T phosphorylation and other posttranslational signaling in a 
specific cell compartment. In addition, other interacting kinases we picked up with 
the Y2H screens were BCKDK, PKM, MAP4K1, CDK4 and MAP2K2. NBEA might be 
an important scaffold for the formation of many different signaling complexes. 
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5.6. Conclusions 
In this study we have provided the first evidence for nuclear localization of NBEA 
and identified a NLS. The possible interaction of the PBW domain module with a 
number of transcription factors suggests a role in regulating transcription. This 
was further substantiated with the functional interaction with NOTCH1, which has 
previously been shown to be a genetic interactor in D. melanogaster and C. 
Elegans model systems. Our data also suggest that the ACA domain module may 
play a role in PKA substrate presentation. Taken together, this study provides 
experimental evidence to the multifaceted role of NBEA in signaling networks 
relevant for ASD. 
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5.8. Supporting information 
S5.1 Figure – Specificity of the homemade antibody for endogenous NBEA 
A) HEK293T cells, which do not express NBEA endogenously, were transfected with the 
pcDNA3.1-FLAG-Nbea construct. Confocal images show an exclusive colocalization 
between Flag (yellow) and NBEA (magenta) for cells that overexpress FLAG-NBEA. 
Untransfected HEK293T cells do not show any non-specific immunostaining for NBEA. 
Nuclei were stained with DAPI (cyan). Separate confocal images are shown in greyscale. A 
2D Z-projection of the confocal Z-stack is shown as well (Z-project). White bar = 10µm B) 
The NBEA antibody detects overexpressed FLAG-NBEA at the expected molecular weight 
of 327 kDa in HEK293T cell lysate (lane 2) compared to untransfected HEK293T cells (lane 
1). GAPDH is shown for normalization. C) The protein of 327 kDa is endogenously detected 
by the home-made antibody in N2a cell lysates (lane 1 and 3). This is NBEA-specific, since 
this fragment cannot be detected anymore in N2a cell lysates transfected with Nbea-
specific shRNA (lane 1 and 3). GAPDH is shown for normalization. 
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S5.1 Table – Primers per gene used for qRT-PCR and for site-directed mutagenesis PCR of 
pEGFP-DPBW. 
The sequences of the primers are presented in a 5’ to 3’ orientation. Nbea: Neurobeachin; 
Ppia: peptidylprolyl isomerase A; Gadd45a: growth arrest and DNA-damage-inducible 
alpha; Hes5: hairy and enhancer of split 5 (Drosophila); Hey1: hairy/enhancer-of-split 
related with YRPW motif 1; Id3: inhibitor of DNA binding 3; Id4: inhibitor of DNA binding 4 
 
 Forward primer Reverse primer 
RT-qPCR 
Nbea CTTTGTGCGGATCAACAGG CATTGATGGAGTTGGCAAGA 
Ppia GCGTCTCCTTCGAGCTGTTT TGCCTTCTTTCACCTTCCCAA 
Gadd45
a TGGTGACGAACCCACATTCA AGTCATCTCTGAGCCCTCGT 
Notch1 GGATGACCTAGGCAAGTCGG CCAGCAACACTTTGGCAGTC 
Hes5 CGCTCGCTAATCGCCTC CTTCCGCAGTCGGTTTTTCTC 
Hey1 CGGACGAGAATGGAAACTTG GTCTTTTCCTGGCCAAAACC 
Id3 GCTTAGCCAGGTGGAAATCCT AGCTCAGCTGTCTGGATCG 
Id4 CGATGGATGGCCAGGTGTG CTCCGGTGGCTTGTTTCTCT 
Muta-
genesis 
PCR 
PCR1 
TACTGGGAGGATGATCTTCGT 
CGACGGGCAGCATTTGTTCGA 
AATGCCTTTGGCTC 
GAGCCAAAGGCATTTCGAACA 
AATGCTGCCCGTCGACGAAGA 
TCATCCTCCCAGTA 
PCR2 
GCCTGGATTACTGGGAGGATG 
ATCTTGCTGCAGCGGCCGCAT 
TTGTTCGAAATGCCTTT 
AAAGGCATTTCGAACAAATGC 
GGCCGCTGCAGCAAGATCATC 
CTCCCAGTAATCCAGGC 
 
S5.2 Table – Y2H interaction partners for the NBEA ACA domain module. 
a Number of independent colonies or hits compared to the total number of hits for the 
specific interaction partner. 
b Pubmed ID (PMID) of articles linking between the gene and ASD. 
c Known PKA substrates according to www.phosphosite.org . y = yes 
d Other neurological disorders linked to the gene with the corresponding phenotype MIM 
number (OMIM) or PMID. 
Gene 
name Gene ID 
Ind/
Hitsa 
Autism-
related 
PMIDb 
PKA sub-
stratec Other neurological disordersd 
Actb 11461 1/1  / y 
Baraitser-Winter syndrome 
(OMIM: 243310); Dystonia (OMIM: 
607371) 
Aes 14797 1/1  /  / 
 Afp 163310737 6/6 22152641  / 
 Appl1 72993 1/1  /  / 
 Asnsd1 70396 1/1  /  / 
 Atp5b 11947 1/1  /  / 
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Atpif1 11953 1/1  /  / 
 Banp 53325 1/1  /  / 
 
Bckdk 12041 1/1 
22956686
, 
24449431  / BCKDK deficiency (OMIM: 614923) 
Cdk4 12567 2/2  /  / 
 
Cog4 102339 1/1  /  / 
Congenital disorder of 
glycosylation type IIj (OMIM: 
613489) 
Col1a2 12843 1/1  /  / 
 
Col4a1 12826 2/3  /  / 
Porencephaly 1 (OMIM: 175780); 
Brain small vessel disease (OMIM: 
607595) 
Col4a2 12827 1/1  /  / Porencephaly 2 (OMIM: 614483) 
Cops3 26572 1/1  /  / 
Cerebral palsy and epilepsy (PMID: 
23695280) 
Ctnnbl1 66642 1/1  /  / 
 Cttnbp2n
l 80281 1/1  /  / 
 Ddx17 67040 1/1  /  / 
 Eif3f 66085 1/1  /  / 
 Eif3L 223691 1/1  /  / 
 Exoc7 53413 1/1  /  / 
 Fam58b 69109 1/1  /  / 
 Fam73a 215708 1/3  /  / 
 Fam96b 68523 1/1  /  / 
 
Flna 192176 1/1 21653829 y 
Epileptic encephalopathy (PMID: 
23934111); Periventricular 
heterotopia (OMIM: 300049) 
Fth1 14319 1/1  /  / 
 
Ftl1 14325 1/1  /  / 
Neuroferritinopathy (OMIM: 
606159) 
Fubp1 51886 1/1  /  / 
 Fxr2 23879 2/2  /  / 
 Gabarap 56486 1/1 /  / 
 Gbf1 107338 1/1 / y 
 
Gigyf2 227331 1/1 25170348  / 
Parkinson disease 11 (OMIM: 
607688) 
Gnb1 14688 1/1 /  / 
 
Grn 14824 1/1 /  / 
Primary progressive aphasia 
(OMIM: 607485); Neuronal ceroid 
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lipofuscinosis (OMIM: 614706) 
Hip1 215114 1/1 /  / 
Williams Beuren syndrome, 
epilepsy, learning difficulties 
(PMID: 23756441) 
Hnrnpf 98758 1/1 25378250  / 
 HnrnpL 15388 1/1  /  / 
 
Hspd1 15510 1/1  /  / 
Spastic paraplegia 13 (OMIM: 
605280), Hypomyelinating 
leukodystrophy 4 (OMIM: 612233) 
Igfbp5 16011 1/1  /  / 
 Kansl1l 68691 1/1  /  / 
 
Lamb1 16777 1/1 
15128462
, 
25774865
, 
15523497  / Lissencephaly 5 (OMIM: 615191) 
Map2k2 26396 1/1  /  / 
Cardiofaciocutaneous syndrome 4 
(OMIM: 615280) 
Map4k1 26921 1/1  / y 
 Mapre1 13589 1/1  /  / 
 Mcrs1 51812 1/1  /  / 
 Mettl14 210529 1/1  /  / 
 Mical1 171580 1/1  /  / 
 Mrfap1 67568 1/2  /  / 
 Mta2 23942 1/1  /  / 
 Mtch1 56462 1/1  /  / 
 Myl3 17897 1/1  /  / 
 Ncaph 215387 1/1  /  / 
 Ncaph2 52683 1/1  /  / 
 Ndufb9 66218 1/1  /  / 
 Nono 53610 1/1  /  / 
 P4ha2 18452 1/1  /  / 
 
Phgdh 236539 1/1  /  / 
Neu-lavoxa syndrome 1 (OMIM: 
256520), phosphoglycerate 
dehydrogenase deficiency (OMIM: 
601815) 
Pkm 18746 1/1  /  / 
 Plg 18815 1/1  /  / 
 Polr1b 20017 1/1  /  / 
 Ppp2r3c 59032 1/1  /  / 
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Ppp2r5e 26932 1/1  /  / 
 
Psap 19156 1/1  /  / 
Combined saposin deficiency 
(OMIM: 611721), Gaucher disease 
(OMIM: 610539) 
Psmb1 19170 1/1  /  / 
 Rnf123 84585 1/1  /  / 
 
Rogdi 66049 1/1  /  / 
Kohlschutter-Tonz syndrome 
(OMIM: 226750) 
Rpl24 68193 1/1  /  / 
 Sept10 103080 1/1  /  / 
 Sf3b2 319322 2/2  /  / 
 Sfpq 71514 1/3 25378250  / 
 Suv420h
2 232811 1/1  /  / 
 Svil 225115 1/1  /  / 
 Tcf25 66855 1/1  /  / 
 Tmem18
1a 77106 1/1  /  / 
 Triobp 110253 1/1  /  / 
 
Tuba1a 22142 1/1 25378250  / 
Lissencephaly 3 (OMIM: 611603), 
Polymicrogyria, Pachygyria 
(22948023) 
Upk1a 109637 1/1  /  / 
 Wdr31 71354 1/1  /  / 
 Zfhx2 239102 1/1  /  / 
 Zfp36l1 12192 1/1  /  / 
 Zfp748 212276 1/1  /  / 
 Zfp827 622675 1/1  /  / 
 Zfp865 319748 1/1  /  / 
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S5.3 Table – Y2H interaction partners for the NBEA PBW domain module (see next page). 
a Number of independent colonies or hits compared to the total number of hits for the 
specific interaction partner. 
b Pubmed ID (PMID) of articles linking between the gene and ASD. 
c Known PKA substrates according to www.phosphosite.org . y = yes 
d Other neurological disorders linked to the gene with the corresponding phenotype MIM 
number (OMIM) or PMID. 
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Gene 
name Gene ID 
Ind/ 
Hitsa 
Autism-
related 
PMIDa 
PKA 
sub-
strateb 
Other neurological disordersc 
Ascl1 17172 1/2  / / Haddad syndrome (OMIM: 209880) 
Crebzf 233490 2/3  / /  / 
Cttnbp2nl 80281 1/1  / /  / 
Fbxl11 225876 1/1  / /  / 
Hey1 15213 1/3 20868653 /  / 
Hivep1 110521 1/1  / /  / 
Kif4 16571 1/1  / / X-linked mental retardation (OMIM: 300923) 
Notch1 18128 1/1  / /  / 
Nup153 218210 2/2  / /  / 
Pias1 56469 1/1 25378250 /  / 
Rasa1 218397 1/1 21525081 /  / 
Rnf2 19821 1/1  / /  / 
Smarce1 57376 10/46  / / Coffin-Siris syndrome (PMID: 25169878) 
Sox11 20666 1/1 18992374 / 
Coffin-Siris syndrome (PMID: 
25169878); Mental retardation 
(OMIM: 615866) 
Sox6 20679 1/1  / /  / 
Sox7 20680 1/1  / /  / 
Sox9 20682 1/1 20868653 y  / 
Taf1 270627 1/2 22213401 / X-linked Dystonia-Parkinsonism (OMIM: 314250) 
Tox4 268741 4/6  / /  / 
Zbtb16 235320 1/1  / / 
Skeletal defects, genital hypoplasia 
and mental retardation (OMIM: 
612447) 
Zfp287 170740 1/1  / /  / 
Zhx1 22770 1/1  / /  / 
Zic1 22771 1/1  / /  / 
CXXC5 67393 2/3  / /  / 
Hes5 15208 1/2  / /  / 
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S5.4 Table: GO terms showing significant overrepresentation in proteins interacting with 
the ACA domain module. Complete results on the 9th of April 2015 from BiNGO analysis 
within cytoscape of the protein list interacting with the NBEA ACA domain module. A 
hypergeometric test with Benjamini & Hochberg False Discovery rate correction was 
performed with a significance level of 0.01. The whole annotation was used as a reference 
set. The results are shown for one of the three GO categories: molecular function, cellular 
component or biological process. GO-ID : Gene Ontology identification, x : number of 
interacting proteins with the specific GO-ID. X: total number of interacting proteins with 
any GO-ID within the specific GO category. n : number of proteins in the whole mouse 
genome with the specific GO-ID. N: total number of proteins in the whole mouse genome 
with any GO-ID within the specific GO category. 
 
Biological process 
Selected ontology file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/GO_Biological_Process 
Selected annotation file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/M_musculus_default 
 
No annotations were retrieved for the following entities: DDX17, ZFP865, FTL1, TUBA1A, 
PKM, FXR2, MCRS1, MAP4K 
GO-ID corr p-value x n X N Description Genes in test set 
9987 1.2026E-6 47 8929 72 28957 
cellular 
process 
SUV420H2|MTCH1|NDUFB9
|HIP1|ASNSD1|PLG|ZFP827
|AFP|ACTB|NCAPH|GABARA
P|HSPD1|ZFP36L1|ATP5B|
METTL14|UPK1A|FTH1|PSM
B1|PSAP|FLNA|PHGDH|MT
A2|CTNNBL1|APPL1|BANP|
SEPT10|SVIL|MAP2K2|IGFB
P5|EXOC7|NONO|NCAPH2|
GBF1|AES|BCKDK|HNRNPL|
SFPQ|P4HA2|EIF3L|CDK4|P
OLR1B|HNRNPF|FUBP1|GN
B1|RPL24|EIF3F|MAPRE1 
44237 4.6393E-4 31 5372 72 28957 
cellular 
metabolic 
process 
SUV420H2|NDUFB9|HIP1|A
SNSD1|PLG|ZFP827|AFP|HS
PD1|ZFP36L1|ATP5B|METTL
14|PSMB1|PSAP|PHGDH|B
ANP|MAP2K2|NONO|GBF1|
AES|BCKDK|HNRNPL|SFPQ|
P4HA2|EIF3L|CDK4|POLR1B
|HNRNPF|FUBP1|GNB1|RPL
24|EIF3F 
8152 6.1621E-4 34 6472 72 28957 
metabolic 
process 
SUV420H2|NDUFB9|HIP1|A
SNSD1|PLG|ZFP827|AFP|HS
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PD1|ZFP36L1|ATP5B|METTL
14|FTH1|MICAL1|PSMB1|P
SAP|PHGDH|BANP|MAP2K2
|NONO|GBF1|AES|BCKDK|
HNRNPL|SFPQ|P4HA2|EIF3L
|CDK4|POLR1B|HNRNPF|FU
BP1|MYL3|GNB1|RPL24|EIF
3F 
44238 1.7524E-3 30 5588 72 28957 
primary 
metabolic 
process 
SUV420H2|HIP1|ASNSD1|PL
G|ZFP827|AFP|HSPD1|ZFP3
6L1|ATP5B|METTL14|PSMB
1|PSAP|PHGDH|BANP|MAP
2K2|NONO|GBF1|AES|BCKD
K|HNRNPL|SFPQ|P4HA2|EIF
3L|CDK4|POLR1B|HNRNPF|
FUBP1|GNB1|RPL24|EIF3F 
16043 2.9876E-3 16 1979 72 28957 
cellular 
component 
organizatio
n 
SUV420H2|SVIL|HIP1|NCAP
H2|ACTB|NCAPH|GABARAP
|ATP5B|UPK1A|COL1A2|PO
LR1B|RPL24|PHGDH|MAPRE
1|MTA2|BANP 
6996 4.8546E-3 11 1026 72 28957 
organelle 
organizatio
n 
SUV420H2|SVIL|HIP1|POLR
1B|NCAPH2|RPL24|MAPRE1
|MTA2|NCAPH|GABARAP|B
ANP 
 
 
Cellular compartment 
Selected ontology file : 
jar:file:C:\ProgramFiles\Cytoscape_v2.8.3\plugins\BiNGO.jar!/GO_Cellular_Component 
Selected annotation file : 
jar:file:C:\ProgramFiles\Cytoscape_v2.8.3\plugins\BiNGO.jar!/M_musculus_default 
 
No annotations were retrieved for the following entities: ZFP865, FTL1, PKM, MAP4K, 
PHGDH, LAMB1, KANSL1L, GIGYF2 
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GO-ID 
corr p-
value x n X N Description Genes in test set 
44424 2.3159E-12 57 9547 75 29351 
intracellular 
part 
SUV420H2|MTCH1|HIP1|TCF2
5|MRFAP1|TRIOBP|ACTB|TUB
A1A|PPP2R5E|FTH1|CTNNBL1
|APPL1|DDX17|MAP2K2|EXO
C7|COG4|ATPIF1|AES|RNF123
|SFPQ|POLR1B|MYL3|RPL24|
MAPRE1|NDUFB9|GRN|ZFP82
7|AFP|NCAPH|GABARAP|HSP
D1|ZFP36L1|ATP5B|FXR2|PPP
2R3C|MICAL1|PSMB1|PSAP|F
LNA|MTA2|BANP|SEPT10|SVI
L|ZFHX2|MCRS1|NONO|NCAP
H2|GBF1|BCKDK|HNRNPL|CO
PS3|P4HA2|EIF3L|CDK4|HNR
NPF|FUBP1|EIF3F 
5622 3.7927E-12 57 9783 75 29351 intracellular 
SUV420H2|MTCH1|HIP1|TCF2
5|MRFAP1|TRIOBP|ACTB|TUB
A1A|PPP2R5E|FTH1|CTNNBL1
|APPL1|DDX17|MAP2K2|EXO
C7|COG4|ATPIF1|AES|RNF123
|SFPQ|POLR1B|MYL3|RPL24|
MAPRE1|NDUFB9|GRN|ZFP82
7|AFP|NCAPH|GABARAP|HSP
D1|ZFP36L1|ATP5B|FXR2|PPP
2R3C|MICAL1|PSMB1|PSAP|F
LNA|MTA2|BANP|SEPT10|SVI
L|ZFHX2|MCRS1|NONO|NCAP
H2|GBF1|BCKDK|HNRNPL|CO
PS3|P4HA2|EIF3L|CDK4|HNR
NPF|FUBP1|EIF3F 
43229 8.9968E-11 50 8081 75 29351 
intracellular 
organelle 
SUV420H2|MTCH1|HIP1|TCF2
5|MRFAP1|TRIOBP|ACTB|TUB
A1A|FTH1|CTNNBL1|APPL1|D
DX17|COG4|ATPIF1|AES|SFPQ
|POLR1B|MYL3|RPL24|MAPRE
1|NDUFB9|GRN|ZFP827|NCA
PH|GABARAP|HSPD1|ZFP36L1
|ATP5B|PPP2R3C|MICAL1|PS
MB1|PSAP|FLNA|MTA2|BANP
|SEPT10|SVIL|ZFHX2|MCRS1|
NONO|NCAPH2|GBF1|BCKDK|
HNRNPL|COPS3|P4HA2|EIF3L|
CDK4|HNRNPF|FUBP1 
43226 8.9968 50 8106 75 29351 organelle SUV420H2|MTCH1|HIP1|TCF2
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E-11 5|MRFAP1|TRIOBP|ACTB|TUB
A1A|FTH1|CTNNBL1|APPL1|D
DX17|COG4|ATPIF1|AES|SFPQ
|POLR1B|MYL3|RPL24|MAPRE
1|NDUFB9|GRN|ZFP827|NCA
PH|GABARAP|HSPD1|ZFP36L1
|ATP5B|PPP2R3C|MICAL1|PS
MB1|PSAP|FLNA|MTA2|BANP
|SEPT10|SVIL|ZFHX2|MCRS1|
NONO|NCAPH2|GBF1|BCKDK|
HNRNPL|COPS3|P4HA2|EIF3L|
CDK4|HNRNPF|FUBP1 
43231 2.6514E-8 43 7110 75 29351 
intracellular 
membrane-
bounded 
organelle 
SUV420H2|MTCH1|NDUFB9|G
RN|HIP1|TCF25|MRFAP1|ZFP
827|TRIOBP|NCAPH|GABARAP
|HSPD1|ZFP36L1|ATP5B|PPP2
R3C|FTH1|PSMB1|PSAP|FLNA
|MTA2|CTNNBL1|APPL1|BAN
P|DDX17|ZFHX2|COG4|MCRS
1|NONO|NCAPH2|ATPIF1|GBF
1|AES|BCKDK|HNRNPL|COPS3
|SFPQ|P4HA2|EIF3L|CDK4|PO
LR1B|HNRNPF|FUBP1|MAPRE
1 
43227 2.6514E-8 43 7122 75 29351 
membrane-
bounded 
organelle 
SUV420H2|MTCH1|NDUFB9|G
RN|HIP1|TCF25|MRFAP1|ZFP
827|TRIOBP|NCAPH|GABARAP
|HSPD1|ZFP36L1|ATP5B|PPP2
R3C|FTH1|PSMB1|PSAP|FLNA
|MTA2|CTNNBL1|APPL1|BAN
P|DDX17|ZFHX2|COG4|MCRS
1|NONO|NCAPH2|ATPIF1|GBF
1|AES|BCKDK|HNRNPL|COPS3
|SFPQ|P4HA2|EIF3L|CDK4|PO
LR1B|HNRNPF|FUBP1|MAPRE
1 
44464 9.6522E-8 61 
1425
6 75 29351 cell part 
SUV420H2|MTCH1|HIP1|TCF2
5|MRFAP1|TRIOBP|ACTB|TUB
A1A|UPK1A|PPP2R5E|FTH1|F
AM73A|CTNNBL1|APPL1|DDX
17|MAP2K2|EXOC7|COG4|AT
PIF1|AES|RNF123|SFPQ|POLR
1B|MYL3|RPL24|MAPRE1|ND
UFB9|GRN|PLG|ZFP827|AFP|
NCAPH|GABARAP|HSPD1|ZFP
36L1|ATP5B|FXR2|PPP2R3C|
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MICAL1|PSMB1|PSAP|FLNA|
MTA2|BANP|SEPT10|SVIL|ZFH
X2|MCRS1|NONO|NCAPH2|G
BF1|BCKDK|HNRNPL|COPS3|P
4HA2|EIF3L|CDK4|HNRNPF|F
UBP1|GNB1|EIF3F 
5623 9.6522E-8 61 
1425
7 75 29351 cell 
SUV420H2|MTCH1|HIP1|TCF2
5|MRFAP1|TRIOBP|ACTB|TUB
A1A|UPK1A|PPP2R5E|FTH1|F
AM73A|CTNNBL1|APPL1|DDX
17|MAP2K2|EXOC7|COG4|AT
PIF1|AES|RNF123|SFPQ|POLR
1B|MYL3|RPL24|MAPRE1|ND
UFB9|GRN|PLG|ZFP827|AFP|
NCAPH|GABARAP|HSPD1|ZFP
36L1|ATP5B|FXR2|PPP2R3C|
MICAL1|PSMB1|PSAP|FLNA|
MTA2|BANP|SEPT10|SVIL|ZFH
X2|MCRS1|NONO|NCAPH2|G
BF1|BCKDK|HNRNPL|COPS3|P
4HA2|EIF3L|CDK4|HNRNPF|F
UBP1|GNB1|EIF3F 
5737 2.3461E-7 40 6765 75 29351 cytoplasm 
MTCH1|NDUFB9|GRN|HIP1|
MRFAP1|AFP|TRIOBP|ACTB|N
CAPH|GABARAP|HSPD1|ZFP36
L1|ATP5B|TUBA1A|FXR2|PPP
2R5E|PPP2R3C|FTH1|MICAL1|
PSMB1|PSAP|FLNA|APPL1|SE
PT10|SVIL|MAP2K2|EXOC7|C
OG4|ATPIF1|GBF1|BCKDK|HN
RNPL|RNF123|COPS3|P4HA2|
EIF3L|CDK4|RPL24|EIF3F|MAP
RE1 
5634 2.2586E-6 29 4149 75 29351 nucleus 
SUV420H2|HIP1|TCF25|MRFA
P1|ZFP827|TRIOBP|NCAPH|ZF
P36L1|PPP2R3C|PSMB1|MTA2
|CTNNBL1|APPL1|BANP|DDX1
7|ZFHX2|MCRS1|NONO|NCAP
H2|GBF1|AES|HNRNPL|COPS3
|SFPQ|EIF3L|CDK4|POLR1B|H
NRNPF|FUBP1 
32991 2.3815E-6 22 2493 75 29351 
macromole
cular 
complex 
SEPT10|IGFBP5|EXOC7|ACTB|
GABARAP|BCKDK|HNRNPL|AT
P5B|COPS3|TUBA1A|PPP2R5E
|EIF3L|CDK4|POLR1B|HNRNPF
|MYL3|PSMB1|GNB1|RPL24|E
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IF3F|MAPRE1|MTA2 
44446 5.4059E-6 22 2627 75 29351 
intracellular 
organelle 
part 
SUV420H2|MTCH1|NDUFB9|S
EPT10|NONO|GBF1|GABARAP
|HSPD1|BCKDK|ATP5B|COPS3
|TUBA1A|EIF3L|CDK4|POLR1B
|HNRNPF|MYL3|PSAP|RPL24|
FLNA|MAPRE1|MTA2 
43234 5.6190E-6 19 1995 75 29351 
protein 
complex 
SEPT10|IGFBP5|EXOC7|ACTB|
GABARAP|BCKDK|ATP5B|COP
S3|TUBA1A|PPP2R5E|EIF3L|C
DK4|POLR1B|MYL3|PSMB1|G
NB1|EIF3F|MAPRE1|MTA2 
44422 7.5470E-6 22 2703 75 29351 
organelle 
part 
SUV420H2|MTCH1|NDUFB9|S
EPT10|NONO|GBF1|GABARAP
|HSPD1|BCKDK|ATP5B|COPS3
|TUBA1A|EIF3L|CDK4|POLR1B
|HNRNPF|MYL3|PSAP|RPL24|
FLNA|MAPRE1|MTA2 
44444 2.5791E-5 27 4193 75 29351 
cytoplasmic 
part 
MTCH1|NDUFB9|GRN|HIP1|A
CTB|GABARAP|HSPD1|ZFP36L
1|ATP5B|TUBA1A|FTH1|PSAP
|FLNA|APPL1|SEPT10|MAP2K
2|EXOC7|COG4|ATPIF1|GBF1|
BCKDK|P4HA2|EIF3L|CDK4|RP
L24|EIF3F|MAPRE1 
5581 1.5926E-4 3 19 75 29351 collagen COL1A2|COL4A2|COL4A1 
5587 9.0133E-4 2 6 75 29351 
collagen 
type IV COL4A2|COL4A1 
30935 9.0133E-4 2 6 75 29351 
sheet-
forming 
collagen 
COL4A2|COL4A1 
43228 1.3820E-3 14 1798 75 29351 
non-
membrane-
bounded 
organelle 
SUV420H2|SEPT10|SVIL|TRIO
BP|ACTB|GABARAP|TUBA1A|
EIF3L|POLR1B|MICAL1|MYL3|
RPL24|FLNA|MAPRE1 
43232 1.3820E-3 14 1798 75 29351 
intracellular 
non-
membrane-
bounded 
organelle 
SUV420H2|SEPT10|SVIL|TRIO
BP|ACTB|GABARAP|TUBA1A|
EIF3L|POLR1B|MICAL1|MYL3|
RPL24|FLNA|MAPRE1 
5938 1.4370E-3 4 109 75 29351 cell cortex SEPT10|MAP2K2|EXOC7|ACTB 
5852 2.6817E-3 2 11 75 29351 
eukaryotic 
translation EIF3L|EIF3F 
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initiation 
factor 3 
complex 
44448 4.3418E-3 3 64 75 29351 
cell cortex 
part SEPT10|EXOC7|ACTB 
5856 4.3418E-3 10 1137 75 29351 
cytoskeleto
n 
SEPT10|SVIL|TUBA1A|MICAL1
|MYL3|FLNA|MAPRE1|TRIOBP
|ACTB|GABARAP 
5881 4.4755E-3 2 15 75 29351 
cytoplasmic 
microtubule TUBA1A|MAPRE1 
5743 7.0541E-3 5 303 75 29351 
mitochondr
ial inner 
membrane 
MTCH1|NDUFB9|ATP5B|PSAP
|HSPD1 
44429 7.1712E-3 6 460 75 29351 
mitochondr
ial part 
BCKDK|MTCH1|NDUFB9|ATP5
B|PSAP|HSPD1 
44452 7.1712E-3 2 20 75 29351 
nucleolar 
part EIF3L|POLR1B 
19866 7.5100E-3 5 315 75 29351 
organelle 
inner 
membrane 
MTCH1|NDUFB9|ATP5B|PSAP
|HSPD1 
70013 8.0343E-3 7 655 75 29351 
intracellular 
organelle 
lumen 
BCKDK|EIF3L|CDK4|POLR1B|N
ONO|GBF1|MTA2 
43233 8.0499E-3 7 659 75 29351 
organelle 
lumen 
BCKDK|EIF3L|CDK4|POLR1B|N
ONO|GBF1|MTA2 
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Molecular function 
Selected ontology file : 
jar:file:C:\ProgramFiles\Cytoscape_v2.8.3\plugins\BiNGO.jar!/GO_Molecular_Function 
Selected annotation file : 
jar:file:C:\ProgramFiles\Cytoscape_v2.8.3\plugins\BiNGO.jar!/M_musculus_default 
 
No annotations were retrieved for the following entities: ZFP865, FTL1, PKM, MCRS1, 
NCAPH2, MAP4K, LAMB1, KANSL1L, GIGYF2, NCAPH 
GO-
ID 
corr p-
value x n X N Description Genes in test set 
5488 2.4039E-8 53 10294 73 28966 binding 
MTCH1|HIP1|MRFAP1|TRIOBP
|ACTB|TUBA1A|UPK1A|PPP2R
5E|FTH1|PHGDH|CTNNBL1|D
DX17|MAP2K2|IGFBP5|AES|R
NF123|SFPQ|COL4A2|COL4A1
|POLR1B|MYL3|MAPRE1|GRN
|SF3B2|ZFP748|ZFP827|AFP|
GABARAP|HSPD1|ZFP36L1|AT
P5B|FXR2|PPP2R3C|MICAL1|P
SAP|FLNA|MTA2|BANP|SEPT1
0|SVIL|ZFHX2|NONO|GBF1|B
CKDK|HNRNPL|COPS3|COL1A
2|P4HA2|EIF3L|CDK4|HNRNP
F|FUBP1|EIF3F 
5515 4.4226E-6 34 5384 73 28966 
protein 
binding 
GRN|SF3B2|HIP1|MRFAP1|TRI
OBP|ACTB|GABARAP|HSPD1|
ATP5B|TUBA1A|UPK1A|FXR2|
PPP2R3C|FLNA|MTA2|CTNNB
L1|BANP|SEPT10|SVIL|IGFBP5
|NONO|GBF1|AES|RNF123|C
OPS3|SFPQ|COL1A2|COL4A1|
P4HA2|EIF3L|CDK4|POLR1B|H
NRNPF|MAPRE1 
5201 2.2626E-3 3 25 73 28966 
extracellular 
matrix 
structural 
constituent 
COL1A2|COL4A2|COL4A1 
3723 6.5102E-3 8 598 73 28966 RNA binding 
DDX17|HNRNPL|SFPQ|FXR2|N
ONO|HNRNPF|FUBP1|ZFP36L
1 
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Table S5.5: GO terms showing significant overrepresentation in proteins interacting with 
the PBW domain module. Complete results on the 9th of April 2015 from BiNGO analysis 
within cytoscape of the protein list interacting with the NBEA PBW domain module. A 
hypergeometric test with Benjamini & Hochberg False Discovery rate correction was 
performed with a significance level of 0.01. The whole annotation was used as a reference 
set. The results are shown for one of the three GO categories: molecular function, cellular 
component or biological process. GO-ID : Gene Ontology identification, x : number of 
interacting proteins with the specific GO-ID. X: total number of interacting proteins with 
any GO-ID within the specific GO category. n : number of proteins in the whole mouse 
genome with the specific GO-ID. N: total number of proteins in the whole mouse genome 
with any GO-ID within the specific GO category. 
 
Biological process 
Selected ontology file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/GO_Biological_Process 
Selected annotation file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/M_musculus_default 
 
No annotations were retrieved for the following entities: RASA1, NUP153 
 
GO-ID corr p-value x n X N Description Genes in test set 
6355 1.1986E-13 15 1192 23 28959 
regulation of 
transcription, 
DNA-dependent 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|HEY1|HIVEP1|SOX9|S
OX6|SOX7|ZFP287|HES5
|TAF1 
51252 1.1986E-13 15 1212 23 28959 
regulation of 
RNA metabolic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|HEY1|HIVEP1|SOX9|S
OX6|SOX7|ZFP287|HES5
|TAF1 
6350 1.1986E-13 16 1563 23 28959 transcription 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
45449 1.1986E-13 17 1980 23 28959 
regulation of 
transcription 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
10556 4.2686E-13 17 2166 23 28959 
regulation of 
macro-molecule 
biosynthetic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
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7|ZFP287|HES5|TAF1 
19219 4.9074E-13 17 2225 23 28959 
regulation of 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
10468 4.9074E-13 17 2229 23 28959 
regulation of 
gene expression 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
51171 5.0912E-13 17 2252 23 28959 
regulation of 
nitrogen 
compound 
metabolic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
31326 5.4743E-13 17 2278 23 28959 
regulation of 
cellular 
biosynthetic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
9889 5.7778E-13 17 2300 23 28959 
regulation of 
biosynthetic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
60255 2.4928E-12 17 2527 23 28959 
regulation of 
macromolecule 
metabolic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
34645 3.3039E-12 16 2099 23 28959 
cellular macro-
molecule 
biosynthetic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
9059 3.3039E-12 16 2109 23 28959 
Macro-molecule 
biosynthetic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
80090 3.6700E-12 17 2625 23 28959 
regulation of 
primary 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
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metabolic 
process 
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
31323 7.3276E-12 17 2749 23 28959 
regulation of 
cellular 
metabolic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
10467 9.0622E-12 16 2281 23 28959 gene expression 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
90304 1.1016E-11 16 2319 23 28959 
nucleic acid 
metabolic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
19222 1.7811E-11 17 2934 23 28959 
regulation of 
metabolic 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
44249 9.9011E-11 16 2693 23 28959 
cellular 
biosynthetic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
6139 1.0842E-10 16 2718 23 28959 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
9058 1.4843E-10 16 2783 23 28959 
biosynthetic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
34641 3.4074E-10 16 2947 23 28959 
cellular nitrogen 
compound 
metabolic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
6807 5.0341E-10 16 3032 23 28959 
nitrogen 
compound 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
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metabolic 
process 
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
10629 1.2171E-9 9 482 23 28959 
negative 
regulation of 
gene expression 
NOTCH1|HEY1|ZBTB16|H
IVEP1|SOX9|SOX6|RNF2|
HES5|PIAS1 
45941 6.7635E-9 9 588 23 28959 
positive 
regulation of 
transcription 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
10605 8.8550E-9 9 609 23 28959 
negative 
regulation of 
macro-molecule 
metabolic 
process 
NOTCH1|HEY1|ZBTB16|H
IVEP1|SOX9|SOX6|RNF2|
HES5|PIAS1 
10628 1.0860E-8 9 626 23 28959 
positive 
regulation of 
gene expression 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
45935 1.3249E-8 9 643 23 28959 
positive 
regulation of 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
16481 1.4083E-8 8 427 23 28959 
negative 
regulation of 
transcription 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5
|PIAS1 
9892 1.5136E-8 9 658 23 28959 
negative 
regulation of 
metabolic 
process 
NOTCH1|HEY1|ZBTB16|H
IVEP1|SOX9|SOX6|RNF2|
HES5|PIAS1 
51173 1.5775E-8 9 664 23 28959 
positive 
regulation of 
nitrogen 
compound 
metabolic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
10557 1.5775E-8 9 666 23 28959 
positive 
regulation of 
macromolecule 
biosynthetic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
44260 1.6106E-8 16 3903 23 28959 
cellular macro-
molecule 
metabolic 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
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process OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
6357 1.6271E-8 9 673 23 28959 
regulation of 
transcription 
from RNA 
polymerase II 
promoter 
NOTCH1|HIVEP1|SOX11|
SOX9|ASCL1|SOX6|SOX7
|RNF2|HES5 
45934 1.9895E-8 8 457 23 28959 
negative 
regulation of 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolic 
process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5
|PIAS1 
51172 2.2447E-8 8 466 23 28959 
negative 
regulation of 
nitrogen 
compound 
metabolic 
process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5
|PIAS1 
31328 2.2447E-8 9 705 23 28959 
positive 
regulation of 
cellular 
biosynthetic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
9891 2.5022E-8 9 716 23 28959 
positive 
regulation of 
biosynthetic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
10558 2.6241E-8 8 480 23 28959 
negative 
regulation of 
macro-molecule 
biosynthetic 
process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5
|PIAS1 
31327 3.1541E-8 8 493 23 28959 
negative 
regulation of 
cellular 
biosynthetic 
process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5
|PIAS1 
9890 3.4361E-8 8 500 23 28959 
negative 
regulation of 
biosynthetic 
process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5
|PIAS1 
45892 6.9360E-8 7 340 23 28959 
negative 
regulation of 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5 
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transcription, 
DNA-dependent 
10604 7.0342E-8 9 818 23 28959 
positive 
regulation of 
macromolecule 
metabolic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
51253 7.0342E-8 7 343 23 28959 
negative 
regulation of 
RNA metabolic 
process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5 
43170 7.1291E-8 16 4402 23 28959 
Macro-molecule 
metabolic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
31325 8.5580E-8 9 843 23 28959 
positive 
regulation of 
cellular 
metabolic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
31324 1.0473E-7 8 587 23 28959 
negative 
regulation of 
cellular 
metabolic 
process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|SOX6|RNF2|HES5
|PIAS1 
48522 1.3347E-7 11 1639 23 28959 
positive 
regulation of 
cellular process 
NOTCH1|HEY1|ZBTB16|S
OX11|SOX9|ASCL1|SOX6
|SOX7|ZFP287|HES5|PIA
S1 
9893 1.5422E-7 9 909 23 28959 
positive 
regulation of 
metabolic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|ZFP287|
HES5|PIAS1 
50789 3.3528E-7 18 6699 23 28959 
regulation of 
biological 
process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|Z
IC1|HIVEP1|SOX9|SOX6|
SOX7|ZFP287|HES5|TAF1 
9987 3.5235E-7 20 8929 23 28959 cellular process 
CREBZF|SMARCE1|NOTC
H1|ZBTB16|SOX11|ASCL
1|ZHX1|RNF2|FBXL11|PI
AS1|KIF4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|Z
FP287|HES5|TAF1 
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1708 3.7318E-7 4 44 23 28959 
cell fate 
specification 
NOTCH1|SOX9|ASCL1|SO
X6 
48518 4.3205E-7 11 1854 23 28959 
positive 
regulation of 
biological 
process 
NOTCH1|HEY1|ZBTB16|S
OX11|SOX9|ASCL1|SOX6
|SOX7|ZFP287|HES5|PIA
S1 
45893 5.1146E-7 7 472 23 28959 
positive 
regulation of 
transcription, 
DNA-dependent 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|HES5 
51254 5.2431E-7 7 475 23 28959 
positive 
regulation of 
RNA metabolic 
process 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|SOX7|HES5 
65007 8.3330E-7 18 7126 23 28959 
biological 
regulation 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|Z
IC1|HIVEP1|SOX9|SOX6|
SOX7|ZFP287|HES5|TAF1 
10001 9.8389E-7 4 57 23 28959 
glial cell 
differentiation 
NOTCH1|SOX9|ASCL1|SO
X6 
44237 1.0359E-6 16 5372 23 28959 
cellular 
metabolic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
45165 1.0834E-6 5 156 23 28959 
cell fate 
commitment 
NOTCH1|SOX9|ASCL1|SO
X6|HES5 
50794 1.3271E-6 17 6374 23 28959 
regulation of 
cellular process 
CREBZF|NOTCH1|ZBTB16
|SOX11|ASCL1|ZHX1|RN
F2|FBXL11|PIAS1|HEY1|
HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
48519 1.3910E-6 10 1625 23 28959 
negative 
regulation of 
biological 
process 
NOTCH1|HEY1|ZBTB16|H
IVEP1|SOX9|ASCL1|SOX6
|RNF2|HES5|PIAS1 
42063 1.5439E-6 4 65 23 28959 gliogenesis 
NOTCH1|SOX9|ASCL1|SO
X6 
44238 1.6900E-6 16 5588 23 28959 
primary 
metabolic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
48856 4.2254 11 2363 23 28959 anatomical SMARCE1|NOTCH1|HEY1
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E-6 structure 
development 
|ZBTB16|ZIC1|SOX11|SO
X9|ASCL1|SOX6|RNF2|H
ES5 
48709 4.2798E-6 3 21 23 28959 
Oligo-
dendrocyte 
differentiation SOX9|ASCL1|SOX6 
7399 4.2798E-6 8 995 23 28959 
nervous system 
development 
SMARCE1|NOTCH1|ZIC1|
SOX11|SOX9|ASCL1|SOX
6|HES5 
45944 4.9458E-6 6 415 23 28959 
positive 
regulation of 
transcription 
from RNA 
polymerase II 
promoter 
NOTCH1|SOX11|SOX9|AS
CL1|SOX6|HES5 
48523 5.6144E-6 9 1441 23 28959 
negative 
regulation of 
cellular process 
NOTCH1|ZBTB16|HIVEP1
|SOX9|ASCL1|SOX6|RNF
2|HES5|PIAS1 
8152 1.2614E-5 16 6472 23 28959 
metabolic 
process 
CREBZF|NOTCH1|SOX11|
ASCL1|ZHX1|RNF2|FBXL1
1|PIAS1|HEY1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287
|HES5|TAF1 
7275 1.2614E-5 11 2660 23 28959 
multicellular 
organismal 
development 
SMARCE1|NOTCH1|HEY1
|ZBTB16|ZIC1|SOX11|SO
X9|ASCL1|SOX6|RNF2|H
ES5 
48731 1.5841E-5 10 2151 23 28959 
system 
development 
SMARCE1|NOTCH1|HEY1
|ZBTB16|ZIC1|SOX11|SO
X9|ASCL1|SOX6|HES5 
7389 1.9266E-5 5 291 23 28959 
pattern 
specification 
process 
NOTCH1|ZBTB16|ZIC1|A
SCL1|RNF2 
30154 2.0361E-5 9 1697 23 28959 
cell 
differentiation 
NOTCH1|HEY1|ZBTB16|Z
IC1|SOX11|SOX9|ASCL1|
SOX6|HES5 
32502 2.4007E-5 11 2855 23 28959 
developmental 
process 
SMARCE1|NOTCH1|HEY1
|ZBTB16|ZIC1|SOX11|SO
X9|ASCL1|SOX6|RNF2|H
ES5 
1501 2.4013E-5 5 307 23 28959 
skeletal system 
development 
NOTCH1|ZBTB16|ZIC1|S
OX9|SOX6 
48869 2.4034E-5 9 1740 23 28959 
cellular 
developmental 
process 
NOTCH1|HEY1|ZBTB16|Z
IC1|SOX11|SOX9|ASCL1|
SOX6|HES5 
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45665 2.6604E-5 3 40 23 28959 
negative 
regulation of 
neuron 
differentiation NOTCH1|ASCL1|HES5 
21778 3.6377E-5 2 5 23 28959 
Oligo-
dendrocyte cell 
fate 
specification ASCL1|SOX6 
21779 3.6377E-5 2 5 23 28959 
Oligo-
dendrocyte cell 
fate 
commitment ASCL1|SOX6 
21780 3.6377E-5 2 5 23 28959 
glial cell fate 
specification ASCL1|SOX6 
48663 4.9912E-5 3 50 23 28959 
neuron fate 
commitment NOTCH1|ASCL1|HES5 
7417 5.0218E-5 5 364 23 28959 
central nervous 
system 
development 
NOTCH1|ZIC1|SOX9|ASC
L1|SOX6 
45747 5.2568E-5 2 6 23 28959 
positive 
regulation of 
Notch signaling 
pathway HEY1|ASCL1 
7219 5.7435E-5 3 53 23 28959 
Notch signaling 
pathway NOTCH1|HEY1|ASCL1 
48468 7.5070E-5 6 694 23 28959 
cell 
development 
NOTCH1|ZBTB16|SOX9|A
SCL1|SOX6|HES5 
21781 1.2158E-4 2 9 23 28959 
glial cell fate 
commitment ASCL1|SOX6 
45596 1.4846E-4 4 223 23 28959 
negative 
regulation of 
cell 
differentiation 
NOTCH1|SOX9|ASCL1|HE
S5 
8593 1.4846E-4 2 10 23 28959 
regulation of 
Notch signaling 
pathway HEY1|ASCL1 
16568 2.0176E-4 4 242 23 28959 
chromatin 
modification 
SMARCE1|RNF2|FBXL11|
TAF1 
122 2.7581E-4 4 263 23 28959 
negative 
regulation of 
transcription 
from RNA 
polymerase II 
promoter 
HIVEP1|SOX6|RNF2|HES
5 
48708 2.8975 2 14 23 28959 astrocyte NOTCH1|SOX6 
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E-4 differentiation 
51093 3.0746E-4 4 272 23 28959 
negative 
regulation of 
developmental 
process 
NOTCH1|SOX9|ASCL1|HE
S5 
45595 3.0862E-4 5 546 23 28959 
regulation of 
cell 
differentiation 
NOTCH1|SOX9|ASCL1|HE
S5|PIAS1 
60284 3.6060E-4 4 285 23 28959 
regulation of 
cell 
development 
NOTCH1|SOX9|ASCL1|HE
S5 
6325 3.8164E-4 4 290 23 28959 
chromatin 
organization 
SMARCE1|RNF2|FBXL11|
TAF1 
16043 4.5615E-4 8 1979 23 28959 
cellular 
component 
organization 
SMARCE1|NOTCH1|SOX9
|SOX6|RNF2|FBXL11|PIA
S1|TAF1 
17145 4.5615E-4 2 18 23 28959 
stem cell 
division NOTCH1|ZBTB16 
1837 5.6014E-4 2 20 23 28959 
epithelial to 
mesenchymal 
transition NOTCH1|SOX9 
35116 7.3726E-4 2 23 23 28959 
embryonic 
hindlimb 
morphogenesis NOTCH1|ZBTB16 
22008 7.7753E-4 5 675 23 28959 neurogenesis 
NOTCH1|SOX9|ASCL1|SO
X6|HES5 
51276 8.0757E-4 4 358 23 28959 
chromosome 
organization 
SMARCE1|RNF2|FBXL11|
TAF1 
60740 9.8122E-4 2 27 23 28959 
prostate gland 
epithelium 
morphogenesis NOTCH1|SOX9 
1709 9.8122E-4 2 27 23 28959 
cell fate 
determination ASCL1|HES5 
60512 1.0460E-3 2 28 23 28959 
prostate gland 
morphogenesis NOTCH1|SOX9 
48513 1.0804E-3 7 1680 23 28959 
organ 
development 
NOTCH1|HEY1|ZIC1|SOX
9|ASCL1|SOX6|HES5 
9653 1.1758E-3 6 1186 23 28959 
anatomical 
structure 
morphogenesis 
NOTCH1|HEY1|ZBTB16|S
OX9|SOX6|RNF2 
9952 1.2883E-3 3 163 23 28959 
anterior/posteri
or pattern 
formation NOTCH1|ZBTB16|RNF2 
32501 1.3686E-3 11 4554 23 28959 
multicellular 
organismal 
SMARCE1|NOTCH1|HEY1
|ZBTB16|ZIC1|SOX11|SO
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process X9|ASCL1|SOX6|RNF2|H
ES5 
50793 1.4188E-3 5 783 23 28959 
regulation of 
developmental 
process 
NOTCH1|SOX9|ASCL1|HE
S5|PIAS1 
35137 1.4635E-3 2 34 23 28959 
hindlimb 
morphogenesis NOTCH1|ZBTB16 
48610 1.7977E-3 3 185 23 28959 
reproductive 
cellular process NOTCH1|ZBTB16|SOX9 
51147 1.7977E-3 2 38 23 28959 
regulation of 
muscle cell 
differentiation SOX9|PIAS1 
30850 1.9751E-3 2 40 23 28959 
prostate gland 
development NOTCH1|SOX9 
45664 2.2963E-3 3 203 23 28959 
regulation of 
neuron 
differentiation NOTCH1|ASCL1|HES5 
48732 2.3756E-3 3 206 23 28959 
gland 
development NOTCH1|SOX9|ASCL1 
32582 2.9061E-3 2 50 23 28959 
negative 
regulation of 
gene-specific 
transcription NOTCH1|HES5 
3002 2.9061E-3 3 230 23 28959 regionalization NOTCH1|ZBTB16|RNF2 
60517 2.9061E-3 1 1 23 28959 
epithelial cell 
proliferation 
involved in 
prostatic bud 
elongation SOX9 
3264 2.9061E-3 1 1 23 28959 
regulation of 
cardioblast 
proliferation NOTCH1 
7400 2.9061E-3 1 1 23 28959 
neuroblast fate 
determination ASCL1 
60767 2.9061E-3 1 1 23 28959 
epithelial cell 
proliferation 
involved in 
prostate gland 
development SOX9 
14807 2.9061E-3 1 1 23 28959 
regulation of 
somitogenesis NOTCH1 
45606 2.9061E-3 1 1 23 28959 
positive 
regulation of 
epidermal cell NOTCH1 
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differentiation 
45618 2.9061E-3 1 1 23 28959 
positive 
regulation of 
keratinocyte 
differentiation NOTCH1 
61100 2.9061E-3 1 1 23 28959 
lung 
neuroendocrine 
cell 
differentiation ASCL1 
61101 2.9061E-3 1 1 23 28959 
Neuro-
endocrine cell 
differentiation ASCL1 
61102 2.9061E-3 1 1 23 28959 
stomach neuro-
endocrine cell 
differentiation ASCL1 
61103 2.9061E-3 1 1 23 28959 
carotid body 
glomus cell 
differentiation ASCL1 
61104 2.9061E-3 1 1 23 28959 
adrenal 
chromaffin cell 
differentiation ASCL1 
14016 2.9061E-3 1 1 23 28959 
neuroblast 
differentiation ASCL1 
14017 2.9061E-3 1 1 23 28959 
neuroblast fate 
commitment ASCL1 
60165 2.9061E-3 1 1 23 28959 
regulation of 
timing of 
subpallium 
neuron 
differentiation ASCL1 
7507 2.9360E-3 3 233 23 28959 
heart 
development NOTCH1|SOX9|SOX6 
14031 3.0351E-3 2 54 23 28959 
mesenchymal 
cell 
development NOTCH1|SOX9 
1942 3.2389E-3 2 56 23 28959 
hair follicle 
development NOTCH1|SOX9 
48762 3.2822E-3 2 57 23 28959 
mesenchymal 
cell 
differentiation NOTCH1|SOX9 
22404 3.2822E-3 2 57 23 28959 
molting cycle 
process NOTCH1|SOX9 
22405 3.2822E-3 2 57 23 28959 
hair cycle 
process NOTCH1|SOX9 
48565 3.3733 2 58 23 28959 digestive tract NOTCH1|ASCL1 
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E-3 development 
50767 3.4577E-3 3 251 23 28959 
regulation of 
neurogenesis NOTCH1|ASCL1|HES5 
42303 3.5323E-3 2 60 23 28959 molting cycle NOTCH1|SOX9 
42633 3.5323E-3 2 60 23 28959 hair cycle NOTCH1|SOX9 
45597 3.6643E-3 3 258 23 28959 
positive 
regulation of 
cell 
differentiation NOTCH1|ASCL1|PIAS1 
16570 3.8344E-3 2 63 23 28959 
histone 
modification RNF2|TAF1 
48232 3.8344E-3 3 264 23 28959 
male gamete 
generation NOTCH1|ZBTB16|SOX9 
7283 3.8344E-3 3 264 23 28959 
Spermato-
genesis NOTCH1|ZBTB16|SOX9 
60485 4.1212E-3 2 66 23 28959 
mesenchyme 
development NOTCH1|SOX9 
51960 4.1212E-3 3 272 23 28959 
regulation of 
nervous system 
development NOTCH1|ASCL1|HES5 
16569 4.1909E-3 2 67 23 28959 
covalent 
chromatin 
modification RNF2|TAF1 
51239 4.3003E-3 5 1074 23 28959 
regulation of 
multicellular 
organismal 
process 
NOTCH1|SOX9|ASCL1|ZF
P287|HES5 
3006 4.3003E-3 3 278 23 28959 
reproductive 
developmental 
process NOTCH1|ZBTB16|SOX9 
7420 4.4055E-3 3 281 23 28959 
brain 
development NOTCH1|ZIC1|ASCL1 
55123 4.4375E-3 2 70 23 28959 
digestive system 
development NOTCH1|ASCL1 
43065 4.4375E-3 3 283 23 28959 
positive 
regulation of 
apoptosis NOTCH1|ZBTB16|ASCL1 
43068 4.4850E-3 3 286 23 28959 
positive 
regulation of 
programmed 
cell death NOTCH1|ZBTB16|ASCL1 
42981 4.4850E-3 4 640 23 28959 
regulation of 
apoptosis 
NOTCH1|ZBTB16|SOX9|A
SCL1 
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30278 4.4850E-3 2 73 23 28959 
regulation of 
ossification NOTCH1|SOX9 
10942 4.4850E-3 3 292 23 28959 
positive 
regulation of 
cell death NOTCH1|ZBTB16|ASCL1 
43067 4.4850E-3 4 649 23 28959 
regulation of 
programmed 
cell death 
NOTCH1|ZBTB16|SOX9|A
SCL1 
48133 4.4850E-3 1 2 23 28959 
male germ-line 
stem cell 
division ZBTB16 
7221 4.4850E-3 1 2 23 28959 
positive 
regulation of 
transcription of 
Notch receptor 
target NOTCH1 
42078 4.4850E-3 1 2 23 28959 
germ-line stem 
cell division ZBTB16 
60516 4.4850E-3 1 2 23 28959 
primary 
prostatic bud 
elongation SOX9 
8356 4.4850E-3 1 2 23 28959 
asymmetric cell 
division ZBTB16 
7538 4.4850E-3 1 2 23 28959 
primary sex 
determination SOX9 
7542 4.4850E-3 1 2 23 28959 
primary sex 
determination, 
germ-line SOX9 
46533 4.4850E-3 1 2 23 28959 
negative 
regulation of 
photoreceptor 
cell 
differentiation NOTCH1 
18992 4.4850E-3 1 2 23 28959 
germ-line sex 
determination SOX9 
19100 4.4850E-3 1 2 23 28959 
male germ-line 
sex 
determination SOX9 
60163 4.4850E-3 1 2 23 28959 
subpallium 
neuron fate 
commitment ASCL1 
60166 4.4850E-3 1 2 23 28959 
olfactory pit 
development ASCL1 
10941 4.7611E-3 4 662 23 28959 
regulation of 
cell death 
NOTCH1|ZBTB16|SOX9|A
SCL1 
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35466 4.9732E-3 4 671 23 28959 
regulation of 
signaling 
pathway 
NOTCH1|HEY1|ZIC1|ASC
L1 
10552 5.2236E-3 2 81 23 28959 
positive 
regulation of 
gene-specific 
transcription 
from RNA 
polymerase II 
promoter NOTCH1|HES5 
9790 5.5016E-3 4 692 23 28959 
embryonic 
development 
NOTCH1|ZBTB16|SOX6|R
NF2 
50769 5.9418E-3 2 87 23 28959 
positive 
regulation of 
neurogenesis NOTCH1|ASCL1 
9888 5.9418E-3 4 709 23 28959 
tissue 
development 
NOTCH1|SOX9|ASCL1|SO
X6 
51216 6.0887E-3 2 89 23 28959 
cartilage 
development SOX9|SOX6 
60429 6.0887E-3 3 334 23 28959 
epithelium 
development NOTCH1|SOX9|ASCL1 
902 6.0887E-3 3 334 23 28959 
cell 
morphogenesis NOTCH1|SOX9|SOX6 
22612 6.1168E-3 2 90 23 28959 
gland 
morphogenesis NOTCH1|SOX9 
21529 6.1168E-3 1 3 23 28959 
spinal cord 
oligo-
dendrocyte cell 
differentiation ASCL1 
21530 6.1168E-3 1 3 23 28959 
spinal cord 
oligo-
dendrocyte cell 
fate 
specification ASCL1 
35110 6.1168E-3 1 3 23 28959 
leg 
morphogenesis ZBTB16 
46532 6.1168E-3 1 3 23 28959 
regulation of 
photoreceptor 
cell 
differentiation NOTCH1 
45603 6.1168E-3 1 3 23 28959 
positive 
regulation of 
endothelial cell 
differentiation NOTCH1 
42668 6.1168 1 3 23 28959 auditory HES5 
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E-3 receptor cell 
fate 
determination 
30502 6.1168E-3 1 3 23 28959 
negative 
regulation of 
bone 
mineralization SOX9 
7276 6.2011E-3 3 342 23 28959 
gamete 
generation NOTCH1|ZBTB16|SOX9 
10720 6.5481E-3 2 95 23 28959 
positive 
regulation of 
cell 
development NOTCH1|ASCL1 
43193 6.7859E-3 2 97 23 28959 
positive 
regulation of 
gene-specific 
transcription NOTCH1|HES5 
51094 6.8377E-3 3 356 23 28959 
positive 
regulation of 
developmental 
process NOTCH1|ASCL1|PIAS1 
35113 6.9540E-3 2 99 23 28959 
embryonic 
appendage 
morphogenesis NOTCH1|ZBTB16 
30326 6.9540E-3 2 99 23 28959 
embryonic limb 
morphogenesis NOTCH1|ZBTB16 
32989 7.5876E-3 3 372 23 28959 
cellular 
component 
morphogenesis NOTCH1|SOX9|SOX6 
60528 7.5876E-3 1 4 23 28959 
secretory 
columnal 
luminar 
epithelial cell 
differentiation 
involved in 
prostate 
glandular acinus 
development NOTCH1 
7386 7.5876E-3 1 4 23 28959 
compartment 
pattern 
formation NOTCH1 
60737 7.5876E-3 1 4 23 28959 
prostate gland 
morphogenetic 
growth SOX9 
70168 7.5876 1 4 23 28959 negative SOX9 
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E-3 regulation of 
biomineral 
formation 
60164 7.5876E-3 1 4 23 28959 
regulation of 
timing of 
neuron 
differentiation ASCL1 
51152 7.5876E-3 1 4 23 28959 
positive 
regulation of 
smooth muscle 
cell 
differentiation PIAS1 
2040 7.5876E-3 1 4 23 28959 
sprouting 
angiogenesis NOTCH1 
48598 7.9463E-3 3 383 23 28959 
embryonic 
morphogenesis NOTCH1|ZBTB16|RNF2 
21700 8.1295E-3 2 110 23 28959 
developmental 
maturation NOTCH1|HES5 
19953 8.3990E-3 3 392 23 28959 
sexual 
reproduction NOTCH1|ZBTB16|SOX9 
48589 8.4445E-3 2 113 23 28959 
developmental 
growth NOTCH1|SOX9 
30324 8.4445E-3 2 113 23 28959 
lung 
development NOTCH1|ASCL1 
10551 8.6554E-3 2 115 23 28959 
regulation of 
gene-specific 
transcription 
from RNA 
polymerase II 
promoter NOTCH1|HES5 
30323 8.6554E-3 2 115 23 28959 
respiratory tube 
development NOTCH1|ASCL1 
2051 8.9076E-3 1 5 23 28959 
osteoblast fate 
commitment NOTCH1 
3157 8.9076E-3 1 5 23 28959 
endocardium 
development NOTCH1 
3160 8.9076E-3 1 5 23 28959 
endocardium 
morphogenesis NOTCH1 
60009 8.9076E-3 1 5 23 28959 
Sertoli cell 
development SOX9 
9912 8.9076E-3 1 5 23 28959 
auditory 
receptor cell 
fate 
commitment HES5 
60120 8.9076 1 5 23 28959 inner ear HES5 
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E-3 receptor cell 
fate 
commitment 
35107 9.0584E-3 2 120 23 28959 
appendage 
morphogenesis NOTCH1|ZBTB16 
35108 9.0584E-3 2 120 23 28959 
limb 
morphogenesis NOTCH1|ZBTB16 
48736 9.5682E-3 2 124 23 28959 
appendage 
development NOTCH1|ZBTB16 
60173 9.5682E-3 2 124 23 28959 
limb 
development NOTCH1|ZBTB16 
60541 9.9786E-3 2 127 23 28959 
respiratory 
system 
development NOTCH1|ASCL1 
 
Cellular component 
 
Selected ontology file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/GO_Cellular_Component 
Selected annotation file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/M_musculus_default 
 
No annotations were retrieved for the following entities: NUP153 
 
GO-ID corr p-value x n X N Description Genes in test set 
5634 2.8728E-15 22 4149 24 29353 nucleus 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|ZFP2
87|HES5|TAF1 
43231 1.1271E-10 22 7111 24 29353 
intracellular 
membrane-
bounded 
organelle 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|ZFP2
87|HES5|TAF1 
43227 1.1271E-10 22 7123 24 29353 
membrane-
bounded 
organelle 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|ZFP2
87|HES5|TAF1 
43229 1.0743 22 8082 24 29353 intracellular CREBZF|SMARCE1|NOTCH1|
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E-9 organelle ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|ZFP2
87|HES5|TAF1 
43226 1.0743E-9 22 8107 24 29353 organelle 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|ZFP2
87|HES5|TAF1 
44424 2.8823E-8 22 9548 24 29353 
intracellular 
part 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|ZFP2
87|HES5|TAF1 
5622 4.1362E-8 22 9784 24 29353 intracellular 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|ZIC1|HIV
EP1|SOX9|SOX6|SOX7|ZFP2
87|HES5|TAF1 
44464 6.2364E-6 23 14257 24 29353 cell part 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|RASA1|ZI
C1|HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
5623 6.2364E-6 23 14258 24 29353 cell 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|RNF2|FBXL11|PIAS1
|KIF4|TOX4|HEY1|RASA1|ZI
C1|HIVEP1|SOX9|SOX6|SOX
7|ZFP287|HES5|TAF1 
44451 1.5889E-3 4 372 24 29353 
nucleoplasm 
part ZBTB16|SOX6|RNF2|TAF1 
5654 2.2495E-3 4 418 24 29353 nucleoplasm ZBTB16|SOX6|RNF2|TAF1 
44428 4.3558E-3 5 907 24 29353 nuclear part 
SMARCE1|ZBTB16|SOX6|RN
F2|TAF1 
31981 4.9759E-3 4 540 24 29353 
nuclear 
lumen ZBTB16|SOX6|RNF2|TAF1 
70013 8.9807E-3 4 655 24 29353 
intracellular 
organelle 
lumen ZBTB16|SOX6|RNF2|TAF1 
5. Nuclear presence of NBEA and interaction with NOTCH1 
 
157 
 
43233 8.9807E-3 4 659 24 29353 
organelle 
lumen ZBTB16|SOX6|RNF2|TAF1 
31974 9.9530E-3 4 690 24 29353 
membrane-
enclosed 
lumen ZBTB16|SOX6|RNF2|TAF1 
 
 
Molecular function 
 
Selected ontology file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/GO_Molecular_Function 
Selected annotation file : jar:file:C:\Program 
Files\Cytoscape_v2.8.3\plugins\BiNGO.jar!/M_musculus_default 
 
No annotations were retrieved for the following entities: / 
 
GO-ID corr p-value x n X N Description Genes in test set 
3677 7.5905E-21 21 1671 25 28967 DNA binding 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|FBXL11|PIAS1|KIF4
|TOX4|HEY1|ZIC1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287|H
ES5|TAF1 
3676 9.6286E-18 21 2435 25 28967 
nucleic acid 
binding 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|CXXC5|ASCL
1|ZHX1|FBXL11|PIAS1|KIF4
|TOX4|HEY1|ZIC1|HIVEP1|S
OX9|SOX6|SOX7|ZFP287|H
ES5|TAF1 
30528 2.7411E-14 15 1093 25 28967 
transcription 
regulator 
activity 
CREBZF|NOTCH1|ZBTB16|S
OX11|ASCL1|ZHX1|RNF2|PI
AS1|HEY1|HIVEP1|SOX9|SO
X6|SOX7|ZFP287|HES5 
3700 8.8050E-11 11 686 25 28967 
transcription 
factor activity 
CREBZF|NOTCH1|HEY1|ZBT
B16|SOX11|SOX9|ASCL1|SO
X6|SOX7|ZHX1|ZFP287 
5488 4.6924E-9 24 10294 25 28967 binding 
CREBZF|SMARCE1|NOTCH1|
ZBTB16|SOX11|NUP153|CX
XC5|ASCL1|ZHX1|RNF2|FBX
L11|PIAS1|KIF4|TOX4|HEY1
|RASA1|ZIC1|HIVEP1|SOX9|
SOX6|SOX7|ZFP287|HES5|T
AF1 
43565 1.6151 8 538 25 28967 sequence- CREBZF|NOTCH1|SOX11|SO
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E-7 specific DNA 
binding 
X9|ASCL1|SOX6|SOX7|ZHX1 
43566 3.3943E-5 4 114 25 28967 
structure-
specific DNA 
binding 
NOTCH1|ZBTB16|ASCL1|HE
S5 
8270 1.0397E-4 8 1313 25 28967 
zinc ion 
binding 
ZIC1|HIVEP1|CXXC5|ZHX1|R
NF2|ZFP287|FBXL11|PIAS1 
10843 2.1069E-4 3 63 25 28967 
promoter 
binding SOX9|SOX6|SOX7 
44212 2.1069E-4 3 65 25 28967 
DNA 
regulatory 
region 
binding SOX9|SOX6|SOX7 
46914 2.2220E-4 8 1536 25 28967 
transition 
metal ion 
binding 
ZIC1|HIVEP1|CXXC5|ZHX1|R
NF2|ZFP287|FBXL11|PIAS1 
5515 2.2220E-4 14 5384 25 28967 
protein 
binding 
CREBZF|NOTCH1|ZBTB16|N
UP153|ASCL1|RNF2|FBXL11
|PIAS1|HEY1|RASA1|ZIC1|S
OX9|SOX6|TAF1 
16564 2.2220E-4 4 217 25 28967 
transcription 
repressor 
activity ZBTB16|HIVEP1|RNF2|PIAS1 
3690 2.2220E-4 3 74 25 28967 
double-
stranded 
DNA binding ZBTB16|ASCL1|HES5 
16563 4.0573E-4 4 260 25 28967 
transcription 
activator 
activity 
NOTCH1|SOX11|SOX9|ZFP2
87 
46872 8.6661E-4 10 3147 25 28967 
metal ion 
binding 
NOTCH1|ZBTB16|ZIC1|HIVE
P1|CXXC5|ZHX1|RNF2|ZFP2
87|FBXL11|PIAS1 
43169 8.6661E-4 10 3182 25 28967 
cation 
binding 
NOTCH1|ZBTB16|ZIC1|HIVE
P1|CXXC5|ZHX1|RNF2|ZFP2
87|FBXL11|PIAS1 
43167 8.6661E-4 10 3191 25 28967 ion binding 
NOTCH1|ZBTB16|ZIC1|HIVE
P1|CXXC5|ZHX1|RNF2|ZFP2
87|FBXL11|PIAS1 
3705 2.0493E-3 2 36 25 28967 
RNA 
polymerase II 
transcription 
factor 
activity, 
enhancer 
binding SOX11|SOX7 
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35326 2.0570E-3 2 37 25 28967 
enhancer 
binding SOX11|SOX7 
 
S5.1 Appendix: Nuclear localization signal prediction results obtained with NucPred. A 
NucPred score is given for the protein sequence of NBEA. The NBEA amino acid sequence 
is shown combined with color coding for positively and negatively influencing 
subsequences for nuclear localization. The color coding legend is shown at the bottom of 
the sequence. A red framework highlights the penta-arginine sequence in the DUF1088 
domain that is predicted to be a nuclear localization signal. 
The NucPred score for your sequence is 0.56  
   1    MASDKPGPGLEPQPVALLAVGAGGGAGGGGAMGEPRGAAGSGPVVLPAGM    50 
  51    INPSVPIRNIRMKFAVLIGLIQVGEVSNRDIVETVLNLLVGGEFDLEMNF   100 
 101    IIQDAESITCMTELLEHCDVTCQAEIWSMFTAILRKSVRNLQTSTEVGLI   150 
 151    EQVLLKMSAVDDMIADLLVDMLGVLASYSITVKELKLLFSMLRGESGIWP   200 
 201    RHAVKLLSVLNQMPQRHGPDTFFNFPGCSAAAIALPPIAKWPYQNGFTLN   250 
 251    TWFRMDPLNNINVDKDKPYLYCFRTSKGVGYSAHFVGNCLIVTSLKSKGK   300 
 301    GFQHCVKYDFQPRKWYMISIVHIYNRWRNSEIRCYVNGQLVSYGDMAWHV   350 
 351    NTNDSYDKCFLGSSETADANRVFCGQLGAVYVFSEALNPAQIFAVHQLGP   400 
 401    GYKSTFKFKSESDIHLAEHHKQVLYDGKLASSIAFSYNAKATDAQLCLES   450 
 451    SPKENASIFVHSPHALMLQDVKAIVTHSIHSAIHSIGGIQVLFPLFAQLD   500 
 501    NRQLNDSQVETTVCATLLAFLVELLKSSVAMQEQMLGGKGFLVIGYLLEK   550 
 551    SSRVHITRAVLEQFLSFAKYLDGLSHGAPLLKQLCDHILFNPAIWIHTPA   600 
 601    KVQLSLYTYLSAEFIGTATIYTTIRRVGTVLQLMHTLKYYYWVINPADSS   650 
 651    GIAPKGLDGPRPSQKEIISLRAFMLLFLKQLILKDRGVKEDELQSILNYL   700 
 701    LTMHEDENIHDVLQLLVALMSEHPASMIPAFDQRNGIRVIYKLLASKSES   750 
 751    IWVQALKVLGYFLKHLGHKRKVEIMHTHSLFTLLGERLMLHTNTVTVTTY   800 
 801    NTLYEILTEQVCTQVVHKPHPEPDSTVKIQNPMILKVVATLLKNSTPSAE   850 
 851    LMEVRRLFLSDMIKLFSNSRENRRCLLQCSVWQDWMFSLGYINPKSSEEQ   900 
 901    KITEMVYNIFRILLYHAIKYEWGGWRVWVDTLSIAHSKVTYEAHKEYLAK   950 
 951  MYEEYQRQEEENIKKGKKGNVSTISGLSSQTAGAKGGMEIREIEDLSQSQ  1000 
1001  SPESETDYPVSTDTRDLLMSTKVSDDILGSSDRPGSGVHVEVHDLLVDIK  1050 
1051  AEKVEATEVKLDDMDLSPETLVGGENGALVEVESLLDNVYSAAVEKLQNN  1100 
1101  VHGSVGIIKKNEEKDNGPLITLADEKEELPNSSTPFLFDKIPRQEEKLLP  1150 
1151  ELSSNHIIPNIQDTQVHLGVSDDLGLLAHMTASVELTCTSSIMEEKDFRI  1200 
1201  HTTSDGVSSVSERELASSTKGLDYAEMTATTLETESSNSKAVPNVDAGSI  1250 
1251  ISDTERSDDGKESGKEIRKIQTTATTQAVQGRSSTQQDRDLRVDLGFRGM  1300 
1301  PMTEEQRRQFSPGPRTTMFRIPEFKWSPMHQRLLTDLLFALETDVHVWRS  1350 
1351  HSTKSVMDFVNSNENIIFVHNTIHLISQMVDNIIIACGGILPLLSAATSP  1400 
1401  TGSKTELENIEVTQGMSAETAVTFLSRLMAMVDVLVFASSLNFSEIEAEK  1450 
1451  NMSSGGLMRQCLRLVCCVAVRNCLECRQRQRDRGSKSSHGSSKPQEAPHS  1500 
1501  VTAASASKTPLENVPGNLSPIKDPDRLLQDVDINRLRAVVFRDVDDSKQA  1550 
1551  QFLALAVVYFISVLMVSKYRDILEPQRETARTGSQPGRNIRQEINSPTST  1600 
1601  VVVIPSIPHPSLNHGLLAKLMPEQSFAHSFYKETPATFPDTVKEKETPTP  1650 
1651  GEDIQLESSVPHTDSGMGEEQVASILDGAELEPAAGPDAMSELLSTLSSE  1700 
1701  VKKSQESLTEHPSEMLKPAPSISSISQTKGINVKEILKSLVAAPVEIAEC  1750 
1751  GPEPIPYPDPALKREAHAILPMQFHSFDRSVVVPVKKPPPGSLAVTTVGA  1800 
1801  TAAGSGLPTGSTSSIFAAPGATPKSMINTTGAVDSGSSSSSSSSSFVNGA  1850 
1851  TSKNLPAVQTVAPMPEDSAENMSITAKLERALEKVAPLLREIFVDFAPFL  1900 
1901  SRTLLGSHGQELLIEGLVCMKSSTSVVELVMLLCSQEWQNSIQKNAGLAF  1950 
1951  IELINEGRLLCHAMKDHIVRVANEAEFILNRQRAEDVHKHAEFESQCAQY  2000 
2001  AADRREEEKMCDHLISAAKHRDHVTANQLKQKILNILTNKHGAWGAVSHS  2050 
2051  QLHDFWRLDYWEDDLRRRRRFVRNAFGSTHAEALLKSAVEYGTEEDVVKS  2100 
2101  KKAFRSQAIVNQNSETELMLEGDDDAVSLLQEKEIDNLAGPVVLSTPAQL  2150 
2151  IAPVVVAKGTLSITTTEIYFEVDEDDAAFKKIDTKVLAYTEGLHGKWMFS  2200 
2201  EIRAVFSRRYLLQNTALEVFMANRTSVMFNFPDQATVKKVVYSLPRVGVG  2250 
2251  TSYGLPQARRISLATPRQLYKSSNMTQRWQRREISNFEYLMFLNTIAGRT  2300 
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2301  YNDLNQYPVFPWVLTNYESEELDLTLPGNFRDLSKPIGALNPKRAVFYAE  2350 
2351  RYETWEEDQSPPFHYNTHYSTATSALSWLVRIEPFTTFFLNANDGKFDHP  2400 
2401  DRTFSSIARSWRTSQRDTSDVKELIPEFYYLPEMFVNSNGYHLGVREDEV  2450 
2451  VVNDVDLPPWAKKPEDFVRINRMALESEFVSCQLHQWIDLIFGYKQRGPE  2500 
2501  AVRALNVFHYLTYEGSVNLDSITDPVLREAMEAQIQNFGQTPSQLLIEPH  2550 
2551  PPRSSAMHLCFLPQSPLMFKDQMQQDVIMVLKFPSNSPVTHVAANTLPHL  2600 
2601  TIPAVVTVTCSRLFAVNRWHNTVGLRGAPGYSLDQAHHLPIEMDPLIANN  2650 
2651  SGVNKRQITDLVDQSIQINAHCFVVTADNRYILICGFWDKSFRVYSTETG  2700 
2701  KLTQIVFGHWDVVTCLARSESYIGGDCYIVSGSRDATLLLWYWSGRHHII  2750 
2751  GDNPNSSDYPAPRAVLTGHDHEVVCVSVCAELGLVISGAKEGPCLVHTIT  2800 
2801  GDLLRALEGPENCLFPRLISVSSEGHCIIYYERGRFSNFSINGKLLAQME  2850 
2851  INDSTRAILLSSDGQNLVTGGDNGVVEVWQACDFKQLYIYPGCDAGIRAM  2900 
2901    DLSHDQRTLITGMASGSIVAFNIDFNRWHYEHQNRY                        
2936 
Positively and negatively influencing subsequences are coloured according to the 
following scale: 
(non-
nuclear) negative ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
||||||||||||||||| positive (nuclear) 
Appendix 5.2: Nuclear export signal prediction results obtained with NetNES 1.1. The 
bio-informatics results for leucine-rich NES prediction in the NBEA protein obtained with 
NetNES 1.1. Each amino acid of NBEA has a NES-score. A prediction for a NES is made 
when the NES-score is higher than a predefined threshold within the tool. The NES scores 
for each amino acid compared to the threshold level are visualized in a graph. 
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S5.2 Figure – A 2D Z-projection of endogenous NBEA in N2a cells 
A 2D Z-projection of endogenous NBEA (yellow) in N2a cells is shown. DAPI (cyan) was 
used to stain the nucleus. The separate images are shown in greyscale. White bar = 10µm. 
 
 
 
S5.3 Figure – Human protein atlas data for endogenous NBEA 
A) Confocal image obtained from the Human protein atlas database 
(www.proteinatlas.org) of SH-SY5Y, human neuroblast cells for endogenous NBEA (green) 
immunostaining. DAPI (blue) was used to stain the nucleus. Another antibody was used for 
NBEA immunostaining than is used in this article, namely HPA040385. B) A larger 
magnification is shown from the area in the merged panel A, which is marked with a 
dashed, white line. 
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S5.4 Figure – A 2D Z-projection of the EGFP-DPBW fusion protein without or with the 
NLS mutation 
A) A 2D Z-projection of the EGFP-DPBW fusion protein (yellow) in N2a cells is shown. DAPI 
(cyan) was used to stain the nucleus. The separate images are shown in greyscale. White 
bar = 10µm B) A 2D Z-projection of the EGFP-DPBWMUT fusion protein (yellow) in N2a cells 
is shown. DAPI (cyan) was used to stain the nucleus. The separate images are shown in 
greyscale. White bar = 10µm 
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S5.5 Figure – A 2D Z-projection of overexpressed NICD and endogenous NBEA in N2a 
cells 
A 2D Z-projection of endogenous NBEA (yellow) and overexpressed NICD (magenta) in N2a 
cells is shown. DAPI (cyan) was used to stain the nucleus. The separate images are shown 
in greyscale. White bar = 10µm 
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The large genetic heterogeneity of ASD, with more than 100 associated genes, 
might reflect the phenotypic heterogeneity. The question still remains if there is 
one unifying etiology underlying the core symptoms of ASD. One way to unravel 
this enigma, is to characterize all ASD candidate genes to find any common 
molecular pathways, biological functions or commonly affected brain regions. In 
the end this information might tell us if we should keep considering ASD as one 
spectrum or should start categorizing the spectrum into newly defined disorders, 
with more delineated borders. 
In this research project, one of these ASD candidate genes, Neurobeachin (NBEA) 
was further characterized. As the GH240B Nbea+/- mice, with ASD-like behaviors 
had increased BDNF levels in their hippocampus and an ASD patient showed 
aberrant morphology of blood platelet DCGs, the hypothesis was that NBEA not 
only regulated synaptic vesicle secretion, but also DCG secretion.  
This hypothesis is now further supported by the finding described in this thesis 
that the blood platelet DCGs of GH240B Nbea+/- mice have an aberrant 
ultrastructural morphology as well. In addition, these mice are smaller than wild-
type mice, which we originally predicted to be caused by a defect in regulated 
secretion of GH-containing DCGs. Therefore, this mouse model was chosen to 
further explore the molecular function of NBEA in regulated secretion. However, 
the discrepancy, with the gene-trap Nbea+/- mice, which are not smaller, alarmed 
us to re-evaluate the promoterless human growth hormone genomic fragment 
that was inserted into the Nbea gene to generate the GH240B mouse model.  
Despite a previous examination in the original study by Jones et al. 140, showing no 
pituitary hGH mRNA expression by RT-PCR, we did detect hGH expression at 
mRNA and protein level in the pituitary of GH240 Nbea+/- mice. Driven by hGH 
overexpression in the hypothalamus, an auto/paracrine negative feedbackloop 
eventually causes decreased secretion of mGH into the circulation, resulting in the 
observed dwarfism of these mice. This finding, although explaining the 
discrepancy between the GH240B and the gene-trap Nbea+/- mice, created the 
necessity to reconsider previous results obtained through this GH240B mouse 
model (Table 6.1.). 
Comparing results obtained from the GH240B Nbea mice with the gene-trap Nbea 
mice, shows that besides the discrepancy of dwarfism, there are mostly 
consistencies between these two mouse models, like the cyanosis at birth and 
decreased neuronal glutamate responsiveness. An aberrant blood platelet DCG 
morphology as observed in the ASD patient with a de novo balanced translocation 
disrupting the NBEA gene, was also described in the GH240B Nbea+/- mice. The 
observed altered PKA-mediated phosphorylation pattern of proteins in blood 
platelets of and increased hippocampal BDNF levels in GH240B Nbea+/- mice are 
indirectly supported by the increased PKA-mediated phosphorylation of CREB in 
β-TC3 cells with NBEA KD. Increased phosphorylation of CREB results in increased 
cAMP-dependent transcription of CREB target genes, like Bdnf. In addition, NBEA 
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has been shown in vitro to bind to PKA RII subunits, which makes it plausible that 
NBEA can affect PKA-mediated phosphorylation of several PKA substrates by 
altering the subcellular localization of PKA. 
The effect of NBEA on the cytoskeleton is still poorly described and will have to be 
investigated more, especially within the context of cellular transport and 
morphology. The chance that, by affecting the PKA-mediated phosphorylation of 
cytoskeleton modulators, NBEA will have an indirect effect on the cytoskeleton, 
like observed in the blood platelets of GH240B Nbea+/- mice for Calpain-2, is very 
likely. In gene-trap Nbea-/- neurons, aberrant F-actin accumulation was seen. 
NBEA is an ASD candidate gene in humans, which supports that the GH240B 
Nbea+/- mouse model consequently showed ASD-like behaviors. In D. 
melanogaster Rg loss of function resulted in impaired associative odor learning, 
due to impaired short term memory. Similarly, GH240B Nbea+/- mice showed 
delayed learning and memory in the Morris water maze. A recent publication 
even observed deficits in social interactions of these flies 193. However, since 
altered IGF-1 levels have been described in ASD patients, play a role in 
synaptogenesis and the mTOR pathway, it cannot be excluded that the GH240B 
Nbea+/- mice exhibit a mixed phenotype due to the observed decreased IGF-1 
levels, mixed with decreased NBEA levels. Therefore it is still advisable to assess if 
ASD-like behaviors still exists in the gene-trap Nbea+/- mouse model, after which 
these mice could be used as an ASD mouse model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Summary of (non)supporting data for results obtained in GH240B Nbea KO or 
heterozgous mice. (Next page) Overexpression of hGH in the GH240B Nbea knockout (KO) 
or heterozygous (Het) mice obfuscates if the previously obtained results with these mice 
are a genuine consequence of NBEA deficiency. An overview of supporting (+) or 
nonsupporting (-) data is given, obtained from the gene-trap Nbea mouse model, cell-lines 
and other animal models. A cell is grey when a study in cell-lines is not applicable 
 
  
 
 GH240B Nbea mice Gene-trap Nbea mice Cell-lines Human/Fly/worm/zebrafish 
KO 
Perinatal death through 
cyanosis135 
(+) Perinatal death 
through cyanosis141 
 (-) Viable at birth (Fly)155 
Reduced glutamate 
responsiveness138 
(+) Reduced glutamate 
responsiveness138 
Not studied Not studied 
Het 
Dwarfism135 (-) No dwarfism112  (-) No dwarfism (Human)95 
Abnormal DCG blood 
platelets194 
Not studied Not studied (+) Abnormal DCG blood platelets 
(Human)95 
ASD-like behaviors143 Not studied  (+) NBEA is an ASD candidate gene 
based on 11 ASD cases (Human)  
(+) Defective social interactions in 
Rugose loss of function (Fly)193 
(+) Impaired short term memory 
(Fly)155,156 
Increased BDNF levels in 
hippocampus143 
Not studied (+) Increased PKA-
mediated phosphorylation 
of CREB in β-tc3 cells143 
(+) Increased BDNF levels in ASD 
patients (not specific for NBEA 
deficiency)144–146 
Decreased level of Actin-
associated peptides194 
(+) Ectopic 
accumulation of F-actin 
in neurons142 
Not studied Not studied 
Altered PKA-mediated 
phosphorylation in blood 
platelets and brain lysates194 
Not studied (+) Increased PKA-
mediated phosphorylation 
of CREB in β-tc3 cells194 
Not studied 
. 
  6. General conclusion 
 
169 
 
Through comparing two Nbea haploinsufficient mouse models, this hGH artifact 
could be discovered in the GH240B mice. This finding should be a warning to all 
users of animal models to pay attention to the way a model is generated and to 
always validate that no possible artifacts are present, even when this model was 
generated by a company. Recent studies in the host laboratory revealed more 
mouse models containing a hGH expression artifact, where a hGh minigene was 
used for its introns and polyadenylation signal to enhance expression of the 
AlfpCre, the Pdx1-CreLate, the RIP-Cre, the MIP-GFP and the Nestin-Cre transgene, 
but seemed to result in hGH expression as well 195–197. This approach was used for 
many transgenic mouse models as it has been shown that insertion of these 
sequences are essential for efficient expression of the transgene.  Due to the hGH 
expression in the hypothalamus, the AlfpCre mice show reduced mGH secretion 
and dwarfism as well, as was described for the GH240B Nbea+/- mice. In contrast 
to the GH240B Nbea+/- mice, behavioral tests in the Nestin-Cre mice showed 
reduced cued and context-dependent anxiety 198. Besides the GH receptor, hGH 
has been shown to activate the prolactin receptor in mice as well, which is known 
to have an anxiolytic outcome 195,197,199. This suggests that the increased anxiety 
described in the GH240B Nbea+/- mice could have been even more pronounced 
without the aberrant hGH overexpression. 
 
Besides studies in mice, this project contained a molecular approach, searching 
for physical interaction partners of NBEA. Since NBEA is a large protein (327 kDa), 
the decision was made to separately look for interaction partners of its two 
conserved domain modules, ACA and PBW. For these domains little is known on 
their molecular function.  
The two Y2H screens generated many hits, which were analyzed based on gene 
ontology term enrichment. Besides additional evidence for a role for NBEA in S/T 
phosphorylation, (neurotransmitter) receptor trafficking and cytoskeleton 
modulation and providing insights into specific molecular mechanisms for NBEA in 
these functions, a novel possible function in regulating transcription was 
uncovered. Following this lead, nuclear localization of NBEA was demonstrated. 
This could be attributed to the DUF1088 domain, which contains a classical NLS. In 
humans this domain is only present in Nbea and Lrba, the latter of which has also 
been observed to translocate to the nucleus 148. The minor nuclear fraction of 
NBEA (~20%), compared to a major presence in the cytoplasm, can explain why 
this nuclear expression was overlooked in previous studies. However, this nuclear 
presence does make an interaction of full length NBEA with transcription factors 
and modulators more plausible.  
Evidence for interaction of NBEA with the Notch intracellular domain (NICD) was 
obtained through the Y2H screen with the PBW-domain module. NICD was shown 
to partly co-localize with full length NBEA and functional analysis of Notch-
mediated transcription, showed that NBEA is a negative regulator. Together with 
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previous findings in D. melanogaster and C. elegans showing a genetic interaction, 
and a nuclear co-immunoprecipitation of NBEA with NICD by Yatim et al., 
evidence for an actual physical interaction is accumulating. To complete the 
knowledge about this molecular mechanism, it should be assessed how exactly 
NBEA regulates Notch-mediated transcription. A start could be by assessing 
altered S/T phosphorylation of NICD following NBEA KD and its effect on the NICD 
transcriptional activity. Furthermore, it might be of interest to assess this 
interaction in the correct developmental context. A preliminary analysis of 
primary hippocampal cultures in the host laboratory (in collaboration with Prof. 
Dr. Bagni) showed a similar timing for Nbea and Notch1 mRNA expression, 
peaking at early developmental stages and declining following neuronal 
maturation (Fig 6.1). The expression of mouse Nbea mRNA in vivo is the highest 
during the neonatal period as well, and falls to 50% during the first 25 postnatal 
days 117. In D. melanogaster a nuclear presence of Rg in neuroblasts delaminating 
from the ectoderm is detected during embryonic developmental stages 8-9 152. 
Together, these data indicate the importance of studying NBEA function in an 
early stage in neuronal development, especially in the context of the Notch 
signaling pathway and the regulation of transcription. It would be interesting to 
perform next generation sequencing to compare mRNA expression patterns 
between Nbea+/- and wild-type neurons, early in development. This method will 
not only provide more details about which specific Notch targets are affected 
more by altered NBEA levels, but will also give the opportunity to link other 
downstream differentially expressed proteins with the possible interacting ASD-
linked transcription factors that were described by the Y2H screens, f.e. SOX9 and 
SOX11. 
 
 
Figure 6.1. Similar timing of expression between Notch1 and Nbea mRNA in primary 
hippocampal cultures 
Preliminary data in primary hippocampal cultures (n=2 cultures/DIV stage) with RT-qPCR 
show a similar timing of expression between Notch1 and Nbea mRNA, with the highest 
expression at DIV4 followed by a decline. The highest expression of the classical Notch 
targets Hes5, Hey1 and Id3 is at DIV8, with the exception of Id4 at DIV4. The RT-qPCR data 
was normalized to the reference mRNA GAPDH and is shown relative to DIV18. DIV= days 
in vitro 
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The Notch pathway might be more important in the development of ASD than 
expected, but indirectly. This does not mean we should sequence the Notch genes 
in ASD patients, since mutations in this gene would lead to more dramatic 
developmental phenotypes. It means that it can be interesting to look at 
mutations in genes that converge on the same important pathways, causing ASD 
and maybe even co-occurring morbidities. Mutations in regulators or modulators 
of important developmental pathways will result in less dramatic clinical 
phenotypes, but might result in more subtle neurodevelopmental disorders.  
This PhD project showed that NBEA is a negative regulator of Notch-mediated 
transcription and can also play a role in modulating transcription in general. 
Furthermore, the Y2H screens provided a list of interesting proteins that might 
interact with full length NBEA and provide novel molecular insights into the 
already known functionalities of NBEA. It will be interesting to assess if NBEA 
forms different complexes containing PP2A, and thus regulates S/T 
phosphorylation in a more complex way, than by only affecting the subcellular 
localization of PKA. In addition, it would be nice to confirm that full length NBEA 
can bind the several identified PKA substrates, bringing them in closer proximity 
to PKA. Another project will be to look into the different interactions with 
cytoskeletal components and the role of these interactions in neuronal migration 
and neurotransmitter receptor trafficking, with a specific focus on the interaction 
between GABARAP and NBEA. 
Since NBEA is only affected in a limited number of patients, and some of these 
patients do not have a detailed description, it is not clear whether there might be 
an association with NBEA deficiency and other co-occuring disorders. It can be 
hypothesized that the chance of NBEA being implicated in other neurological 
disorders will be high, because of its multifunctionality. Furthermore, this can be 
deduced from the neurological diseases related to the possible interaction 
partners of NBEA obtained with the Y2H screens, like epilepsy and mental 
retardation. 
A disadvantage of performing Y2H screens with two separate conserved domain 
modules is that this approach does not guarantee that full length NBEA will 
interact with the same partners as well. Performing GST-pulldown assays or co-
immunoprecipitations with full length NBEA might not be the best 
complementary studies, since these methods will not pick up weak and transient 
interactions in contrast to a Y2H screen. A way to overcome this would be to 
combine these techniques with cross-linking, although the risk will exist that non-
interacting proteins in the neighbourhood will be cross-linked as well. Co-
localization analysis, as was performed for NBEA and NICD can provide an extra 
hint, but still only looks at a fixed moment and does not prove a direct physical 
interaction. A way to validate transient and weak interactions in living cells could 
be by performing a bimolecular fluorescence complementation (BiFC) assay, or a 
Förster resonance energy transfer (FRET) assay. Both of these assays result in 
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proximity-based fluorescence as a read-out and will only require cloning of the 
proteins of interest into specifically designed plasmids. However, this will be a 
challenge for full length NBEA since this is a large protein to express on its own 
and is very difficult to clone into different plasmids. Nonetheless the data 
obtained in this manuscript, showing physical interactions based on Y2H, should 
still be confirmed with a second technique and by using full length NBEA. 
 
In general, this research project helped to unravel an artifact in an ASD mouse 
model, but still found consistencies for the data obtained with the GH240B Nbea 
mouse by comparing it with other Nbea/Rg models, in vitro data and ASD 
patients. Specifically, this project contributed to findings confirming the role of 
NBEA in blood platelet DCG morphology and as an AKAP, affecting PKA-mediated 
phosphorylation in blood platelets, but also in the brain. Furthermore, a novel 
function for NBEA was revealed, affecting transcription and specifically impairing 
the Notch signaling pathway. And lastly, a foundation was set for further research, 
contributing to knowledge about the exact molecular mechanisms of NBEA. 
Taking into account the functions of NBEA, an ASD candidate gene,  extra support 
can be found for the implication of neural growth, synaptic transmission, 
transcription regulation, cytoskeleton and trafficking and even PKA-mediated 
phosphorylation in the etiology of ASD. The future for unraveling the etiology of 
ASD will lie in a more complete diagnosis of patients, giving a full description of all 
their disorders and “abnormalities”. And accounting for this when performing 
GWAS or other genetic analysis. The focus will really be in looking at pathways 
and protein networks, rather than focusing on single genes, although knowledge 
about these single genes will be of great value. However, it still might be that the 
search for convergence within the heterogeneity of ASD will not be at the level of 
genes and pathways, but may be higher, at the level of brain structure and 
function 30. A great role for bio-informatics will lie in finding subgroups of proteins 
networks, contributing to different aspects in the spectrum of ASD. It will be only 
when this pathology can completely be understood, that rational initiatives can be 
commenced to treat the disabilitating symptoms of ASD. 
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Popular summary  
Autism spectrum disorders (ASD) are neurodevelopmental disorders that 
manifests itself before the age of three. This group of disorders is characterized by 
problems with social and communicative interactions, as well as repetitive 
behaviour and restricted interests. At present no cure exists for ASD and the 
symptoms are mostly treated with behavioral therapy. Studies of identical twins 
and families show an important role for genetics in the cause of ASD. In fact, 
already hundreds of genes have been identified as causal, but they all only 
account for 1% or less of the total ASD population. Above all, the genetic cause is 
still unknown for the majority of the ASD patients.  
 
At the Center for Human Genetics (KU Leuven) a mutation was discovered in the 
Neurobeachin gene in one ASD patient. This gene had not been linked to ASD 
before, but in the meantime eleven ASD patients with a mutation affecting the 
Neurobeachin gene have been described. Similar to many other ASD candidate 
genes, the protein Neurobeachin is enriched in the brain. Mice with a complete 
loss of Neurobeachin die at birth due to oxygen deficiency, caused by an 
impairment of the nerves to signal to the respiratory muscles. Mice heterozygous 
for the Neurobeachin deletion do survive at birth and show ASD-like behaviors. 
This supports a role for Neurobeachin in the etiology of ASD. 
 
As the exact working mechanism for Neurobeachin was largely unknown, this 
project aimed to contribute to its characterization. To achieve this, the 
heterozygous Neurobeachin mouse model was used and a screen was performed 
for proteins binding important domains of the Neurobeachin protein. 
 
By investigating the cause of the dwarfism observed in the heterozygous 
Neurobeachin mice, an artifact was discovered. The manner in which this mouse 
was created led to exogenous presence of human growth hormone, which caused 
a decreased release of mouse growth hormone. Nonetheless, we also observed 
consistencies between the heterozygous Neurobeachin mouse and the ASD 
patient by studying blood platelets and found additional evidence for a role of 
Neurobeachin in regulating phosphorylation by protein kinase A. Protein kinase A 
can alter the activity of other proteins through their phosphorylation and by doing 
this play a role in modulating learning and memory. 
 
Finally, several binding proteins were identified for important domains of 
Neurobeachin. An analysis of these proteins showed that many of these were 
nuclear proteins. Consistent with this finding we discovered partial nuclear 
localization of Neurobeachin and a role for Neurobeachin in regulating 
transcription. More specifically, we showed that Neurobeachin negatively 
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regulated the Notch signaling pathway, which is important for brain development. 
Furthermore, the analysis of this screen for binding proteins provided the basis for 
further research. Using the knowledge about the biological role of these binding 
proteins can provide more insights into the biological role of Neurobeachin itself. 
In conclusion this PhD project contributed to more insights into the biological role 
of Neurobeachin, which could contribute to a better understanding of the cause 
of ASD as well. 
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Samenvatting van het onderzoek 
Autisme spectrum stoornissen (ASS) worden gedefinieerd als een 
ontwikkelingsstoornis van de hersenen die al aanwezig is voor 3-jarige leeftijd. 
Deze groep van stoornissen wordt gekenmerkt door problemen met sociale en 
communicatieve interacties, alsook door repetitief gedrag en beperkte interesses. 
Momenteel bestaat er nog geen geneesmiddel voor ASS en worden de 
symptomen vooral behandeld door middel van gedragstherapie. Op basis van 
studies in ééneiïge tweelingen en families zien we dat er een belangrijke erfelijke 
factor betrokken is in het ontstaan van ASS. Hiervoor zijn er reeds honderden 
genen gekend, maar deze genen verklaren de oorzaak elk maar maximum voor 1% 
van alle personen met ASS. Bovendien zijn er nog veel personen met ASS, 
waarvoor de oorzaak niet geweten is.   
In het Centrum voor Menselijke Erfelijkheid (KU Leuven) was er een mutatie in het 
Neurobeachine gen ontdekt bij een patiënt met ASS. Dit gen was voorheen in de 
literatuur nog niet gelinkt met ASS, maar er blijken ondertussen reeds 11 
personen met ASS een genetische afwijking van het Neurobeachine gen te 
hebben. Zoals vele andere ASS kandidaatgenen, is het eiwit Neurobeachine veel 
aanwezig in de hersenen. We weten dat muizen met een volledig verlies van 
Neurobeachine, sterven bij de geboorte door ademnood, omdat de zenuwen geen 
signaal meer kunnen doorgeven aan de ademhalingsspieren. Muizen 
heterozygoot voor de Neurobeachine deletie overleven wel en vertonen 
gedragingen gelijkaardig aan ASS. Dit levert extra bewijs dat een afwijking van het 
Neurobeachine gen ASS kan veroorzaken. 
Omdat het exacte werkingsmechanisme van Neurobeachine grotendeels nog 
ongekend was, had dit project als doel om dit verder te karakteriseren. Hiervoor 
werd enerzijds het heterozygote Neurobeachine muismodel gebruikt en 
anderzijds gezocht naar eiwitten die aan belangrijke domeinen van het 
Neurobeachine eiwit binden.  
Door te onderzoeken waarom de heterozygote Neurobeachine muizen kleiner 
waren dan gewone muizen, ontdekten we een artefact. De wijze waarop deze 
muis gemaakt was had geleid tot abnormale aanwezigheid van menselijk 
groeihormoon en hierdoor een verminderde vrijzetting van muis groeihormoon. 
Desondanks observeerden we, bij een studie van bloedplaatjes, overeenkomsten 
tussen de heterozygote Neurobeachine muis en een ASS patiënt en vonden we 
bijkomende evidentie voor een rol van Neurobeachine in fosforylatie door 
proteïne kinase A. Proteïne kinase A kan via de fosforylatie van andere eiwitten, 
hun werking versterken of afzwakken en speelt zo bijvoorbeeld een belangrijke rol 
in het moduleren van leerprocessen en geheugenvorming. 
Ten slotte identificeerden we verschillende bindende eiwitten voor belangrijke 
domeinen van Neurobeachine. Hierbij toonde een analyse dat veel van deze 
eiwitten kerneiwitten zijn. Consistent met deze bevinding, hebben we de 
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gedeeltelijke lokalisatie van Neurobeachine in de kern ontdekt, alsook een rol in 
het regelen van transcriptie. Meer bepaald, had Neurobeachine hierdoor een 
effect op de Notch signaalcascade, die belangrijk is voor de ontwikkeling van de 
hersenen. Door deze brede analyse hebben we een basis kunnen leggen voor 
verder onderzoek, waarbij kennis over de rol van de bindende eiwitten, doordat 
ze samenwerken met Neurobeachine, meer inzicht zal bieden over de mogelijke 
rol van het Neurobeachine eiwit zelf. 
In conclusie heeft dit doctoraatsproject bijgedragen aan meer inzicht in de 
biologische rol van Neurobeachine en draagt dit zo ook bij aan meer inzicht in de 
mogelijke ontstaansmechanismen van ASS. 
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